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General introduction and thesis outline
10 Chapter 1
INtroduCtIoN 
Despite many recent improvements in the medical treatment of cancer, surgical removal 
remains the single most important curative treatment option for solid tumors. For a 
curative resection, complete resection of the tumor, as confirmed by histopathological 
evaluation, is essential. To minimize comorbidity it is important to spare vital 
structures (e.g. nerves, ureters, bile ducts). While there are several imaging modalities 
available that can visualize tumor size, location and relation to vital structures up to 
a certain extent in the preoperative setting,1 during surgery, other than incidental use 
of intraoperative ultrasonography, surgeons still mainly rely on visual inspection and 
palpation to determine what should be resected and what should be spared.
Unfortunately, it can be challenging to discriminate tumor tissue from normal 
tissue by visual inspection and palpation and as a result, irradical resections and 
damage to vital structures still occur relatively frequently.2-4  Therefore, there is a need 
for an imaging modality that can provide the surgeon with real-time information 
during surgery on the exact location of tissues to be resected and tissues to be avoided.
oPtICaL IMaGING
Optical imaging using near-infrared (NIR) fluorescence is a technique that has 
the potential to fulfill this need. Advantages of NIR fluorescent light (700-900 nm, 
Figure 1) include high tissue penetration (millimeters to centimeters deep) and low 
autofluorescence, thereby providing sufficient contrast.5 Because the human eye is 
insensitive to NIR wavelengths, the use of NIR light does not alter the surgical field. 
Recently developed intraoperative imaging systems are able to provide simultaneous 
acquisition of surgical anatomy (white light, color video) and NIR fluorescence 
signal.6-8 Furthermore, systems are available that can simultaneously acquire and 
display multiple separate fluorescence wavelengths, enabling labeling of tumors on 
one channel and vital structures on a second channel.6 Therefore, the use of NIR 
fluorescence imaging could potentially be of great value in the intraoperative detection 
of critical anatomical structures and oncologic targets. 
In addition to NIR fluorescence imaging systems, exogenous NIR fluorescent 
contrast agents are necessary to visualize specific tissues. Ideally, tumor cells are 
labeled by targeted contrast agents. However, the only NIR fluorescent contrast agents 
currently registered by the U.S. Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for clinical applications are the non-targeted indocyanine 
green (ICG; peak emission ≈ 820 nm) and methylene blue (peak emission ≈ 700 nm).
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SeNtINeL LyMPH Node deteCtIoN
Sentinel lymph node (SLN) mapping, as introduced in the treatment of cutaneous 
melanoma by Donald Morton9 is now considered part of the standard of care in 
cutaneous melanoma, breast cancer and vulvar cancer.  The SLN is the lymph node 
that drains directly from the tumor and is therefore most likely to be the node to which 
tumor cells will first metastasize. By injecting a tracer around the primary tumor, the 
SLN can be identified and resected by following the drainage of that tracer. If the 
SLN contains no tumor cells, it is unlikely that the remaining lymph nodes contain 
metastases and the resection of these nodes and the associated comorbidity can be 
avoided.
Currently, SLN mapping typically involves the injection of a radiotracer 
preoperatively and injection of a blue dye shortly prior to surgery. Using this combined 
technique, high sensitivity and low false negative rates are achieved. However, these 
methods have their disadvantages. The use of a radiotracer exposes caregivers and 
patients to ionizing radiation and may not be possible in all clinics due to regulatory 
issues. Local injection of a blue dye stains the surgical field in an unnatural color that 
persists for several months after surgery and can not be visualized when it is covered 
by overlying tissue. The use of NIR fluorescence has the potential to overcome these 
limitations and simplify the use of SLN mapping in various cancer types. Indeed, the 
Figure 1. Absorption of light by various components varies over the wavelength spectrum, resulting in an 
optimal window for fluorescence imaging in the NIR light region between 650 and 900 nm. OxyHb, oxygenated 
hemoglobin; DeoxyHb, deoxygenated hemoglobin. Figure reprinted from Chance.32 With permission, Copyright 
Clearance Center Rightslink.
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first studies have been described that use the currently available ICG in combination 
with an intraoperative NIR fluorescence imaging system for SLN mapping in breast 
cancer,6, 10 gynecologic cancer7, 11 and gastrointestinal malignances12. 
tuMor MarGIN deteCtIoN aNd IMaGe-GuIded 
reSeCtIoN
Different strategies can be followed to detect malignant cells or tissues during surgery. 
The various hallmarks of cancer can be used as a target for imaging strategies: increased 
growth and growth factor signaling receptors, limitless replicative potential, sustained 
angiogenesis, and increased proteolytic activity resulting in tissue invasion and 
metastasis.13 Development of these probes is the focus of intensive research and many 
have been tested in a preclinical setting. Enzyme activatable probes allow detection 
of proteases that are relatively abundant in malignant tissue, which can be associated 
with specific characteristics of the tumor, e.g. invasive, aggressive or metastatic 
tendency. These agents are injected in a quenched (i.e. non-fluorescent) state, resulting 
in minimal fluorescence at the time of administration. After cleavage by the specific 
enzyme, the agent becomes dequenched (i.e., fluorescent), resulting in a high signal-
to-background (SBR). Examples of activatable agents that have been used in animal 
cancer models are activatable polyarginine-based cell-penetrating peptides that detect 
matrix metalloproteinases,14 activity-based probes that target cysteine cathepsins,15 
and several commercially available probes that have been developed by Weissleder 
et al., which are activated by cathepsins or matrix metalloproteinases (PerkinElmer, 
Waltham, USA).16, 17
Instead of detection of tumor-associated proteases, molecular-specific detection 
of cancer cells can be performed using a specific targeting ligand or monoclonal 
antibody conjugated to a fluorophore. Tumor detection by exploiting the increased 
growth factor receptor expression of tumors has been described in all kinds of different 
tumors. In these studies, fluorophores that were coupled to monoclonal antibodies 
targeting the epidermal growth factor receptor, Her2/neu receptor, or vascular 
endothelial growth factor receptor were used.18-21 For imaging of tumor angiogenesis, 
targeting of alpha-v-beta-3 (αvβ3) integrin, a critically important adhesion molecule 
in the regulation of angiogenesis, is a widely used strategy. Targeting of αvβ3 integrin 
by cyclic arginine-glycine-aspartate conjugated to various non-quenched or quenched 
fluorophores has been reported.22-24 Finally, in analogy with PET technology, increased 
glucose metabolism due to increased expression of membrane glucose transporter 
proteins in intracranial gliomas has been reported.25 
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IdeNtIFICatIoN oF vItaL StruCtureS
In order to identify vital structures by using NIR fluorescence contrast agents, a 
distinction should be made between hollow and solid structures. Hollow structures, 
such as bile ducts, ureters and blood vessels can be visualized if contrast agents can be 
delivered intraluminally, whereas solid structures, as for example the nerves, can be 
visualized by targeting specific cellular markers, as membrane proteins. 
Hollow structures can be visualized either by direct injection or by means of 
excretion from for example the liver or kidneys. ICG is excreted by the liver into the 
bile and has indeed been shown to identify bile ducts during surgery.26-28 MB is cleared 
both hepatically and renally and has been shown to identify both ureters and bile 
ducts.29
The identification of nerves requires the development of novel contrast agents. 
Advances have been made in the development of nerve targeting probes, although 
many hurdles still exist as the probes are fluorescent in a lower wavelength than the 
NIR spectrum, thereby lowering tissue penetration and suffering from increased 
autofluorescence.30 Another strategy is to use fluorescent peptides that target the nerve 
sheath, avoiding the need to cross the blood-nerve-barrier.31
outLINe oF tHe tHeSIS
This thesis is divided in two parts: in Part I focus lies on preclinical validation of 
NIR fluorescence image-guided surgery, Part II describes clinical translation of this 
technique and first-in-human studies.
Part I, chapter 2 describes the intraoperative identification of colorectal liver 
metastases using NIR fluorescence and a novel integrin αvβ3 targeted probe in an 
experimental rat tumor model. Chapter 3 explores the use of a protease activatable NIR 
fluorescent probe for intraoperative identification of tumor margins in a rat model 
of breast cancer and subsequent image-guided resection of breast tumors. In chapter 
4, the clinically available probe indocyanine green (ICG) is used to intraoperatively 
identify colorectal liver metastases in an experimental rat tumor model.
In part II, chapter 5, NIR fluorescence imaging is used for ex vivo SLN mapping 
in colorectal cancer, to allow the use of novel probes that are not yet approved for 
clinical in vivo injections. First, this technique is validated in a swine model, where 
in vivo injections are compared to ex vivo injections. Subsequently, this technique is 
translated to the clinic in a pilot series of human colorectal cancer specimens. Chapters 
6 and 7 are focused on the use of NIR fluorescence imaging for SLN mapping in breast 
cancer. In chapter 6, the development of an improved imaging system with reduced 
size and optimization of ICG:HSA dose are described. Whether premixing with HSA 
is indeed beneficial for SLN mapping in breast cancer patients is then studied in a 
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randomized trial in chapter 7. The use of intraoperative NIR fluorescence imaging 
for SLN mapping is reported in cervical cancer patients and vulvar cancer patients in 
chapter 8 and chapter 9, respectively.
In breast reconstructive surgery using free skin flaps, good oxygenation of the 
transplanted tissue is essential for flap survival. Imaging of vascular anatomy may help 
the surgeon in choosing the vessels to be used for transplantation and has the potential 
to improve outcomes. Chapter 10 describes intraoperative imaging of perforator vessels 
using NIR fluorescence in patients undergoing diep inferior epigastric perforator 
(DIEP) flap breast reconstruction after mastectomy.
As no tumor targeted NIR fluorescent probes are yet available for clinical 
application, the enhanced permeability and retention effect could potentially be 
used for tumor identification by non-targeted probes. In chapter 11 it is attempted 
to visualize tumors intraoperatively after ICG injection in pancreatic cancer patients. 
Furthermore, visualization of bile ducts is studied using NIR fluorescence imaging. 
Chapter 12 describes the use of NIR fluorescence imaging to intraoperatively visualize 
colorectal liver metastases in patients who were injected with ICG prior to surgery. 
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Near-infrared (NIR) fluorescence optical imaging is a promising technique to assess 
the extent of colorectal metastases during curative-intended surgery. However, NIR 
fluorescence imaging of liver metastases is highly challenging due to hepatic uptake 
and clearance of many fluorescent dyes. In the current study, the biodistribution and 
the ability to demarcate liver and peritoneal metastases were assessed during surgery 
in a syngeneic rat model of colorectal cancer using an integrin αvβ3-directed NIR 
fluorescence probe. 
Methods
Liver tumors and peritoneal metastases were induced in 7 male WAG/Rij rats by 
subcapsular inoculation of 0.5 x106 CC531 colorectal cancer rat cells into three distinct 
liver lobes. Intraoperative and ex vivo fluorescence measurements were performed 24 
(N = 3 rats, 7 tumors) and 48 h (N = 4 rats, 9 tumors) after intravenous administration 
of the integrin αvβ3-directed NIR fluorescence probe. 
results
Colorectal metastases had a minimal two-fold higher NIR fluorescence signal than 
healthy liver tissue and other abdominal organs (p < 0.001). The tumor-to-background 
ratio was independent of time of imaging (24 h vs. 48 h post-injection; p = 0.31), which 
facilitates flexible operation planning in future clinical applications. Total fluorescence 
intensity was significantly correlated with the size of metastases (R2 = 0.92 for the 24 h 
group, R2 = 0.96 for the 48 h group).
Conclusion
These results demonstrate that colorectal intra-abdominal metastases can be clearly 
demarcated during surgery using an integrin αvβ3  targeting NIR fluorescence probe. 
Translating these findings to the clinic will have an excellent potential to substantially 
improve the quality of cancer surgery.
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INtroduCtIoN
Survival of colorectal cancer patients is largely restricted by the occurrence of 
metastases, predominantly in the liver. In the course of the disease, up to 50% of 
patients will eventually develop liver metastases.1 If confined to the liver, surgery offers 
a possible curative treatment option with 5-year survival rates of 35-40%.2 However, 
at the time of surgery, adequate assessment of the extent of the disease is still limited, 
resulting in a 40-50% recurrence rate.3 Clearly, innovative visualization techniques are 
needed to facilitate intraoperative assessment of the extent of the cancer tissue and to 
guide the subsequent surgical removal of these tumors with adequate margins in an 
attempt to increase the complete resection rate.
Real-time visualization of cancer cells using near-infrared (NIR) fluorescence 
optical imaging is a promising technique to assess the extent of colorectal metastases 
during curative-intended surgery.4-6 However, optical imaging of liver metastases 
is highly challenging due to the high absorptivity of liver tissue for visble light and 
hepatic uptake and clearance of many fluorescent dyes.7, 8 Recent studies demonstrated 
successful identification of breast, lung and glioblastoma cancers by targeting a member 
of the integrin family, integrin αvβ3.
9-13 Integrins are cell-surface transmembrane 
heterodimeric glycoproteins that are involved in cell adhesion, matrix interaction 
and cell signaling pathways. Integrin αvβ3 plays a key role in the early phase of tumor 
angiogenesis, tumor cell migration and is overexpressed in various cancer types, 
including colorectal cancer.14-17 Because hepatocytes show little expression of integrin 
αvβ3,
16, 18 it is expected that NIR fluorescence probes targeting integrin αvβ3 result in 
little background in the liver.9 Therefore, the aim of this study was to investigate the 
biodistribution and the ability to clearly demarcate liver and peritoneal metastases 
during surgery in a syngeneic rat model of colorectal cancer using an integrin αvβ3-
directed NIR fluorescence probe.
MaterIaLS aNd MetHodS
animal model
Rat CC531 colorectal cancer cells were cultured in RPMI 1640 supplemented with 2 mM 
L-glutamine (Gibco, Invitrogen Ltd, Carlsbad, USA), 10% heat-inactivated fetal calf 
serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin sulphate.19 In order to induce 
liver and peritoneal metastases, CC531-syngeneic male WAG/Rij rats (Charles River, 
Maastricht, the Netherlands) weighing 300-350 g underwent median laparotomy and 
the liver was exposed. Subsequently, 500,000 CC531 cells (50 µl) were subcapsularly 
inoculated into the left and right main liver lobes, and the right accessory liver lobe.19 
To prevent tumor spill, puncture sites were covered with a small sponge, directly after 
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tumor cell injection. Four weeks after inoculation, metastases of approximately 5 mm 
in diameter had originated in the liver. The Animal Welfare Committee of the Leiden 
University Medical Center approved the experiments.
NIr fluorescence probe
The NIR fluorescence probe IntegriSense®680 (PerkinElmer, Waltham, USA) with 
peak absorbance at 680 nm was used for fluorescence imaging. IntegriSense680 
consists of a small non-peptide integrin αvβ3 antagonist,
20 which is conjugated to the 
NIR fluorescence probe VivoTag®-S680 (PerkinElmer). 
Intraoperative NIr fluorescence camera system 
The Fluobeam® system (Fluoptics, Grenoble, France) was used for these experiments 
and has been described previously.21 In short, the Fluobeam system is composed of a 
100 mW laser emitting at 690 nm with an illumination power of 2.6 mW/cm2 and a 
12-bit CCD camera. The animal is placed under the laser and illuminated by white 
light filtered with a band-pass filter (350-650 nm) providing an irradiance of 7x103 lx 
at the animal level. 
animal experiments
All animals were housed in the animal facility of the Leiden University Medical 
Center. Pellet food and fresh tap water were provided ad libitum. The weight of the 
animals was followed throughout the experiment to monitor their general health state. 
Throughout tumor inoculation, imaging and surgical procedures, the animals were 
anesthetized with 5% isoflurane for induction and 2% isoflurane for maintenance 
in oxygen with a flow of 0.8 L/min and placed on an animal bed with an integrated 
nose mask. Rats (N = 7) were injected intravenously into the penile vein with 
IntegriSense680 (12 nmol per animal) 24 h (3 rats, N = 7 tumors) or 48 h (4 rats, 
N = 9 tumors) before imaging. These time points were chosen based on the blood 
pharmacokinetics of IntegriSense680 (PerkinElmer website: www.perkinelmer.
com). Before injection, the level of autofluorescence was determined of metastases, 
surrounding tissue and abdominal organs. During intraoperative NIR fluorescence 
imaging of metastases a median laparotomy was performed followed by a systematic 
exploration of the peritoneal cavity. After intraoperative imaging, livers containing 
metastases were completely excised for additional ex vivo fluorescence measurements. 
Peritoneal metastases identified clinically or by fluorescence were carefully excised. 
Fluorescence intensity of metastases and abdominal organs was determined in vivo 
and ex vivo using the Fluobeam system. After resection, tumors were imaged ex vivo 
using the IVIS Spectrum (Caliper LifeSciences, Hopkinton, USA), which allowed 
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isolation of the IntegriSense680 signal from the background fluorescence by means of 
spectral unmixing.22 
Microscopy
Excised tumors were fixed in 10% buffered formalin overnight and washed in 70% 
ethanol. Following paraffin embedding and mounting, tissue sections specimens of 
4 µm were air-dried and stained with standard hematoxylin-eosin. In parallel, freshly 
excised liver lobes containing tumors were processed for fluorescence microscopy. 
Fresh tumors and surrounding liver tissue blocks of approximately 2 cm in diameter 
were incubated with 0.5 ml phalloidin-Alexa Fluor 488 (0.5 µM) and Hoechst 33342 
(48 µM; both from Invitrogen) for 1 hr at room temperature to stain the F-actin 
filaments in particular those of the cell membrane of hepatocytes,23 and the dsDNA at 
the cell nucleus, respectively. Tumors were placed in glass-bottom Petri dish (P35G-
1.5-14-C , Mattek Corporation, Ashland, USA) and analyzed using the Leica TCS 
SP5 inverted confocal microscope (Leica Microsystems, Wetzlar, Germany; HCX PL 
APO 40x;  N.A. 1.25 oil immersion objective). Hoechst, phalloidin-AlexaFluor488 and 
IntegriSense680 were excited by a 405 nm diode, a 488 nm Argon laser and a 633 
HeNe nm laser, respectively. The 12-bit images were analyzed using the Leica LAS AF 
software and the three signals were pseudo-colored with blue for Hoechst, green for 
phalloidin-AlexaFluor488, and red for IntegriSense680. 
Statistical analysis
Fluobeam derived NIR fluorescence data were analyzed using the open-source software 
ImageJ24 by drawing regions of interest at the tumor and at the surrounding tissue 
within a range of 2 mm of the demarcation line of the tumor and the surrounding tissue 
by visual interpretation and measuring the fluorescent intensity of the 12-bit images. 
Merged images of visible light images and NIR fluorescence light images generated 
by the Fluobeam system were created using Adobe Photoshop CS3 Software (version 
10.0.1, Adobe Systems Inc., San Jose, USA). IVIS Spectrum derived NIR fluorescence 
data were analyzed using LivingImage software (version 3.2, Caliper LifeSciences, 
Hopkinton, USA) using the methods described above. Statistical analysis and 
generation of graphs were performed using GraphPad Prism Software (version 5.01, 
La Jolla, USA). Mean fluorescence intensity and associated standard deviations were 
reported. Unpaired and paired t-tests were used for testing differences of fluorescence 
intensity between groups. Pearson’s correlation coefficients were calculated for the 
analysis of the size of tumors and the total fluorescence intensity. Statistical tests were 
two-tailed and p < 0.05 was considered significant.
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reSuLtS
Intraoperative detection of colorectal liver metastases
In a total of 7 rats, all colorectal liver metastases (N = 16) were identified during 
surgery with the intraoperative Fluobeam camera system after targeting of integrin 
αvβ3 expression with IntegriSense680 (Fig. 1A). Quantification of the NIR fluorescence 
signal was performed using spectral unmixing with the IVIS Spectrum, enabling 
separation of true IntegriSense680 signal from background fluorescence. The NIR 
fluorescence signal was significantly higher in the colorectal metastases in comparison 
to healthy liver tissue, regardless of the rats were imaged 24 hours after injection (N 
= 7, paired t = 10.8, p < 0.0001) or 48 hours after injection (N = 9, paired t = 6.59, p 
= 0.0002; Fig. 1B). The NIR fluorescence signal of the colorectal metastases was on 
average two-fold higher than that of the healthy liver and the tumor-to-background 
ratio was not significantly different when comparing the 24 hours (mean TBR = 2.04) 
and 48 hours group (mean TBR = 1.81, unpaired t = 1.06, p = 0.31; Fig. 1C). Total 
fluorescence intensity was significantly correlated with the size of metastases (R2 = 0.92 
for the 24 h group, R2 = 0.96 for the 48 h group). Measurements on the IVIS Spectrum 
were in concordance with the visual information provided by the Fluobeam system 
(data not shown). Sectioning of tumor and liver tissue showed a clear demarcation 
of fluorescence signal at the tumor border, which was confirmed by fluorescence 
microscopy (Fig. 2). 
Figure 1. NIr fluorescence detection of colorectal liver metastases using IntegriSense680: a. Intraoperative 
NIR fluorescence detection of a 1.2 * 5 mm CC531 colorectal liver metastasis in a male rat 24 h after injection of 
12 nmol IntegriSense680. Camera exposure time was 15 ms. b. The NIR fluorescence signal of colorectal liver 
metastases and healthy liver tissue is plotted for rats injected with IntegriSense680 after 24 h (N = 3 rats, 7 tumors) 
and 48 h (N = 4 rats, 9 tumors). P values represent paired t-test comparisons. C. Tumor-to-background ratio is 
plotted for rats injected with IntegriSense680 after 24 h and 48 h. There was no significant difference between the 
groups (unpaired t-test, t = 1.06, p = 0.31).
A CB
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biodistribution of IntegriSense680
To assess the potential use of IntegriSense680 in intraoperative identification of 
colorectal metastases in close proximity to other organs in the peritoneal cavity, 
the NIR fluorescence intensity of abdominal organs was quantified 24 and 48 hours 
after injection of IntegriSense680 using the Fluobeam system (Fig. 3). All abdominal 
organs showed fluorescence intensity levels comparable to or lower than the liver. No 
difference was observed between measurements at 24 and 48 hours after injection. 
Intraoperative detection of intra-peritoneal metastases
The sufficiently low fluorescence levels of abdominal organs suggest a potential use of 
IntegriSense680 for identification of peritoneal colorectal metastases. In all animals, 
the peritoneal cavity was carefully inspected for tumor deposits. In several animals, 
several suspected tumors were found in the mesentery (Fig. 4). These nodules were 
Figure 2. ex vivo NIr fluorescence imaging of a colorectal liver metastasis: Shown are a color image (left), a 
NIR fluorescence image (middle left), and a pseudocolored green merge (middle right) of a 0.9 * 1.8 cm CC531 
colorectal liver metastasis within an excised liver lobe. Imaging was performed 48 h after injection of 12 nmol 
IntegriSense680. Camera exposure time was 10 ms. The distance between two major ruler ticks is 1 cm. Ex vivo 
fluorescence microscopy (right) of a freshly resected liver lobe containing a CC531 colorectal liver metastasis 
after incubation with Hoechst (dsDNA, pseudo-colored blue) and phalloidin-AlexaFluor488 (F-actin filaments, 
pseudo-colored green). The IntegriSense680 signal is pseudo-colored red. The dashed line indicates the transition 
zone between the normal liver (left bottom corner) and the liver tumor (right upper corner). 
Figure 3. In vivo biodistribution of IntegriSense680: Fluorescence intensity of colorectal CC531 liver 
tumors and abdominal organs was measured using the Fluobeam camera system in two rats before (level of 
autofluorescence), 24 h and 48 h after administration of 12 nmol IntegriSense680. Camera exposure time was 10 
ms. Bars represent mean ± SD. 
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fluorescent and were confirmed as malignancies by histological analyses. Total 
fluorescence was significantly correlated with the size of mesenterial metastases (R2 




We have demonstrated the potential use of the NIR fluorescence probe IntegriSense680 
for intraoperative tumor identification in both colorectal metastases confined to the 
Figure 4. NIr fluorescence imaging of colorectal CC531 mesenterial metastases using IntegriSense680 and 
the intraoperative camera system:  Shown are a color image (top left), a NIR fluorescence image (top middle), 
and a pseudocolored green merge of the two images (top right) of a part of the jejunum and accompanied 
mesentery of a rat bearing multiple CC531 mesenterial metastases. A – E indicate suspected metastases, LN 
indicates mesenteric lymph nodes, Neg indicates area selected as negative control). Imaging was performed 24 h 
after injection of 12 nmol IntegriSense680. Camera exposure time was 20 ms. The distance between two major 
ruler ticks is 1 cm. H&E staining (bottom left) of a 4 µm formalin-fixed, paraffin-embedded tissue section of the 
metastasis indicated by B (dashed square, top right). The size, NIR fluorescence measurements and presence of 
tumor cells of the indicated regions (top right) are tabulated at the bottom right panel. Total NIRF is the total NIR 
fluorescence signal of the region-of-interest. Average NIRF is the total NIR fluorescence signal of the region-of-
interest divided by the area. Total NIR fluorescence was significantly correlated with the size of the metastases 
(R2 =  0.99).
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liver and metastases elsewhere in the peritoneal cavity. To our knowledge, the current 
study is the first study on targeting liver metastases using a targeted NIR fluorophore. 
NIR fluorescence imaging within the peritoneal cavity is often hampered by high levels 
of background fluorescence. Despite these difficulties, IntegriSense680 provided an 
adequate tumor-to-background ratio to identify tumors in the vicinity of abdominal 
organs. The targeting ligand of IntegriSense680 is a non-peptide integrin αvβ3 antagonist 
that is derived from the full-length RGD tripeptide.20 This non-peptide molecule has 
a significantly improved affinity in comparison with the full-length RGD peptides, 
which have been used in imaging studies.10, 25-27 No difference was observed between 
imaging 24 hours post administration and imaging 48 hours post administration. 
This broad window of intraoperative imaging facilitates flexible operation planning in 
future clinical applications. 
Peritoneal metastases
In the current study, we were able to detect both liver and peritoneal metastases. 
Although the model is set up as a liver tumor model, some rats also developed peritoneal 
metastases, particularly those bearing larger liver tumors. Peritoneal spreading of 
tumor cells could have derived from tumor spill during the inoculation procedure 
or “real” metastases from large liver tumors.28 Although, this may be a biologically 
relevant difference, it possesses no alteration for the purpose of the current study. 
During the experiments, no clinically evident intra-abdominal or lung metastases 
were found that were not NIR fluorescent. 
It is well known that small metastases can easily be missed on preoperative 
imaging studies, as CT or MRI. Previously, a minimal detectable number of tumor 
cells of approximately 13,000 was reported with the CC531 colorectal cancer cell line 
and NIR fluorescence imaging,21 reflecting submillimeter tumor depositions. NIR 
fluorescence imaging could therefore potentially be used in the clinic as an adjunct to 
preoperative staging, for intraoperative detection of metastases that were not observed 
on preoperative tumor dissemination imaging. 
Clinical implications
Integrin αvβ3 as a targeting ligand has been studied extensively in a preclinical 
setting.18, 29, 30 Several clinical studies have been performed using integrin αvβ3 as 
a target for radioimmunotherapy in breast cancer and glioblastoma patients.11, 25 
Although radiotracers are potentially useful for diagnosis and treatment by means 
of radioimmunotherapy, their applicability during surgery is limited due to a lack of 
intraoperative visualization of the tracer. Nonetheless, these studies suggest a successful 
introduction of integrin αvβ3 as a targeting ligand for NIR fluorescence image-guided 
surgery in the clinic, which will enable real-time, intraoperative visualization of tumor 
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cells. A major hurdle to be taken is clinical approval of novel NIR fluorophores. Currently, 
indocyanine green and methylene blue are the sole NIR fluorophores available for 
clinical applications. Both compounds have suboptimal properties for intraoperative 
applications and both are not easily conjugated to a targeting ligand. Ishizawa and 
colleagues have demonstrated the possibility of intraoperative identification of 
colorectal liver metastases after intravenous injection of indocyanine green.31 In this 
study, colorectal liver metastases displayed a fluorescence pattern described as “rim 
fluorescence”, where the tumor itself is not fluorescent, but the surrounding liver 
tissue is. Ishizawa et al suggest that this is caused by decreased biliary excretion of 
indocyanine green around the tumor. Whereas this is an interesting observation for the 
detection of hepatic colorectal metastases, the mechanism exploited for this purpose 
(biliary excretion) prevents this from being used for extra-hepatic intra-abdominal 
colorectal metastases. This is of particular importance, as the detection of extra-
hepatic metastases is a determining factor for clinical decision making. Furthermore, 
the efficacy of this probe for tumor imaging is strongly dependent on biliary excretion 
and liver function, limiting its applicability in some patients. Many research groups are 
working on advancing novel NIR fluorescence fluorophores to the clinic. When these 
agents become available for clinical testing, NIR fluorescence image-guided surgery 
will have the potential to greatly improve surgical practice and patient outcome.
CoNCLuSIoN
NIR fluorescence image-guided surgery has the potential to improve surgical 
oncology by addressing one of its most fundamental challenges, the complete and en 
bloc resection of tumors. The current study demonstrates the feasibility of employing 
a novel NIR fluorescence contrast agent, IntegriSense680, for the intraoperative 
detection of colorectal metastases in a syngeneic rat model. Clinical translation of 
NIR fluorescence agents such as IntegriSense680 is pivotal for improving the quality 
of cancer surgery.
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a syngeneic rat model of primary breast 
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abStraCt
Tumor involvement of resection margins is found in a large proportion of patients 
who undergo breast-conserving surgery. Near-infrared (NIR) fluorescence imaging 
is an experimental technique to visualize cancer cells during surgery. To determine 
the accuracy of real-time NIR fluorescence imaging in obtaining tumor-free resection 
margins, a protease-activatable NIR fluorescence probe and an intraoperative camera 
system were used in the EMR86 orthotopic syngeneic breast cancer rat model. 
Influence of concentration, timing and number of tumor cells were tested in the 
MCR86 rat breast cancer cell line. These variables were significantly associated with 
NIR fluorescence probe activation. Dosing and tumor size were also significantly 
associated with fluorescence intensity in the EMR86 rat model, whereas time of 
imaging was not. Real-time NIR fluorescence guidance of tumor resection resulted in 
a complete resection of 17 out of 17 tumors with minimal excision of normal healthy 
tissue (mean minimum and a mean maximum tumor-free margin of 0.2 ± 0.2 mm 
and 1.3 ± 0.6 mm, respectively). Moreover, the technique enabled identification of 
remnant tumor tissue in the surgical cavity. Histological analysis revealed that the 
NIR fluorescence signal was highest at the invasive tumor border and in the stromal 
compartment of the tumor. In conclusion, NIR fluorescence detection of breast 
tumor margins was successful in a rat model. The present study suggests that clinical 
introduction of intraoperative NIR fluorescence imaging has the potential to increase 
the number of complete tumor resections in breast cancer patients undergoing breast-
conserving surgery.
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INtroduCtIoN
Incomplete tumor resections are an important clinical problem in breast cancer 
surgery. Tumor involvement of resection margins is found in 5-40% of patients who 
undergo breast-conserving surgery and these patients require additional surgery or 
intensified radiotherapy.1-4 Furthermore, additional biopsies of the surgical cavity after 
primary resection have been shown to contain residual disease in 10% of patients 
with tumor-free specimen margins.5 As a result, 5-year isolated local recurrences rates 
of 6.7-11% are reported in patients with tumor-free specimen margins treated with 
breast-conserving surgery and radiotherapy.6 The occurrence of local relapse reduces 
the 15-year breast cancer specific and overall survival.6 Consequently, increase of the 
radical resection rate will likely improve breast cancer outcome. Intraoperative real-
time visualization of cancer cells is a promising method to achieve that goal.7
Near-infrared (NIR) fluorescence imaging is an experimental technique that 
can be used to visualize cancer cells during surgery. In current surgical practice, 
surgeons can only rely on palpation and visual inspection. Therefore, the use of NIR 
fluorescence imaging can be of great value, as already demonstrated in patients with 
glioma and liver cancer.8-10 Advantages of NIR fluorescence light (700-900nm) include 
high tissue penetration (up to several centimeters deep) and low autofluorescence 
providing sufficient signal-to-background ratio.11 Moreover, as the human eye is 
insensitive to NIR wavelengths, the use of NIR light will not interfere with the surgical 
field. 
NIR fluorescence probes can target tumor cells through several mechanisms. 
For example, fluorophores can be conjugated to a tumor-specific antibody (e.g. 
directed to the Her-2/neu receptor), labeled to glucose derivates in order to visualize 
elevated metabolic rate, or autoquenched fluorophores can be activated by enzymatic 
cleavage in order to become fluorescent. The latter is of particular interest as certain 
enzyme systems are upregulated by a wide variety of cancer types, thus providing 
a more universally applicable NIR fluorescence probe. Proteolytic enzymes and 
in particular cathepsins from the cysteine protease family are a good candidate as 
they play essential roles in tumor growth, angiogenesis, resistance to apoptosis, 
and invasion.12, 13 A member of this family, cathepsin B, is commonly active in the 
tumor microenvironment in various human cancers including breast cancer.12, 14-16 
Upregulated expression of cathepsin B is found in tumor, endothelial and immune 
cells, in particular macrophages.13 Cathepsin B overexpression in human breast 
carcinomas is associated with poor differentiation, lymph node involvement, absence 
of estrogen receptor expression and impaired overall survival.17, 18 
The protease-activatable NIR fluorescence probe ProSense (PerkinElmer, 
Waltham, USA) has been shown to detect a variety of tumors in nude or transgenic 
mice.19-31 However, as tumor progression and metastasis are regulated by the 
surrounding microenvironment, it is important to use syngeneic animal models 
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that allow appropriate crosstalk at the invasive tumor border to study probes that are 
activated by proteolytic activity. Moreover, the use of a larger animal model such as the 
rat offers more challenges in terms of tissue penetration of NIR fluorescence probes. 
Therefore, the aim of this study was to assess the technique of NIR fluorescence 
imaging in a syngeneic breast cancer rat model using ProSense and to determine the 
accuracy of intraoperative tumor detection to obtain an adequate tumor-free resection 
margin.
MaterIaLS aNd MetHodS
breast cancer cell line and culture conditions
The MCR86 cell line is a rapidly growing, syngeneic breast cancer cell line derived 
after subcutaneous transplantation of macroscopic lung tumors, which developed in 
a female WAG/Rij rat after intravenous inoculation of MCR83 breast cancer cells.32 
Tumor cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine 
(Gibco, Invitrogen Ltd, Carlsbad, USA), 10% heat-inactivated fetal calf serum, 100 U/
ml penicillin and 0.1 mg/ml streptomycin sulphate.
breast cancer model and tumor induction 
The related EMR86 model is a transplantable, hormone-dependent, metastasizing 
mammary carcinoma that originated in a female WAG/Rij rat bearing a subcutaneously 
implanted estrogen pellet and is developed by our research group (Fig. 1a).33 Tumors 
are only induced and maintained in rats carrying estrogen pellets, whereas tumors 
transplanted into non-estrogenized animals do not grow out. Removal of the 
estrogen pellet induces apoptosis and tumor regression (Fig. 1b). EMR86 tumors are 
histologically classified as high-grade invasive ductaltype adenocarcinomas, with both 
a cribiform and a solid growth pattern. In large tumors areas, comedo type necrosis 
can be appreciated. Tumors have a stromal compartment of approximately 30% 
depending on tumor size (Fig. 1c). EMR86 tumor cells show strong nuclear expression 
of the estrogen and progesterone receptor in more than 90% of cells, but stain negative 
for HER2/neu receptor (Fig. 1d-f). Therefore, EMR86 tumors closely resemble the 
luminal A molecular subtype – the most prevalent subtype of human breast cancer.34, 35 
For tumor induction, fresh EMR86 tumor fragments of 0.5-1 mm3 were 
implanted in the mammary fat pad at four sites of female WAG/Rij rats (Charles 
River, Maastricht, the Netherlands) aging 4-6 months. (A stable cell line from EMR86 
tumor has not yet been established successfully, therefore, tumor transplantation is 
used.) During the same session, an estrogen pellet was implanted subcutaneously in 
the intrascapular region of the neck. The in-house generated pellets consist of 2 mm 
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by 3 mm silicone tubes containing 1.5 mg 17 β-estradiol on a 1:3 cholesterol/paraffin 
basis. Tumor volumes were estimated twice weekly using digital calipers by measuring 
three orthogonal diameters of the tumor and multiplying this product by π/6. All rats 
were housed in the animal facility of the Leiden University Medical Center. Pellet food 
and fresh tap water were provided ad libitum. The weight of the animals was followed 
throughout the experiment to monitor their general health state. The Animal Welfare 
Committee of the Leiden University Medical Center approved the study. The study 
was conducted in concordance with the “Guidelines for the Welfare of Animals in 
Experimental Neoplasia” (Second Edition, 1997) available online at http://www.ncrn.
org.uk/csg/animal_guides_text.pdf.
NIr fluorescence probe
The commercially available, protease-activatable NIR fluorescence probes 
ProSense680 and ProSense750 were used (PerkinElmer). The probes consist of a 
synthetic graft polymer composed of poly-L-lysine that is sterically protected by 
multiple methoxypolyethylene glycol side chains and to which multiple fluorophores 
are attached.19 In this non-activated state, the fluorophores are positioned in close 
proximity to one another, which results in mutual energy transfer and thus inhibition 
of fluorescence emission. After enzymatic cleavage of the backbone, the fluorophores 
Figure 1. description of a syngeneic rat model of hormone-dependent breast cancer: a. EMR86 breast tumors 
originate after transplantation of 0.5 mm3 fresh tumor fragments at the mammary fat path of female Wag/Rij 
rats. Shown is a tumor four weeks after transplantation. b. EMR86 tumors are only induced and maintained in 
rats carrying estrogen pellets. Removal of the estrogen pellet induces apoptosis and tumor regression (N = 16 
tumors, 4 rats). C. EMR86 tumors are histologically classified as high-grade invasive ductal carcinomas, with both 
a cribiform and a solid growth pattern. Tumors have a stromal compartment of approximately 30% depending on 
tumor size.  d-F. EMR86 tumor cells show strong nuclear expression of the estrogen and progesterone receptor 
in more than 90% of cells, but stain negative for HER2/neu receptor. Therefore, EMR86 tumors closely resemble 
the luminal A molecular subtype.
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are released and regain their fluorescent characteristics. A number of cysteine 
proteases are involved in this process. Cathepsin B, and to a lesser degree cathepsin K, 
L, and S, has been demonstrated to be a major contributor to cleavage and activation 
of ProSense.19 ProSense680 and ProSense750 have peak absorption of 680 nm and 750 
nm, respectively. ProSense680 was selected for intraoperative studies and fluorescence 
microscopy because of the better matching of the laser of the intraoperative camera 
system with the peak excitation of ProSense680. ProSense750 was used for cell line 
experiments and non-invasive animal experiments because of the better spectral 
separation of autofluorescence signal. 
Intraoperative NIr fluorescence camera system
The Fluobeam intraoperative NIR fluorescence camera system (Fluoptics, Grenoble, 
France) used in this study has been described previously by our group.36, 37 Briefly, the 
system is composed of a class 3B laser (100mW) emitting at 690 nm resulting in an 
illumination power of 2.6 mW/cm2. Filtered white light (350-650 nm) provides an 
irradiance of 7x103 lx at the focus level. The emitted fluorescence is collected through 
a high pass filter (> 700 nm) by a 12 bits CCD camera resulting in a system spatial 
resolution of 0.17 mm/pixel. 
experimental design
Cell line experiments
For fluorescence measurements, tumor cells were harvested with a solution of 0.25% 
(w/v) EDTA and 0.25% (w/v) trypsin in Hanks’ Buffered Salt Solution (Sigma-Aldrich, 
St. Louis, USA), washed three times in 0.9% phosphate buffered saline and 200 µL 
complete medium suspensions were made and transferred on a 96-well acrylate 
plate (Greiner Bio-one, Alphen aan de Rijn, the Netherlands, #655090; suitable for 
fluorescence measurements) and kept at 37ºC and 5% CO2. At day 2, cells were washed 
and autoquenched ProSense750 (22.5 to 180 nM, 200 µl) was added. At day 3, cells 
were washed and 200 µl complete medium was added. Also, time-dependent studies 
were performed, during which ProSense750 was added at the indicated time-points 
(8 to 48 h). Fluorescence intensity was measured using the Odyssey NIR fluorescence 
scanning device (LI-COR Biosciences, Lincoln, USA). Overlying grids were drawn 
and fluorescence intensity was measured for each well using the Odyssey software 
(Version 2.1). 
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Animal experiments
Throughout injection, imaging and surgical procedures, rats were anaesthetized with 
inhalation of 2% mixture of isoflurane in oxygen. The rats were constantly monitored 
for the rate of the respiration and depth of anesthesia. Before imaging, rats were 
shaved to reduce absorption of the optical signal. A total of 20 rats bearing 77 primary 
mammary tumors varying in size from 0.01 to 1.8 cm3 were used in this study. 
In a dose-dependent and time-dependent experiment, tumor-bearing rats (N 
= 9) were randomly assigned over three ProSense750 dose groups and intravenously 
injected with 2.5, 5 or 10 nmol ProSense750 (150 µl). Whole-body fluorescence was 
measured 24 h and 48 h after administration of ProSense750 using the IVIS Spectrum 
(Caliper LifeSciences, Hopkinton, USA), which allowed separation of the ProSense750 
signal from the background fluorescence by means of spectral unmixing.38 Acquisition 
settings were kept constant for the different dose groups and on the two consecutive 
days. Total photon counts per second were measured for each tumor using the Living 
Image software (Version 3.0, Caliper LifeSciences) and divided by the tumor volume 
as assessed by digital caliper measurement.
In an intra-operative experiment, tumor-bearing rats (N = 7) were operated 
under direct fluorescence guidance 24 h after intravenous administration of 10 nmol 
ProSense680 (150 µl). NIR fluorescence intensity of exposed tumors and surrounding 
tissues was measured with the Fluobeam intraoperative camera system. Tumor-to-
background ratios were calculated by drawing regions of interest at the tumor and 
at the surrounding tissue by visual interpretation and subsequent measurement of 
fluorescent intensity using the open-source software ImageJ.39 Merged visible light 
and NIR fluorescence light images were created using Adobe Photoshop CS3 Software 
(Version 10.0.1, Adobe Systems Inc., San Jose, USA). In order to determine sensitivity 
and specificity of the intraoperative NIR fluorescence technique, an attempt was made 
to completely remove all tumor tissue while removing as little as possible of the normal 
surrounding mammary fat pad tissue strictly based on the fluorescence signal in 5 of 
these 7 rats. Tumors were removed by sharp dissection. Excised tumors were inked 
with India ink, sliced in two or three parts depending on the size of the tumor and 
fixed overnight in 4% buffered formalin and embedded in paraffin (FFPE) blocks, 
mimicking the standard clinical workflow. After resection of the primary tumor, the 
surgical cavity was inspected with the Fluobeam to detect any remnant fluorescent 
tissue. After resection of all remnant fluorescent spots, random biopsies were taken 
of the surgical cavity from every quadrant in order to determine specificity of the 
technique. In one additional rat an irradical resection was performed intentionally to 
test the Fluobeam’s ability to detect remnant tumor tissue. All specimens were fixed in 
formalin as described above. FFPE tumor sections of 4 µm were air-dried and stained 
with hematoxylin and eosin (H&E). The tumor size, the minimum and maximum 
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tumor-free margin and the presence of tumor in the random biopsies were determined 
by an experienced breast pathologist (V.T.H.B.M.S.).
Fluorescence microscopy
Cell line experiments 
Time-dependent microscopic analysis of ProSense680 activation by cultured MCR86 
cancer cells was performed using the LSM510 Zeiss confocal microscope (Jena, 
Germany, 40x/0,75w Ph2 ACHROPLAN objective). A 633 nm laser was used for 
fluorescence excitation and a 650 nm Long Pass for emission. Cells were cultured in 
3.5 cm petri dishes incubated with 33.3 nM ProSense680 in 3 ml medium. Cells were 
kept at 37ºC and imaged for 4.5 hours. 
Ex vivo tumor imaging 
Freshly excised tumors with a wide rim of surrounding normal mammary tissue of 
rats injected with 10 nmol ProSense680 (N = 3) were halved. From one half, a 2 mm 
section was analyzed using the Odyssey scanning device at 21 µm resolution. Tumor 
border was defined as the outer rim of the tumor and its width was approximately 15% 
of the tumor diameter. The other half was snap-frozen on dry ice and stored at -80ºC. 
Unfixed 20 µm sections were measured for fluorescence using the Odyssey scanning 
device at 21 µm resolution. Processing of sections was performed under reduced light 
conditions to prevent photobleaching. Subsequently, the tissue sections were stained 
with H&E. The fluorescence image and the H&E image were merged using Adobe 
Photoshop enabling detailed analysis of the NIR fluorescence distribution along with 
the histological context. 
Statistical analysis
Statistical analyses and generation of graphs were performed using GraphPad Prism 
software (Version 5.01, La Jolla, USA). Continuous variables were analyzed using 
the (paired) t-test for comparison of two groups and one-way analysis of variance 
(ANOVA) for comparison of more than two groups. To test the effect of two 
independent variables two-way ANOVA was used. Trend analysis and one-tailed 
planned comparisons between adjacent groups were conducted. When the assumption 
of homogeneity of variance was violated (Levene’s test), the Brown-Forsythe F-ratio 
was reported. Pearson’s correlation coefficients R were calculated for correlation 
analyses. All statistical tests were two-tailed and P < 0.050 was considered significant.
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reSuLtS
In vitro activation of ProSense by breast cancer rat cell line
The autoquenched NIR fluorescence probe ProSense680 was activated by MCR86 
breast cancer cells within two hours. Microscopic analysis revealed an intracellular 
localization of activated ProSense680 (Fig. 2a-b). Both incubation time (F(3, 36)=1615, 
P < 0.0001) and concentration of ProSense750 (F(3, 36)=3704, P < 0.0001) significantly 
influenced ProSense750 activation as measured by fluorescence intensity (two-
way ANOVA, Fig. 2c). Also, there was an interaction between incubation time and 
ProSense750 concentration (F(9, 36)=230.4, P < 0.0001), indicating that the difference 
in incubation time within ProSense750 concentration groups influenced ProSense750 
activation. Furthermore, fluorescence intensity was highly correlated with number of 
MCR86 cells (F(4, 10.97) = 39.13, P < 0.0001, R = 0.904; Fig. 2d).
Figure 2. In vitro activation of ProSense by syngeneic breast cancer rat cell line: a,b. Fluorescence microscopy 
(LSM510 Zeiss confocal microscope, 40x objective) of a cluster of MCR86 cells, 1 minute (left panel) and 4.5 h 
(right panel) after incubation with ProSense680 (33.3 nM). C. ProSense750 concentration and incubation time 
both significantly influence NIR fluorescence intensity (4.000 MCR86 cells per well, two-way ANOVA, Odyssey 
scanner). Bars represent mean ± SEM (N = 4). d. NIR fluorescence intensity is positively correlated with number 
of MCR86 cells (45 nM ProSense750, 24 h incubation, R = 0.890, P < 0.0001, Odyssey scanner). Bars represent 
mean ± SEM (N = 8).
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In vivo activation of ProSense by syngeneic rat model of primary breast cancer
EMR86 breast tumors were successfully imaged percutaneously using the IVIS 
Spectrum after intravenous administration of ProSense750 (Fig. 3a-b). To test the 
effect of ProSense750 dose and time of imaging on fluorescence intensity, nine rats 
(N = 35 mammary tumors, mean volume = 0.38 ± 0.36 cm3) were randomly assigned 
to three ProSense750 dose groups and were imaged 24 h and 48 h post-injection. 
In concordance with the in vitro data, ProSense750 dose significantly influenced 
fluorescence intensity (F(2,32) = 3.56, P = 0.04, two-way ANOVA, Fig. 3c). Of note, a 
substantial part of the tumors could not be identified in the 2.5 nmol dose group (24 h: 
4 of 11 tumors, 48 h: 7 of 11 tumors) and the 5 nmol dose group (24 h: 2 of 12 tumors, 
48 h: 3 of 12 tumors), whereas in the 10 nmol dose group all tumors were identified. In 
contrast to the in vitro data, time of imaging did not influence fluorescence intensity 
(F(2,32) = 2.47, P = 0.13, two-way ANOVA, Fig. 3c). Furthermore, there was no 
interaction between time of imaging and ProSense750 dose (F(2,32) = 1.06, P = 0.36), 
indicating that the difference in time of imaging within dose groups did not influence 
fluorescence intensity. Based on these results, a dose of 10 nmol was selected for further 
in vivo testing. Imaging 24 h after administration of ProSense was selected for practical 
purposes. With these settings, fluorescence intensity was significantly correlated with 
tumor volume (R = 0.934, P < 0.0001; Fig. 3d), which was in concordance with the in 
vitro data. 
Intraoperative NIr fluorescence-guided resection of primary breast cancer
Using the Fluobeam intraoperative camera system, all primary breast tumors (N = 26 
tumors, 7 rats) were successfully identified 24 h after intravenous administration of 10 
nmol ProSense680 (Fig. 4a). The technique provided a clear demarcation of tumor and 
surrounding mammary fat pad tissue with a mean tumor-to-background ratio of 2.35 
± 0.37 (paired t-test, t = 14.95, P < 0.0001, Fig. 4b). To determine the accuracy of tumor 
margin detection of the intraoperative NIR fluorescence technique, 17 tumors (N = 
5 rats) were resected completely under direct, real-time NIR fluorescence guidance, 
while removing as little as possible of the normal surrounding mammary fat pad tissue 
and processed for histopathological analysis (Fig. 4c). All 17 tumors were completely 
excised with a mean minimum and a mean maximum tumor-free margin of 0.2 ± 0.2 
mm and 1.3 ± 0.6 mm, respectively (Table 1). Mean pathological tumor size was 5.0 ± 
2.1 mm. In two cases, after resection of the primary tumor, remnant fluorescent tissue 
was detected in the surgical cavity with Fluobeam (Table 1). One specimen contained 
a lymph node with metastatic involvement and the other contained a reactive lymph 
node with abundant macrophage influx but no tumor involvement. This false-
positive finding can be explained by the fact that macrophages show high cathepsin 
B expression.13 After resection of all fluorescent spots, random biopsies were taken of 
41Preclinical intraoperative imaging of breast cancer
the surgical cavity from every quadrant. None of the random biopsies (N = 64, 5 rats) 
contained histologically any tumor cells. These results indicate an excellent accuracy 
of the technique.
In one additional rat, an irradical resection was performed intentionally in order to 
show the Fluobeam’s ability to detect remnant tumor tissue. Remnant tumor tissue 
could be detected and subsequently resected under direct NIR fluorescence guidance.
ex vivo NIr fluorescence microscopy
In order to determine the histological localization of ProSense680, tumors were excised 
with a wide rim of normal mammary tissue 24 h after intravenous administration of 
10 nmol ProSense680 (N = 12 tumors, 3 rats; Fig. 5a). Fluorescence imaging of 2 mm 
thick, fresh tumor slices revealed that the NIR fluorescence intensity was 1.6 ± 0.3 
times higher at the border of the tumor than at its center (paired t-test, t = 4.99, P = 
0.0005, N = 12 tumors; Fig. 5b). In order to obtain more detail about the histological 
Figure 3. In vivo activation of ProSense by syngeneic rat model of primary breast cancer: A. Typical example 
of a spectral unmixed image of an EMR86 tumor-bearing female WAG/Rij rat, acquired 24 h after intravenous 
administration of 10 nmol ProSense750. Shown is the separation of the autofluorescence signal (pseudocolored 
green) and the ProSense750 signal (pseudocolored red; IVIS Spectrum). b. Emission curve plot of the spectrally 
unmixed fluorescence signals from a. demonstrates matching of the tumor signal (red line) with the predefined 
ProSense750 emission curve (blue line), confirming the localization of activated ProSense750 at the tumors. C. In 
a dose-dependent and time-dependent experiment, nine tumor-bearing rats (N = 35 tumors) were randomized to 
three ProSense750 dose groups and imaged 24 h (grey bars) and 48 h (open bars) after intravenous administration 
of ProSense750 using the IVIS Spectrum. Bars represent mean ± SEM. d. Scatter plot of fluorescence intensity 
and tumor volume of the 10 nmol dose group imaged 24 h after intravenous administration of ProSense750 (R = 
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localization of ProSense680, unfixed 20 µm frozen tissue sections were measured for 
fluorescence using the Odyssey and subsequently stained with H&E (Fig. 5c). These 
results showed that NIR fluorescence is mainly located in the stromal compartment of 
the breast tumors and in particular at the tumor border. 
dISCuSSIoN
In the current study, we demonstrated the feasibility of real-time intraoperative NIR 
fluorescence identification of breast tumors in a syngeneic orthotopic breast cancer rat 
model using the protease-activatable probe ProSense. In both the cell line and animal 
experiments, fluorescence intensity was strongly correlated with number of tumor 
cells, tumor size and ProSense dose. In contrast to the in vitro data, time of imaging (24 
h vs. 48 h after administration of ProSense) did not significantly influence fluorescence 
intensity of breast tumors. This is likely a result of the relatively long blood half-life 
of ProSense (half-life in mice 18 h, PerkinElmer website) and may provide flexible 
operation planning in future clinical applications. Histological analysis demonstrated 
Figure 4. Intraoperative NIr fluorescence-guided resection of primary breast cancer and pathological 
assessment: a. Intraoperative NIR fluorescence image showing a 6-mm EMR86 breast tumor in a female WAG/
Rij rat 24 h after intravenous administration of 10 nmol ProSense680 (Fluobeam camera system). Camera 
exposure time was 10 ms.  b. Tumor-to-background ratios were determined in vivo in rats 24 h after intravenous 
administration of 10 nmol ProSense680 (N = 26 tumors, 7 rats). Fluobeam camera exposure time was 10 ms. 
Horizontal lines represent mean ± SD. Mean tumor-to-background ratio was 2.35 ± 0.37. C. Ex vivo color image 
(left panel), NIR fluorescence image (Fluobeam, middle panel) of 3 slices of an EMR86 tumor after resection 
and inking using India ink. The tumor was excised from a rat 24 h after intravenous administration of 10 nmol 
ProSense680. Camera exposure time was 10 ms. Resection margin of the tumor is shown after H&E staining of a 
4 µm FFPE tissue section (right panel).
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that NIR fluorescence intensity of tumors was highest at the invasive tumor border. 
Resection of tumors under real-time NIR fluorescence guidance showed excellent 
accuracy of the technique in the intraoperative detection of tumor margins. These 
results suggest that clinical introduction of intraoperative NIR fluorescence imaging 
using a protease-activatable probe such as ProSense has the potential to increase the 
number of complete tumor resections in breast cancer patients undergoing breast-
conserving surgery. 
Previous studies in which NIR fluorescent and protease-activatable probes were 
tested have utilized xenograft or transgenic mouse models.19-31 A limitation of many 
animal models of breast cancer is that, compared to the human situation, less normal 
mammary tissue is present in relation to tumor size. Therefore, these tumors are easily 
resected by removing all breast tissue. However, this approach does not resemble the 
principles underlying breast-conserving surgery. This study was performed using 
an orthotopic breast cancer model that is syngeneic to immunocompetent female 
WAG/Rij rats. In syngeneic models, tumors are grown in homologous species and 
in the strain in which the tumor has originated. Therefore, these models are more 
representative of the natural tumor-host interaction. Although no preclinical tumor 
model will contain all features of the complex biology of human cancer, this syngeneic 
model has several strengths, including its hormone-sensitivity, cribiform growth 
pattern and its ability to induce regression by estrogen pellet removal. Moreover, this 
model captures several important features of luminal A hormone-dependent, HER2/
neu negative human breast cancer, which is the most predominant subtype of breast 
cancer.34, 35 Another intrinsic limitation of animal models of surgical interventions is 
the potential occurrence of performance bias, because researchers carrying out the 
intervention can not be blinded to the allocated treatment. This form of bias may lead 
to flawed results.40 To surpass these limitations in our study, a one-arm study design was 
chosen using small breast tumors (5.0 ± 2.1 mm). Tumors were excised based on the 
NIR fluorescence signal and examined by a breast pathologist using standard clinical 
methodology. Using this approach, all tumors were completely resected with a mean 
maximum tumor-free resection margin of 1.3 ± 0.6 mm, indicating that a minimal 
amount of normal mammary tissue was resected. Although syngeneic models provide 
a relevant tumor-host interaction, their major drawback is that the tumor cells are 
rodent, and therefore express the rodent homologues of the desired targets. However, 
the main target of ProSense, the cysteine protease family (most particular cathepsin 
B) is strongly conserved amongst mammals.12 Upregulation of cathepsin B has been 
confirmed extensively in human breast cancer.12, 14, 15, 41 It is therefore expected that this 
kind of protease-activated NIR fluorescence probes will be applicable for intraoperative 
NIR fluorescence imaging in a large proportion of breast cancer patients.
Analysis of the histological localization of activated ProSense demonstrated 
that the invasive tumor border exhibited the most intense NIR fluorescence signal. 
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This observation is in concordance with immunohistological analysis of cathepsin B 
reported by others14, 24 and is in line with the pathophysiological role of cathepsins as 
reviewed by Gocheva.42 Cathepsins promote tumor invasion through several possible 
mechanisms. First, they can directly cleave components of the extracellular matrix 
and basement membrane, essentially clearing a path for the migration of tumor 
cells away from the primary tumor. Second, at the cell membrane, cathepsins can 
direct a proteolytic cascade in which they activate other proteases such as matrix 
metalloproteinases and urokinase plasminogen activator, which in turn promotes 
tumor invasion. Third, cleavage of the cell adhesion protein, E-cadherin, at the cell 
surface can disrupt adherens junctions and thus facilitate cancer cell migration and 
invasion.42 Apart from tumor border, NIR fluorescence was higher in the stromal 
compartment of the tumors. This finding is in concordance with Gounaris et al., who 
demonstrated that CD11+ tumor-infiltrating macrophages accounted for 75% of the 
Figure 5. ex vivo NIr fluorescence microscopy of resected breast cancer: a. Ex vivo color image (top panel) 
and NIR fluorescence image (Fluobeam, bottom panel) of an excised EMR86 tumor with surrounding normal 
mammary fat pad. Fluobeam camera exposure time was 10 ms. The tumor was excised from a rat 24 h after 
administration of 10 nmol ProSense680. b. Quantification of NIR fluorescence measurements of tumor tissue 
slices showed that the fluorescence signal was 1.6 ± 0.3 times higher at the border of the tumor than at its center 
(Odyssey scanner, paired t-test, t  = 4.99, P = 0.0005, N = 12 tumors). C. Shown are a color image of H&E staining 
(left panel), a pseudocolored green NIR fluorescence image (middle panel; Odyssey scanner), and a merge of the 
two images (right panel) of a 20 µm frozen section of a 4-mm EMR86 breast tumor with surrounding mammary 





ProSense signal at FACS analysis.29 In summary, as complete resection of breast tumors 
requires adequate visualization of tumor margins, the increased activity of proteolytic 
enzymes at the invasive tumor border provides an excellent target for intraoperative 
NIR fluorescence-guided surgery.     
Future clinical studies will have to provide proof-of-principle of intraoperative 
NIR fluorescence tumor detection. Currently, a number of intraoperative NIR 
fluorescence imaging systems are clinically available and have already been used for 
sentinel lymph node mapping.43-45 It is expected that several tumor-targeting NIR 
fluorescent probes (such as ProSense) will receive regulatory approval within the next 
few years.
A therapeutic challenge of any new breast cancer imaging technology is the 
detection of occult tumor deposits in the breast. These tumor deposits could influence 
surgical decision making, but do not necessarily have a prognostic relevance, because 
in the vast majority of cases postoperative radiation will eradicate these microscopic 
deposits. For instance, in preoperative MR imaging, the identification of additional 
tumor deposits is two to three times higher than the incidence of local recurrence, 
resulting in mastectomies that may not be beneficial to the patient.46 Consequently, 
detection of tumor at the margins would be beneficial, detection of tumor deposits 
beyond the margins, below the cut edge of the lumpectomy cavity, could have the 
potential to increase surgical resection volume (or even mastectomy rates) without 
a benefit in survival. Since the maximum penetration depth for NIR fluorescence 
imaging is currently around 1 cm,47 it is unlikely that intraoperative NIR fluorescence 
imaging will detect occult lesions at several centimeters distance from the primary 
tumor. 
Sensitivity of NIR fluorescence is mostly dependent on photon absorption of 
the tissue, fluorescence excitation power of the light source and concentration of the 
NIR fluorophore in tissue. Required camera exposure times are inversely correlated 
with the amount of fluorescence signal. In the current study, camera exposure times 
of 2-20 ms were used. The field-of-view of the Fluobeam camera system is 7 cm of 
diameter. Therefore, the time needed to evaluate tumor margins and excision cavities 
is at most several seconds. Consequently, this real-time intraoperative technique is 
unlikely to prolong surgical time significantly. 
In conclusion, this study provides preclinical validation of an innovative 
technique in which NIR fluorescence light is used to visualize breast tumors and to 
provide real-time guidance during subsequent resection. Clinical translation of these 
results might be very promising because of high accuracy of the technique, flexible 
surgical planning, increased proteolytic activity at the tumor border and upregulation 
of cathepsin B in a large proportion of breast cancer patients. Therefore, this study 
warrants clinical validation of this technique, once NIR fluorescence probes become 
47Preclinical intraoperative imaging of breast cancer
available for clinical testing, with the ultimate goal to increase the radical resection rate 
of patients undergoing breast-conserving surgery.
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Near-infrared fluorescence imaging of 
liver metastases in rats using indocyanine 
green
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Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) is a 
promising technique to obtain real-time assessment of the extent and number of 
colorectal liver metastases during surgery. The current study aims to optimize dosage 
and timing of ICG administration. 
Materials and methods
Liver tumors were induced in 18 male WAG/Rij rats by subcapsular inoculation of 
CC531 rat colorectal cancer cells into three distinct liver lobes. Rats were divided in 
2 groups: imaging after 24 and 48 hours or 72 and 96 hours after intravenous ICG 
administration. In each time group, rats were allocated to three dose groups: 0.04, 0.08, 
or 0.16 mg ICG. Intraoperative imaging and ex vivo measurements were performed 
using Mini-FLARETM and confirmed by fluorescence microscopy. Fluorescence 
intensity was quantified using the Mini-FLARE software and the difference between 
tumor signal and liver signal (tumor-to-liver ratio; TLR) was calculated.
results
In all 18 rats, all colorectal liver metastases (N = 34), some as small as 1.2 mm, were 
identified using ICG and the Mini-FLARETM imaging system. Average tumor-to-liver 
ratio (TLR) over all groups was 3.0 ± 1.2. TLR was significantly higher in the 72 h 
time group compared to other time points. ICG dose did not significantly influence 
TLR, but a trend was found favoring the 0.08 mg dose group. Fluorescence microscopy 
demonstrated a clear fluorescent rim around the tumor. 
Conclusions
This study demonstrates that colorectal cancer liver metastases can be clearly 
identified during surgery using ICG and the Mini-FLARETM imaging system, with 
optimal timing of 72 h post-injection and an optimal dose of 0.08 mg (0.25 mg/kg) 
ICG. NIR fluorescence imaging has the potential to improve intraoperative detection 
of micrometastases and thus the completeness of resection.
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INtroduCtIoN
With a worldwide annual incidence of approximately 1 million cases and an annual 
mortality of over 500.000 cases, colorectal cancer is the second cause of cancer death 
worldwide.1 The survival of patients with colorectal carcinoma is mostly determined 
by the occurrence of distance metastases. Approximately 30% of patients with CRC 
eventually develop liver metastases.2, 3 When metastases are confined to the liver 
and are resectable, surgical resection can offer a 5-year survival rate of 35-40%.3, 4 
Despite improved surgical techniques, preoperative imaging modalities and improved 
chemotherapy regimens, intrahepatic recurrence rates vary from 11-26%.5-8 This is 
possibly due to an inadequate assessment of the extent of disease before and during 
liver surgery. Currently, the most frequently used imaging modalities to make this 
assessment are computed tomography (CT) and intraoperative ultrasonography 
(IOUS). However, even with the combined use of these modalities, 6-20 % of liver 
metastases can not be identified.9-11 In particular, the detection of small (< 5 mm) 
liver metastases and superficially located liver metastases appears to be difficult.11 New 
imaging modalities are necessary to facilitate a more complete assessment of the extent 
of disease. 
Near-infrared (NIR) fluorescence imaging is a promising technique to 
intraoperatively assess the extent of colorectal liver metastases. Recently, Ishizawa and 
colleagues12 have shown that primary hepatocellular carcinoma and colorectal liver 
metastases could be identified using NIR fluorescence imaging and the NIR fluorescent 
agent indocyanine green (ICG). Colorectal liver metastases could be identified by a 
fluorescent rim around the metastases. They hypothesized that this distinct fluorescent 
pattern is probably based on biliary excretion disorders in the surrounding normal 
liver tissue that is compressed by expanding pressure of the tumor. In their study of 49 
patients, a fixed dose of 0.5 mg/kg ICG was administered preoperatively as part of a 
routine ICG clearance test, which is commonly used in Asia to plan the safe extent of 
hepatectomy. The interval between administration of ICG and surgery varied between 
1 to 7 days. Consequently, the optimal dose of ICG and time of administration before 
surgery remain unclear. 
The goal of our study was to determine the optimal ICG dose and administration 
time before surgery, using a syngeneic rat model of colorectal cancer metastases in 




The colorectal cancer rat CC531 cell line was used for this study. The cell line and 
the induction of liver metastases have been described previously.13 In short, cells were 
cultured in RPMI 1640 supplemented with 2 mM L-glutamine (Gibco, Invitrogen Ltd, 
Carlsbad, USA), 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 0.1 
mg/ml streptomycin sulphate. In order to induce liver metastases, CC531-syngeneic 
male WAG/Rij rats (Harlan, Horst, the Netherlands) weighing approximately 300-
350 g underwent median laparotomy and the liver was mobilized and exposed. 
Subsequently, 125,000 CC531 cells (in 50 µl PBS) were subcapsularly inoculated into 
the left and right main liver lobes and the right accessory liver lobe.13 Four weeks after 
inoculation, metastases ranging from 1.2 to 13.4 mm in size had originated in the liver.
The weight of the animals was followed throughout the experiment to monitor 
their general health state. Throughout tumor inoculation, injection of ICG and 
imaging, the animals were anesthetized with 5% isoflurane for induction and 2% 
isoflurane for maintenance in oxygen with a flow of 0.8 L/min. During anesthesia, the 
respiration rate was constantly monitored. For postoperative analgesia, the analgesic 
buprenorphine (0.1 mg / kg) was used.  The Animal Welfare Committee of the Leiden 
University Medical Center approved the experiments. All animals were housed in the 
animal facility of the Leiden University Medical Center. Pellet food and fresh tap water 
were provided ad libitum.
NIr fluorescent contrast agent
The clinically available NIR fluorescent contrast agent ICG (Pulsion Medical Systems, 
Munich, Germany) was used. Three ICG dose groups were tested: 0.04, 0.08 and 0.16 
mg. Before injection, ICG powder was resuspended in 200 µL sterile water. 
Intraoperative NIr fluorescence imaging system
Imaging of liver metastases was performed using the Mini-FLARETM imaging system 
(described in detail in Chapter 6), which is a miniaturized version of the FLARE™ 
imaging system.14 Briefly, the system consists of two wavelength-isolated light sources: 
a “white” light source, generating 26,600 lx of 400-650 nm light and a “near infrared” 
light source, generating 7.7 mW/cm2 of 760 nm light. Color video and NIR fluorescence 
images are simultaneously acquired and displayed in real-time using custom optics 
and software that separate the color video and NIR fluorescence images. A pseudo-
colored (lime green) merged image of the color video and NIR fluorescence images 
is also displayed. The imaging head is attached to a flexible gooseneck arm, which 
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permits positioning of the imaging head virtually anywhere over the surgical field, and 
at extreme angles. 
experimental design
In a time-dependent and dose-dependent experiment, NIR fluorescence imaging was 
performed in 18 tumor-bearing rats. To minimize surgery-related trauma and distress, 
rats were divided in two groups: imaging after 24 and 48 hours, and imaging after 72 
and 96 hours of ICG administration. In each time group, rats were allocated to three 
dose groups of 0.04, 0.08, or 0.16 mg ICG, which was administered intravenously in 
the penile vein. Each dose group contained 3 rats. ICG dose levels were chosen based 
on clinically relevant doses using human body weight and correspond to doses of 10, 
20 and 40 mg of ICG. The imaging time-points were chosen based on Ishizawa et al.12 
who reported NIR fluorescence imaging is preferably performed at least 24 hours after 
ICG administration. Furthermore, for clinical translation, these time-points must be 
logistically acceptable to use in a clinical setting. For intraoperative imaging, the liver 
and other intra-abdominal organs were exposed after median laparotomy. After the 
first intraoperative imaging session (24 or 72 hours after ICG administration), the 
abdomen was closed in two layers and the animal was imaged again 24 hours later. 
At all time-points, tumor fluorescence and fluorescence of abdominal organs was 
measured.
data analysis
NIR fluorescence data generated with the Mini-FLARETM system were analyzed using 
the Mini-FLARETM software package. Regions-of-interest were drawn on the outline 
of the tumor, liver, kidney, spleen, stomach, small bowel, colon and bladder as traced 
manually by visual interpretation on the white light image. Subsequently, fluorescence 
intensity was automatically calculated and exported to statistical analysis software. 
Fluorescence microscopy
After intraoperative imaging experiments at 48 or 96 hours, the liver was excised 
completely for ex vivo fluorescence measurements. Subsequently, liver tumors were 
sliced in two to examine internal fluorescent patterns using the Mini-FLARETM system. 
Excised tumor slices were snap-frozen on dry ice and stored at -80ºC or were fixed in 
10% buffered formalin overnight, washed in 70% ethanol and subsequently embedded 
in paraffin. Frozen tissue sections were measured for fluorescence using the Nuance 
multispectral imager (CRi, Woburn, USA) mounted on a Leica DM IRE2 inverted 
microscope (Leica, Wetzlar, Germany) and subsequently stained with hematoxylin and 
eosin. White light images where created using the same microscope and subsequently 
merged with fluorescence images.
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Statistical analysis
Statistical analysis and generation of graphs were performed using GraphPad Prism 
Software (version 5.01, La Jolla, USA) and SPSS (version 17.0). Fluorescence intensity 
and tumor size were reported as mean and standard deviation. To test differences 
between dose groups and time groups, repeated measures ANOVA was used with rat 
as random factor and dose, time, and dose by time interaction as fixed effects. When 
the dose by time interaction was not significant, it was subsequently removed from the 
model. Comparisons between doses and between time points were performed using 
least square difference (LSD) adjustment for multiple testing. Statistical tests were two-
tailed and p < 0.05 was considered significant.
reSuLtS
Intraoperative detection of colorectal liver metastases
In 18 rats, syngeneic colorectal liver metastases were induced using the colorectal 
cancer rat cell line CC531. The mean number of metastases per rat was 1.8 ± 0.8 (range 
1 – 3). The mean size of the liver metastases was 5.2 ± 0.3 mm (range 1.2 – 13.4 mm). 
In all 18 rats, all colorectal liver metastases (N = 34) were identified using ICG and the 
Mini-FLARETM imaging system (Fig. 1). 
dose of ICG and time of intraoperative imaging
To determine the influence of ICG dosage and time of imaging, rats were allocated to 
three dose groups and imaged at four time points and tumor-to-liver ratios (TLRs) 
were calculated. At all time-points (24, 48, 72 and 96 hours) and in all dose groups 
(0.04, 0.08 and 0.16 mg), fluorescence intensity of liver metastases was significantly 
higher than the fluorescent intensity of normal liver tissue (P < 0.001). Average TLR 
over all groups was 3.0 ± 1.2. The highest average TLR (4.3 ± 1.8) was reached in the 
0.08 mg dose group and 72 h after intravenous administration (Fig. 2C). 
Repeated measures ANOVA was used to test for differences in TLR between 
dose and time groups. There was a significant effect of time (P < 0.001), but the effects 
of dose (P = 0.12) and dose by time interaction (P = 0.91) were not significant. Dose 
by time interaction was therefore removed from the model. Consequently, the model 
included rat as random factor and dose and time as fixed effects. This model showed 
that the TLR was significantly higher in the 72 h time group compared to the 24 h (P < 
0.001), 48 h (P = 0.001) and 96 h (P = 0.004) time groups (Fig. 2D). Also, the TLR was 
significantly higher in the 96 h time group compared to the 24 h group (P = 0.049). 
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ICG dose did not significantly influence TLRs, but a trend was found favoring the 0.08 
mg dose group (0.08 vs. 0.04, P = 0.06; 0.08 vs. 0.16, P = 0.09). 
Figure 1. Intraoperative detection of colorectal liver metastases using NIr fluorescence: Shown are a color 
image (left), a NIR fluorescence image (middle) and a  pseudo-colored green merge (right) of two CC531 
colorectal liver metastases intraoperatively detected using NIR fluorescence in a male rat 72 h after injection of 
0.08 mg indocyanine green. 
Figure 2 - dose of ICG and timing of intraoperative imaging: a. Fluorescent intensity of the liver in 18 rats 
injected with 0.04, 0.08 or 0.16 after 24, 48, 72 and 96 h. b. Fluorescent intensity of all liver tumors (N = 34) in 
18 rats injected with 0.04, 0.08 or 0.16 mg ICG after 24, 48, 72 and 96 h. C. Average tumor-to-liver ratios and 
standard deviations are plotted for all liver metastases (N = 34) in 18 rats injected with 0.04, 0.08 or 0.16 mg ICG 
after 24, 48, 72 and 96 h. d. Estimated marginal means of tumor-to-liver ratio for rats injected with 0.04, 0.08 
or 0.16 mg ICG after 24, 48, 72 and 96 h using the repeated measures ANOVA and least square difference (LSD) 
adjustment for multiple testing. This model showed that the tumor-to-liver ratio was significantly higher in the 
72 h time group compared to the 24 h (P < 0.001), 48 h (P = 0.001) and 96 h (P = 0.004) time groups. ICG dose 
did not significantly influence tumor-to-liver ratios, but a trend was found favoring the 0.08 mg dose group (0.08 




biodistribution of indocyanine green
Fluorescent intensity of the metastases, liver, kidney, stomach, spleen, small bowel, 
colon and bladder was measured at all time points and in all dose groups (data not 
shown). 
Repeated measures ANOVA was used to test for differences in fluorescent 
intensity of the liver (Fig. 2A) and liver metastases (Fig. 2B) between dose and time 
groups. Dose by time interaction did not significantly effect liver signal (P = 0.1) and 
metastases signal (P = 0.125) and was therefore removed from the model. There was 
a significant effect of time on both liver signal (P < 0.001) and liver metastases signal 
(P < 0.001). No significant effect of dose was found on liver signal (P = 0.061) and 
metastases signal (P = 0.152). This model showed that liver signal and metastases 
signal were both significantly higher in the 24 h group compared to all other time-
points (P < 0.001). 
NIR fluorescence intensity of all organs except for the stomach, colon and 
the small bowel, was lower or equal to the liver signal. Fluorescence intensity of the 
stomach, colon and small bowel was significantly higher compared to other organs 
and had a maximum at 48 and 72 hours.
Microscopic distribution of ICG in liver metastases
To determine the precise location of ICG in the vicinity of the tumor, sliced liver 
metastases were examined for internal fluorescent patterns using the Mini-FLARETM 
system. In all liver metastases a clear fluorescent rim around the tumor was found. 
Frozen tissue sections were examined using the Nuance multispectral imager (CRi, 
Woburn, MA) mounted on a Leica DM IRE2 inverted microscope (Leica, Wetzlar, 
Germany). A clear fluorescent rim was found in stromal tissue in the transition area 
between tumor and normal liver tissue in all liver metastases. In this area, multiple cell 
types that are involved in tissue inflammation (e.g. granulocytes, lymphocytes) were 
found (Fig 3). 
dISCuSSIoN
In the present study, significant differences in TLR were shown between four different 
time points after ICG administration, with an optimal time of imaging of 72 h after ICG 
administration. No significant effects were found with regard to dose level; however, a 
trend was shown favoring 0.08 mg. Moreover, all liver metastases, even as small as 1.2 
mm, could be clearly identified during liver surgery using clinically available ICG and 
the Mini-FLARETM system in this syngeneic rat model.
Highest TLRs were reached 72 h after ICG administration. Fluorescence 
intensity of the liver and the liver metastases were also examined separately. Fluorescent 
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intensity of the liver decreased strongly after 24 h and was not dose dependent. 
Fluorescent intensity of the liver metastases also decreased strongly at 48 h, but a 
small, non-significant peak was found at 72 h. This small peak can be explained by 
the re-uptake of ICG in the small bowel as part of the enterohepatic circulation and 
subsequent passage through the bowel tract, hence the highest TLR at 72 h. 
Regarding ICG dosage, a trend was found favoring the 0.08 mg ICG group. 
Extrapolating to human body weight, this dose corresponds to a dose of 20 mg ICG, 
which is frequently used in a clinical setting. To optimize this technique in clinical 
practice, a dose-finding study is imperative. As ICG is already clinically available and 
FDA-approved, a straightforward translation of our results to the clinic can be made.
It is known that a substantial part of liver metastases, mainly the small (< 5 mm) 
and superficially located, can not be identified using conventional imaging modalities 
such as CT or IOUS. Size of metastases in the present study varied from 1.2 to 13.4 
mm of which 50 % were smaller than 5 mm.  This emphasizes that ICG fluorescence in 
liver surgery might be of great value in detecting small colorectal liver metastases. As 
the currently used preclinical animal model only generated colorectal liver metastases, 
future clinical studies will have to determine the ability of this technique to discriminate 
between malignant and benign lesions of the liver.
Since maximum penetration depth of NIR fluorescence is currently up to 1 cm, 
identification of non-superficially situated liver metastases will be more challenging. 
Figure 3 – Fluorescent microscopy of a colorectal liver metastasis: Shown are a hematoxylin and eosin staining 
(top left), a pseudo-colored green NIR fluorescence image (top middle) and pseudo-colored green merge (top 
right) of a 20 µm frozen tissue section of a colorectal liver metastasis. Furthermore, a phase image (bottom left), 
a pseudo-colored red NIR fluorescence image (bottom middle) and a pseudo-colored red merge (bottom right) 
of a 20 µm frozen tissue section of a colorectal liver metastasis is shown. The fluorescent rim in stromal tissue in 
the transition area between tumor and normal liver tissue can be clearly identified.
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Therefore, intraoperative ICG fluorescence must be regarded as a complement on 
currently used conventional imaging modalities as IOUS and CT. Improvements in 
imaging systems, NIR fluorescence contrast agents and software and reduction in 
background fluorescence may facilitate NIR fluorescence imaging of deeper located 
metastases.
The currently used technique to detect liver metastases using NIR fluorescence 
and ICG is based on the clearance capacity of the liver. It has been described that 
in patients with a cirrhotic liver, or in patients pretreated with chemotherapy, the 
liver function and clearing capacity can be reduced. A reduced liver function could 
also affect the clearance of ICG, which can result in a higher background signal and 
therefore lower contrast. However, it has been shown that even cirrhotic livers have 
an extensive clearance capacity.15 This implies that the currently used technique can 
probably be used in subjects with a reduced liver function. Though, in these patients, 
the optimal time interval between ICG administration and imaging could be longer. 
Future clinical studies have to elaborate on this topic. 
A recent development in liver surgery is the introduction of laparoscopic 
surgery. NIR fluorescence can be of great value, also in laparoscopic surgery, since 
palpation of the liver is not possible and the surgeon can only rely on visual inspection 
and preoperative imaging. To anticipate on this potential new application, laparoscopic 
NIR fluorescence camera systems are presently being developed and tested.16, 17 
In summary, this study demonstrates clear identification of colorectal liver 
metastases during surgery using the clinically available NIR fluorescent agent ICG 
and the Mini-FLARETM system. Imaging 72 h after administration of 0.08 mg ICG 
provided the highest TLRs. In particular, the ability to detect small (< 5 mm) and 
superficially located metastases can be of great value during liver surgery. When the 
current intraoperative identification of colorectal liver metastases can be improved 
using this technique, the resection can potentially be performed more accurately and 
preoperatively missed metastases can be involved in surgical decision making.
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Sentinel lymph node (SLN) mapping in colorectal cancer may have prognostic and 
therapeutic significance, however, currently available techniques are not optimal. We 
hypothesized that the combination of invisible near-infrared (NIR) fluorescent light 
and ex vivo injection could solve remaining problems of SLN mapping in colorectal 
cancer.
Methods
The FLARE™ imaging system was used for real-time identification of SLNs after 
injection of the NIR lymphatic tracer HSA800 in the colon and rectum of (n = 4) pigs. A 
total of 32 SLN mappings were performed in vivo and ex vivo after oncologic resection 
using an identical injection technique. Guided by these results, SLN mappings were 
performed in ex vivo tissue specimens of 24 consecutive colorectal cancer patients 
undergoing resection.
results
Lymph flow could be followed in real-time from the injection site to the SLN using NIR 
fluorescence. In pigs, the SLN was identified in 32/32 (100%) of SLN mappings under 
both in vivo and ex vivo conditions. Clinically, SLNs were identified in all patients (n 
= 24) using the ex vivo strategy within 5 minutes after injection of fluorescent tracer. 
Nine patients showed lymph node involvement (N1-disease).  In one patient, a 3 mm 
mesenteric metastasis was found adjacent to a tumor-negative SLN.
Conclusions
The current pilot study shows proof of principle that ex vivo NIR fluorescence-guided 
SLN mapping can provide high-sensitivity, rapid, and accurate identification of SLNs 
in colon and rectum. This creates an experimental platform to test optimized, non-
FDA-approved NIR fluorescent lymphatic tracers in a clinical setting.
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INtroduCtIoN
The prognosis and quality of life for patients suffering from colorectal cancer 
(CRC) depends on the extent and quality of surgical treatment. Apart from tumor 
characteristics (i.e. stage, differentiation grade), complete surgical removal with en 
bloc regional lymphadenectomy is pivotal for patient prognosis. Metastatic spread to 
regional lymph nodes is one of the most important prognostic factors and determines 
the need for adjuvant chemotherapy. The sentinel lymph node (SLN) is the first lymph 
node that receives lymphatic drainage from a tumor, and identification of the SLN 
and analysis for tumor involvement should predict the status of the remaining lymph 
nodes. The SLN procedure is regarded standard of care in the treatment of breast 
cancer1, 2 and melanoma.3 However, its added value in colorectal cancer has not yet 
been established. 
Retrospective studies on micrometastatic disease in CRC and the risk of 
recurrence are conflicting.4-6 Our group has previously shown that ultra-staging of 
lymph nodes with RT-PCR identifies a subgroup of pN0 patients with an inferior 
prognosis.7 However, this methodology is labor intensive and not used routinely. 
Identifying the SLN in the surgical specimen provides the pathologist with an 
opportunity to optimally stage the lymphatic basin beyond standard H&E analysis 
of the regional nodes.8 Published results on identifying SLN in CRC show variable 
success rates ranging from 58 to 100 percent.9-17 Consequently, there is ample room for 
improvement of mapping methodology.
In the majority of published studies of CRC patients, subserosal, circumferential, 
and peri-tumoral injection of the visible dye isosulfan blue has been used, both in vivo 
and ex vivo.11, 12, 14, 18 Isosulfan blue is distributed rapidly through the afferent lymphatic 
channels, however, due to its small size, the dye particles can readily diffuse through 
the true SLN to second and third tier nodes (a total of up to 21 “sentinel” nodes are 
reported). 15  Isosulfan blue also stains tissue in an unnatural color and provides poor 
overall contrast. 
Dyes that emit fluorescence in the invisible, near-infrared (NIR) portion of the 
electromagnetic spectrum (700 to 900 nm) have several advantages for SLN mapping. 
NIR light penetrates relatively deep into living tissue, and tissue itself has low 
autofluorescence in the NIR, resulting in a high signal-to-background ratio.19 Since 
NIR light is not visible to the human eye, there is no change to the look of the surgical 
field. Several clinical studies have been published on SLN mapping in breast cancer, 
gastric cancer and colon cancer, using the clinically available NIR probe indocyanine 
green.20-24 However, these studies were performed using imaging systems that display 
the NIR signal without the visible image as a surgical anatomical reference. Our group 
has developed a system (FLARE™) that is capable of displaying NIR signal and visible 
image (captured by a color video camera) simultaneously and can superimpose the 
NIR signal over the color image.25, 26
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Previously, our group reported the use of NIR light for real-time intraoperative 
SLN mapping of the gastrointestinal tract.27, 28 These and earlier studies show clear 
advantages of NIR imaging over the conventional blue dyes.29 Of published organic 
molecules, the NIR fluorophore HSA800 emerged as the molecule with the best 
overall performance with respect to entry to the lymphatics, flow to the SLN, retention 
in the SLN, fluorescence yield, and reproducibility. Since HSA800 cannot be translated 
to the clinic without a long and costly regulatory process, we hypothesized that ex 
vivo SLN mapping in colon and rectal cancer could provide all of the benefits of NIR 
fluorescence imaging over visible blue dyes, without the need for regulatory approval, 
and without risk to the patient.
MaterIaLS aNd MetHodS
Lymphatic tracers
The preparation of HSA800 (IRDye 800CW conjugated to human serum albumin) has 
been described in detail previously.27 The ratio of fluorophore (IRDye 800CW; LI-COR, 
Lincoln, USA) to albumin (HSA) was 3:1, estimated using the extinction coefficients 
of HSA (ε280nm = 32,900 M
-1cm-1) and CW800 (ε778nm = 240,000 M
-1cm-1) in PBS. Peak 
absorbance and emission of HSA800 were 778 nm and 795 nm, respectively. A stock 
solution of 10 µM (in pig) or 50 µM (in human) HSA800 in phosphate-buffered saline 
(PBS), pH 7.4 was used for all injections. 
real-time NIr fluorescence imaging
Preclinical SLN mapping was performed using the FLARE™ image-guided surgery 
system as described in detail previously.26 The system is shown schematically in Figure 
1. It consists of two wavelength isolated light sources: a “white” light source, generating 
40,000 lx of 400-650 nm light and a “near infrared” light source, generating 12.5 
mW/cm2 760 nm light over a 15 cm field of view. Color video and NIR fluorescence 
images are simultaneously acquired and displayed in real-time using custom optics 
and software that separate the color video and NIR fluorescence images.26 A pseudo-
colored (lime green) merged image of the color video and NIR fluorescence images is 
also displayed. Clinical SLN mapping was performed using a miniaturized version of 
FLARE™ (Mini-FLARE™), which is described in detail in Chapter 6, with settings of 
20,000 lx of 400-650 nm “white” light and 7 mW/cm2  of 760 nm NIR light.
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animal model systems
Animals were housed in an AAALAC-certified facility staffed by full-time veterinarians 
and were studied under the supervision of an approved institutional protocol. This 
protocol adhered to the “Guide for the Care and Use of Laboratory Animals”, NRC 
1996. 4 female Yorkshire pigs were purchased at 35 kg from E.M. Parsons and Sons 
(Hadley, USA). All animals acclimated to the animal facility for at least 48 hr prior 
to experimentation. Anesthesia was induced with 4.4 mg/kg intramuscular Telazol 
(Fort Dodge Labs, Fort Dodge, USA). The animal was then intubated and anesthesia 
was maintained with 2% isoflurane (Baxter Healthcare Corporation, Deerfield, USA). 
ECG, heart rate, oxygen saturation and body temperature were monitored throughout 
the experiment. At the end of each experiment, euthanasia was induced by rapid 
intravenous injection of 10 mL of Fatal-Plus (Vortech Pharmaceuticals, Dearborn, 
USA), a method consistent with the recommendation of the Panel on Euthanasia of 
the American Veterinary Medical Association.
Figure 1. Schematic of the FLare™ Image-Guided Surgery System: The dichroic mirror directs light below 
and above 650 nm to a color video camera and NIR fluorescence camera, respectively, permitting simultaneous 
acquisition of color video and NIR fluorescence images. The surgeon’s monitor includes a pseudo-colored (lime 
green) merge of the two images.
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Preclinical sentinel lymph node mapping in vivo vs. ex vivo
SLN mapping was performed using a 1 cc syringe equipped with a 27-gauge, ½” needle. 
Each injection consisted of 0.1 cc of HSA800 solution injected subserosally, with the 
needle bevel facing upwards. The injection site was then gently massaged to stimulate 
lymphatic flow through increased hydrostatic pressure.
All animals received multiple injections at separate locations in the colon and 
rectum. For each condition (in vivo and ex vivo) 8 injections were performed in colon 
and 8 injections were performed in the rectum, for a total of 32 injections. The NIR 
fluorescence signal was monitored using the FLARE™ system and the SLN identified by 
watching uninterrupted lymphatic flow reach the first lymph node in real-time. After 
successful identification, the suspected lymph node was resected under fluorescence 
guidance, fixed in 2% paraformaldehyde for 12 hours, frozen in LN2 using Tissue-
Tek OCT, cryo-sectioned at 10 µm, and analyzed by hematoxylin and eosin (H&E) 
staining.
After the in vivo injections, a subtotal colectomy and a total mesorectal excision 
(TME) were performed. The resected bowel specimens were placed on a table and at 
locations that were not injected in vivo, 0.1 cc of HSA800 was injected subserosally, 
identical to the technique used for in vivo injections. Tissue samples were also collected 
and processed for histology as described above.
Time needed to identify the SLN was compared between in vivo and ex vivo 
conditions using an unpaired t-test. Assumption of equal variances was confirmed by 
Levene’s test. Statistical analyses, performed using SPSS software version 17.0 (SPSS 
Inc., Chicago, USA), were two-tailed and p < 0.05 was considered significant.
translation to the clinic
Twenty-four consecutive patients undergoing curative intended surgery for colorectal 
cancer were included.  This study was approved by the Leiden University Medical Center 
Medical Ethics Committee and performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975. All patients underwent a standard oncological 
resection including lymphadenectomy. In case of colon cancer, a segmental colonic 
resection was performed; in case of rectal cancer, a resection following the principles 
of the total mesorectal excision (TME) was performed. Directly following resection, 
bowel segments were delivered fresh to the department of pathology, where the 
specimen was opened anti-mesenterically by the pathologist. In rectal cancer, surgical 
quality audit protocol prohibits altering the perirectal fat in any way. Consequently, 
in rectal cancer, the specimen was opened no further than the rectosigmoid junction. 
1 cc of 50 µM HSA800 was injected submucosally circumferentially with a 5 mm 
margin around the tumor and the injection site was massaged for 5 minutes. After 
5 minutes, the specimen was inspected using Mini-FLARE™. Any fluorescent 
71Ex vivo SLN mapping in colorectal cancer
hotspots were either marked with a suture or directly resected for separate fixation 
in 2% buffered formalin. The specimen was fixed using 2% buffered formalin for 24 h 
(colon) or 48 h (rectum). After fixation, fluorescent nodes were identified under direct 
NIR fluorescence guidance with the Mini-FLARE™ and the specimen was processed 
following the standard clinical protocol. For rectal cancer, the specimen was processed 
using the slicing technique as described by Quirke.30 All lymph nodes (sentinel and 
non-sentinel) were paraffin embedded and 4 µm sections were H&E stained and 
subsequently analyzed by microscope for the presence of tumor cells.
reSuLtS
Preclinical NIr fluorescence-guided SLN identification and resection
In both in vivo and ex vivo conditions, all injections led to a successful identification of a 
SLN (Table 1). Shortly after massaging the injection site, lymphatic flow was visualized 
on the NIR fluorescence image (Figure 2). In all cases, lymphatic flow terminated, 
without interruption, in one or more lymph nodes. 
In colon, we found no difference (Table 1) in the time needed to identify the SLN 
between in vivo (56.4 sec on average) and ex vivo (58.8 sec on average) conditions (t = 
-0.111, p = 0.913). In the rectum, however, ex vivo injection lead to a significantly faster 
identification time for the SLN (26.8 sec on average) compared to in vivo (54.1 sec; t = 
2.942, p = 0.011). Mean time between resection of the bowel and ex vivo injection was 
25 min (range 10 to 57 min). All resected specimens (n = 32) were analyzed by H&E 
histology and confirmed to be lymph node tissue (Figure 2B).
Clinical ex vivo NIr fluorescence-guided SLN mapping in colorectal cancer patients
Patient and tumor characteristics are listed in Table 2.
In a preliminary set of experiments on n = 6 clinical specimens, it was found 
that the subserosal injection technique that worked so well with normal pig specimens 
table 1. Preclinical In Vivo and Ex Vivo Identification Rates for SLN Mapping of 
Pig Colon and Rectum with HSA800











  In vivo 8 8 (100%) 9 56.4 ± 48.3
  Ex vivo 8 8 (100%) 8 58.8 ± 36.2
Rectum
  In vivo 8 8 (100%) 10 54.1 ± 16.3
  Ex vivo 8 8 (100%) 9 26.8 ± 21.3
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did not provide reliable results with human tumor specimens (data not shown). 
Injecting subserosally and circumferentially around human tumors resulted in a larger 
injection site, which outshined lymph nodes close to the tumor. To overcome this 
problem, a submucosal injection technique was used.15, 31 It was also found that due to 
the thickness of human specimens versus normal pig specimens, a high concentration 
(50 µM) of HSA800 was optimal.
Using this optimized strategy, in all 24 consecutive patients, the procedure led 
to a successful detection of SLNs. An example of the NIR fluorescence images of the 
procedure in colon cancer is shown in Figure 3A. In rectal cancer, quality control 
dictates that the specimen is not altered prior to inking, fixation and slicing. As shown 
in Figure 3B, in rectal cancer, nodes were harvested successfully after mesorectal 
slicing. Based on pre- and post-fixation images, the formalin fixation process did not 
appear to alter NIR fluorescence of HSA800. On average, per specimen, 3.0 (range 
1 – 5) SLNs were identified by NIR fluorescence (Table 2). On average, a total of 15.9 
(range 8 – 31) lymph nodes were harvested per specimen. Histological analysis showed 
that 9 of 24 patients had lymph node metastases. In all but one of those cases, at least 
one of the SLNs contained tumor cells. In one patient, however, a small tumor deposit 
(3 mm) was found in the mesentery whereas the SLN was tumor-negative. Although 
no clear lymphatic tissue could be identified (Figure 4), pathological guidelines 
(WHO-classification sixth edition) require that this lesion be classified as a lymph 
node metastasis.  
dISCuSSIoN
The presence of lymph node metastases in CRC patients is the most important 
prognostic factor and an indication for adjuvant chemotherapy. The presence of 
nodal involvement decreases 5-year survival rates by 25 to 35%. Long-term follow-up 
of adjuvant chemotherapy for patients with stage III colon cancer showed a survival 
benefit with a 22 to 33% relative reduction in mortality.32, 33 Therefore, adequate staging 
in order to select patients who may benefit from adjuvant chemotherapy treatment is a 
necessity. Moreover, patients without nodal disease (stage I/II) still develop recurrent 
tumors in up to 25% of the cases within 5 years after surgical resection of the primary 
tumor. This could be due to pathological understaging of the tissue specimen at the 
time of primary treatment. SLN mapping would be a useful method to circumvent this 
problem.11  
Contradicting studies have also been published, showing a high false negative 
rate of SLN mapping in colon cancer.34, 35 These so called skip metastases, a tumor 
negative SLN combined with a positive non-SLN, are an important limiting factor to 
the validity of the SLN procedure. In colorectal cancer, skip metastases rates of 3% - 
60% are reported.11, 36 It has been suggested that these variable rates are caused by the 
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applied SLN identification technique, which could be overcome by a more reliable 
method of identifying the SLN.
The current study shows proof of principle that by using invisible NIR fluorescent 
light and an optimal contrast agent, identification of the lymphatic channels and the 
Figure 2. In vivo and ex vivo SLN Mapping in Colon and rectum: a. Identification of the SLN (arrows) in 
pig colon after in vivo (top row) or ex vivo (bottom row) injection (arrowheads) of 0.1 cc of 10 mM HSA800. 
Shown are the color video (left), NIR fluorescence (middle), and pseudo-colored (lime green) merge of the two 
(right). b. Ex vivo identification of the SLN (arrow) after injection (arrowhead) of 0.1 cc of 10 mM HSA800 (top 
row). Resected negative (-) and positive (+) nodes in rectum (bottom row). Shown are the color video (left), NIR 
fluorescence (middle), and pseudo-colored (lime green) merge of the two (right). Note accumulation of the dye 





SLN is rapid and accurate. In the presented preclinical experiments in pigs, both ex 
vivo NIR fluorescence imaging of the SLN as well as in vivo imaging showed similar 
results. These preclinical results were successfully translated into a pilot clinical study 
in which the SLN was identified ex vivo in all patients. Whereas the NIR fluorescent 
signal of subserosal injections outshined lymph nodes located close to the tumor, 
submucosal injections showed superior results in patient specimens. 
In one patient with three tumor-negative SLNs, a small tumor metastasis was 
found in the mesenteric fat, without any remnants of pre-existent lymphatic tissue 
(Figure 4). According to the WHO-classification, sixth edition, such tumor deposits 
are regarded as lymph node involvement. This is supported by the configuration of 
the lesion, being encapsulated and round. Since the lesion was completely effaced by 
tumor cells and lymphatic tissue was not observable, it is plausible that no lymphatic 
drainage could reach this node and in fact the NIR lymphatic tracer had bypassed this 
Figure 4. Palpable Metastatic Lesion Identified 
in the Mesenteric Fat: H&E histological staining 
of a mesenteric metastasis (25X magnification) not 
identified as a SLN. No nodal tissue was observed.
Figure 3. NIr Fluorescence-Guided SLN Mapping in Patients with Colorectal Cancer: a. Ex vivo 
identification of a SLN (arrow) in the mesentery of the right hemicolon of a patient with a cecal adenocarcinoma 
after submucosal peritumoral injection (arrowhead) of 1 cc of 50 mM HSA800. Shown are the color video (left), 
NIR fluorescence (middle), and pseudo-colored (lime green) merge of the two (right). b. Ex vivo identification 
of a SLN (arrow) in the mesorectum of a patient with a rectal adenocarcinoma after submucosal peritumoral 
injection (arrowhead) of 1 cc of 50 mM HSA800. After 48 hours fixation in 2% buffered formalin, tissue specimen 
was sliced and imaged. Shown are the color video (left), NIR fluorescence (middle), and pseudo-colored (lime 
green) merge of the two (right).
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mass. This phenomenon of lymph node effacement is well known for breast cancer 
patients. The fact that no fluorescence could be measured in the paraffin block of the 
lesion supports this hypothesis.
The great advantage of NIR fluorescence imaging is that the lymphatic channels 
traveling to the SLN are clearly visualized in real-time, even deep within the bowel 
mesentery. NIR fluorescence imaging also permits the use of small volumes (1 cc) of 
a colorless dye, and does not alter the appearance of the surgical field. Furthermore, 
the timing constraints of the technique we describe are very flexible, with successful 
identification of the SLN up to 1 hour after resection of the bowel. 
 These results and earlier findings27, 28 suggest that NIR imaging has the potential 
to simplify the SLN procedure in colorectal cancer, when compared to the use of visible 
contrast agents like isosulfan blue. Therefore, larger studies comparing both techniques 
should be performed. The ex vivo approach10 has certain advantages, such as the use 
of contrast agents that are not yet approved for in vivo administration. The agent used 
in our study, HSA800, has previously been compared to clinically available agents like 
indocyanine green and methylene blue and has clear advantages over them.27 Due to 
conjugation of fluorophore IRDye 800CW to human serum albumin (HSA800), the 
hydrodynamic diameter of the probe increases from less than 1 to 7.4 nm, thereby 
facilitating a better retention in the first (sentinel) node as compared to blue dyes.
 Because the agent is not injected into the patient, adverse reactions and patient 
safety are non-issues. Also, because the injection is performed after resection, it is 
not necessary that the surgeon performs the injection. Therefore, this technique does 
not add any time to the surgery, which is beneficial for the patient and could improve 
acceptance of the technique. In our hospital, the fluorescent dye is injected immediately 
after surgery at the department of pathology, thereby eliminating any interference with 
the surgical procedure. Using this technology, it should now be possible to design even 
more effective lymphatic tracers having higher fluorescence intensity and better lymph 
node retention.
The current NIR fluorescence imaging technique does not interfere with routine 
gross pathology and makes it possible to detect the SLN in sliced sections of rectal 
cancer specimens. Although neoadjuvant radiotherapy is known to affect lymphatic 
channels, even in rectal cancer patients that were treated with radiotherapy, SLNs 
were identified. A possible explanation is that only small amounts of HSA800 need 
to accumulate in the lymph node to be detected by the Mini-FLARE imaging system. 
As the mesorectum was not altered in any way, no lymphatic channels were disrupted. 
Furthermore, because lymph flow is induced by massaging the ex vivo specimen, 
decreased lymphatic flow can be overcome.
Compared to published clinical studies on SLN imaging using blue dyes, an 
important difference with the current study is the condition of the injection site. The 
current preclinical study was performed in healthy pigs, whereas the clinical application 
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of this technique was performed in cancer patients. Large tumors are especially known 
to alter and disrupt lymphatic channels. Since earlier studies show that there is still 
sufficient lymphatic flow to identify lymph nodes,12, 37 we did not expect this to be a 
major problem. Viehl and colleagues showed that with larger tumors, a larger amount 
of blue dye (0.5 cc per cm tumor diameter) should be used to identify the SLN.37 This 
observation suggests an advantage for NIR fluorescence imaging, since in our pilot 
clinical study in which the mean diameter of the tumors was 4.5 cm, a smaller amount 
of dye (1 cc) was sufficient to be able to identify a fluorescent signal in the SLN.
In conclusion, our study suggests that ex vivo SLN mapping using an optimal 
lymphatic tracer and invisible NIR fluorescent light permits real-time imaging of 
lymph flow and identification of the SLN in colon and rectal cancer specimens.
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Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer 
requires optimized imaging systems and lymphatic tracers. 
Methods
A small, portable version of the FLARE™ imaging system, termed Mini-FLARE™, 
was developed for capturing color video and two semi-independent channels of NIR 
fluorescence (700 nm and 800 nm) in real-time. Initial optimization of lymphatic tracer 
dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More 
refined optimization was performed in twenty-four consecutive breast cancer patients. 
All patients received the standard of care using 99mTechnetium-nanocolloid and patent 
blue. In addition, 1.6 mL of indocyanine green adsorbed to human serum albumin 
(ICG:HSA) was injected directly after patent blue at the same location. Patients were 
allocated to one of eight escalating ICG:HSA concentration groups from 50 to 1000 
µM. 
results
The Mini-FLARE™ system was positioned easily in the operating room and could be 
used up to 13” from the patient. Mini-FLARE™ enabled visualization of lymphatic 
channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were 
detected: 35 radioactive (100%), 30 blue (86%), and 35 NIR fluorescent (100%). 
Contrast agent quenching at the injection site and dilution within lymphatic channels 
were major contributors to signal strength of the SLN. Optimal injection dose of 
ICG:HSA ranged between 400 and 800 µM. No adverse reactions were observed. 
Conclusions
We describe the clinical translation of a new NIR fluorescence imaging system and 
define the optimal ICG:HSA dose range for SLN mapping in breast cancer.
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INtroduCtIoN
Sentinel lymph node (SLN) mapping, as introduced for the management of breast 
cancer by Giuliano et al,1 is currently regarded as the standard of care for staging of the 
axilla.2 In general, a combination of radioactive colloid and blue dye is used. However, 
this exposes patients and caregivers to ionizing radiation, and blue dyes cannot be seen 
through skin and fatty tissue. Nonetheless, in recent trials, SLN identification rates of 
95-97% are achieved when using this combination, and use of only one agent results in 
significantly lower identification rates.3-6
Recent preclinical and clinical data have demonstrated that near-infrared 
(NIR) fluorescence imaging using the NIR fluorescence agent indocyanine green 
(ICG) enables real-time transcutaneous and intraoperative visualization of lymphatic 
channels and detection of the SLN.7-14 Therefore, NIR fluorescence imaging could 
provide an alternative for, or an addition to, conventional techniques used for SLN 
mapping. However, to date, clinical data are lacking a direct comparison of NIR 
fluorescence to the combination of radioactive tracer and blue dye. Also, even though 
ICG is the only fluorescent agent currently available in the clinic, it is not an optimal 
lymphatic tracer. Previous preclinical work has demonstrated that adsorption of ICG 
to human serum albumin (HSA, complex is ICG:HSA) increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection and 
better retention in the SLN.15 
Recently, first-in-human clinical testing of ICG:HSA was performed.14 The 
Fluorescence-Assisted Resection and Exploration (FLARE™) imaging system, 
developed by our group14, 16 and used in the trial, is a general-purpose optical imaging 
platform that provides the surgeon with two independent NIR fluorescence channels 
(centered at 700 nm and 800 nm) to see otherwise invisible structures within the 
surgical field. The first generation of FLARE™ was large, expensive to build, and had a 
heavy imaging head that required a specially-designed articulated arm.14 This prevented 
shipment of FLARE™ to researchers around the world, and therefore impeded efficient 
scientific investigation. During the first-in-human clinical testing of FLARE™, it also 
became apparent that contrast agents for SLN mapping were not yet optimal. The goals 
of the present study were to develop a miniaturized version of FLARE™, termed Mini-





A detailed description of the Mini-FLARE™ imaging system and in vitro characterization 
is provided in Supplementary Data (available online at http://www.springerlink.com/
content/r4712247933613tv/). For sterile usage in the operating room, a 0.118” thick 
acrylic splash shield having 95% optical transmission at 800 nm was hermetically 
bonded to a clear plastic drape and sterilized (Medical Technique, Inc., Tucson, USA). 
Preparation of Indocyanine Green adsorbed to Human Serum albumin
ICG (25-mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 
mM) stock solution. Various amounts of this stock solution were transferred to a 50 
cc vial of Cealb (20% human serum albumin (HSA) solution; Sanquin, Amsterdam, 
The Netherlands) to yield ICG in HSA (ICG:HSA) at a final concentration of 50 µM, 
100 µM, 200 µM, 400 µM, 500 µM, 600 µM, 800 µM, or 1000 µM. To obtain a final 
concentration of 800 µM and 1000 µM, ICG was resuspended in 5 cc of sterile water, 
to yield a 6.4-mM stock solution prior to dilution.
Pre-Clinical Characterization
Animals were studied under the supervision of approved institutional protocol. 
Female Yorkshire pigs (E. M. Parsons and Sons, Hadley, USA) averaging 35 kg were 
induced with 4.4-mg/kg intramuscular Telazol (Fort Dodge Labs, Fort Dodge, USA), 
intubated, and maintained with 2% isoflurane (Baxter Healthcare, Deerfield, USA). 
Vital signs were monitored continuously. Excitation fluence rate for white light and 
800-nm excitation light were 26,600 lux and 7.7 mW/cm2, respectively. One hundred 
microliters of the specified ICG:HSA solution was injected intradermally. ICG 
concentration of the ICG:HSA complex was systematically increased from 10 µM 
to 500 µM to explore the counteracting effects of NIR fluorophore quenching at the 
injection site and NIR fluorophore dilution within the lymphatic channels. 
dose-optimization Clinical trial
A 24-patient dose-escalation clinical trial was approved by the Medical Ethics 
Committee of the Leiden University Medical Center and was performed in accordance 
with the ethical standards of the Helsinki Declaration of 1975. All patients that had 
planned to undergo a SLN procedure for invasive breast cancer or extensive high-risk 
carcinoma in situ were eligible for participation in the study. Patients had clinically 
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negative axillary nodes as assessed by palpation and ultrasonography. Exclusion 
criteria were pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine 
green. 
Twenty-four consecutive patients were included. All patients gave informed 
consent and were anonymized. Patients received the standard-of-care SLN procedure. 
For our institution, this implies one periareolar injection of approximately 100 MBq 
99mTechnetium-nanocolloid (mean ± S.D. = 99.6 ± 5.8 MBq) the day before surgery. 
Before the start of the operation, one mL of patent blue V was injected peritumorally 
or periareolarly. Choice of the injection site was left to the surgeon. Directly after 
patent blue injection, 1.6-mL ICG:HSA was administered as four injections at the 
same location as the patent blue injections. After surgical scrub and sterile covering of 
the operation field, NIR fluorescence imaging was performed with the imaging head of 
the Mini-FLARE™ at approximately 30 cm distance to the surgical field. 
The surgical technique consisted of percutaneous assessment of NIR fluorescent 
signal in the breast and the axilla prior to skin incision. The location and length of 
the axillary skin incision was determined by the surgeon. Assessment of the surgical 
field using NIR fluorescence was applied continuously throughout the SLN procedure 
and surgical exploration. If the SLN was not easily detected by NIR fluorescence, the 
gamma probe was used to provide direction for surgical exploration. Camera exposure 
was between 5 to 250 msec as indicated. A SLN exhibiting a signal-to-background 
ratio (SBR) ≥ 1.1 in situ was considered positive by NIR fluorescence. Background 
was chosen as an area within the surgical field, directly adjacent (within 1-2 cm) to 
the SLN.
Routine histopathological frozen analysis of SLNs was performed during surgery. 
If the patient participated in the After Mapping of the Axilla Radiotherapy or Surgery 
(AMAROS) trial and was randomized to the radiotherapy arm, no intraoperative 
frozen analysis was performed. SLNs were fixed in formalin and embedded in paraffin 
for routine hematoxylin, eosin, and immunohistopathological staining for AE1/AE3 at 
three levels, with an interval of 150-250 µm, according to the Dutch guidelines for SLN 
analysis. Patients underwent an axillary lymph node dissection if the SLN was found 
to contain metastases, except for those patients who participated in the radiotherapy 
arm of the AMAROS trial. If isolated tumor cells (ITCs) were found (< 0.2 mm), no 
axillary lymph node dissection was performed.
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, 
USA) was used. Graphs were generated using GraphPad Prism Software (Version 
5.01, La Jolla, USA). To compare the SBR between concentration groups, a one-
way analysis of variance (ANOVA) was performed with pairwise comparison with 
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least square difference (LSD) adjustment for multiple testing. When the assumption 
of homogeneity of variance was violated (Levene’s test), a log10 transformation was 
applied. All statistical tests were two-tailed and P < 0.05 was considered significant.
reSuLtS
design of the Mini-FLare™ Imaging System and In Vitro Characterization
The Mini-FLARE™ imaging system (Figure 1A) is composed of a small portable 
electronics cart and a counter-weighted pole stand that supports the imaging head. 
Unlike FLARE™, Mini-FLARE™ utilizes a flexible gooseneck arm, which permits 
positioning of the imaging head at extreme angles virtually anywhere over the surgical 
field. The only consumable for Mini-FLARE™ is a specially designed acrylic splash 
plate that is hermetically sealed to a plastic drape. Using sterile technique, the shield/
drape is inserted into the imaging head, locked into place, and the drape is unfolded 
to encase the imaging head and imaging system pole stand (Figure 1B). Optical light 
paths for white light (i.e., color video images) and the two semi-independent NIR 
fluorescence channels, one centered at 700 nm emission and the other at 800 nm 
emission, are shown in Figure 1C. 
A
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Figure 1. The Mini-FLARE™ Portable Near-Infrared Fluorescence Imaging System: a. Imaging system, composed 
of electronics/monitor cart and counter-weighted imaging system pole. b. Sterile drape/shield attached to the 
imaging head with other major parts identified. C. Excitation and emission light paths, and filtration for the Mini-




Technical specifications of Mini-FLARE™ are detailed in Table 1. Of note, the 
working distance is up to 13” away from the patient, with field-of-view adjustable 
from 4.7” (12 cm) to 2” (5 cm) simply by moving the device toward or away from the 
surgical field. The cart occupies a volume of only 9.7 cu ft, and weighs only 272 lbs. A 
6-pedal footswitch and autofocus circuit permit hands-free operation. The cost of all 
parts is ≈ $40,000.
Pre-Clinical optimization of NIr Fluorescent Lymphatic tracers
Our group has previously reported that ICG (and ICG:HSA) exhibits intense 
quenching (i.e., reduction of fluorescence emission) as its concentration is increased.15 
That is, increasing concentration actually decreases fluorescence, so there would 
theoretically be no benefit to injecting high concentration for SLN mapping. This 
effect is demonstrated vividly in Figure 2A (left), where the injection site becomes 
dramatically less fluorescent as concentration increases. As a general rule, if the 
table 1. Mini-FLARE™ Imaging System Specifications
Category Specification Description
Physical Size Mobile Cart: 24” W x 24” D x 29” H; Mast Height: 76.5”
Weights
             
Cart: 272 lbs, including all electronics
Arm: 95 lbs, including, stand, gooseneck, and imaging head
Imaging Head: 8.8 lbs.
Arm and Stand Flexible Arm; Reach: 27” – 64” from floor, 42” from center of 
stand. Center of stand up to 11 linear feet from cart
Electrical Voltage and Plug 120 V AC, 60 Hz; single NEMA 5-15 120 V/15 A AC plug
Current 5 A max
Grounding Isolation transformer for all components; redundant chassis 
grounding
Leakage Current < 300 µA (per AAMI/IEC #60601)
Sterility Shield Disposable acrylic shield with ≥95% transmission
Drape Disposable, custom-fit plastic drape bonded to shield 
Light Source Housing Anodized aluminum with integrated liquid cooling 
Elements Custom 25 mm circular LED arrays w/ integrated linear drivers
Electronics Custom control board with embedded microcontroller
Fluence Rates 26,600 lux white light (400-650 nm), 1.08 mW/cm2 of 700 nm 
(656-678 nm) excitation light, 7.70 mW/cm2 of 800 nm (745-779 
nm) excitation light
Optics Working Distance 4” (10 cm) to 13” (32 cm) from patient (reverse telephoto)
Field-of-View 12 cm W  x 9 cm H at 13” working distance
Emission/
Reflectance Channels
Color Video (400-650 nm), 700 nm fluorescence (689-725 
nm), 800 nm fluorescence (800-848 nm), all with simultaneous 
acquisition
Pixel Resolution 640 x 480 for each camera
System Resolution 320 x 320 µm (x,y)
Display Refresh Up to 15 Hz simultaneous acquisition on both cameras
NIR Exposure Time Adjustable from 100 µsec to 8 sec
Hands-Free Optics Automatic focus
Control 6-pedal footswitch
Monitors Number 3 cart-mounted 20”: 2 for operator and 1 for surgeon 
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concentration is high enough to see green color at the injection site, ICG fluorescence 
is severely quenched.
 Importantly, we have recently discovered that dilution of the injected 
NIR fluorophore as it travels through the lymphatic system and mixes with lymph 
counteracts the effect of quenching and results in signal in the SLN that increases with 
concentration, even when the injection site is barely fluorescent (Figure 2A, right). 
This suggests that there will be an “optimal” concentration of injected NIR fluorophore 
such that final signal in the SLN is as high as possible. 
optimization of ICG:HSa dose in women undergoing SLN Mapping for breast 
Cancer
This study aimed to test the feasibility of NIR fluorescence in SLN detection, using 
ICG:HSA and the Mini-FLARE™, in direct comparison with the conventional 
lymphatic tracers radiocolloid and patent blue. Twenty-four consecutive breast cancer 
patients underwent standard-of-care SLN mapping with the addition of preoperative 
ICG:HSA injection and subsequent intraoperative NIR fluorescence imaging. Patient 
and tumor characteristics are provided in Table 2. Use of the Mini-FLARE™ during 
surgery did not interfere with the standard of care. Average time between ICG:HSA 
injection and skin incision was 16 ± 3 minutes (Table 3). In all patients (N = 24), 
NIR fluorescence imaging enabled visualization of the SLN (Figure 3). A total of 35 
SLNs were identified, which were all radioactive and NIR fluorescent (Table 3). Five 
SLNs from four patients did not have blue staining from patent blue. In all patients, 
the NIR fluorescence signal in the SLN was detected before patent blue. Average time 
between skin incision and resection of the first SLN was 17 ± 5 minutes. After all nodes 
detected using NIR fluorescence were resected, the axilla was systematically inspected 
for any remaining radioactivity. No additional radioactive nodes were identified that 
were not detected by NIR fluorescence. No adverse reactions associated with the use of 
ICG:HSA or the Mini-FLARE™ occurred. Two patients experienced a wound infection 
requiring antibiotics and one patient underwent surgical re-exploration because of an 
expanding hematoma following axillary lymph node dissection (Table 3). 
A second objective of this trial was to determine the optimal concentration 
of injected ICG:HSA for NIR fluorescence SLN mapping, i.e. which concentration 
provides the highest SBR in the SLN. Because ICG and ICG:HSA exhibit intense 
quenching as their concentrations are increased (typically above 50 μM), there would 
be theoretically no advantage of injecting higher doses of ICG:HSA. However, dilution 
of the lymphatic tracer occurs upon injection in the breast and uptake by the lymphatic 
system counteracting the quenching effect. To assess the relationship between the 
concentration of injected NIR fluorescent lymphatic tracer and final SBR in the SLN, 
patients were allocated to 8 ICG:HSA concentration groups ranging from 50 μM to 
1000 μM. The concentration of ICG:HSA influenced the SBR and showed a normal 
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distribution (Figure 2B). The variances of the concentration groups were not equal 
(Levene’s test, P = 0.02). A log10 transformation of the data could account for part 
of the unequal variances (Levene’s test, P = 0.05). A one-way ANOVA with pairwise 
comparison with LSD adjustment for multiple comparison showed that the SBRs of 
the 400, 500, 600, and 800 µM concentration groups were significantly higher than of 
the 50, 100, 200, and 1000 µM concentration groups (200 vs. 400, P = 0.001; 200 vs. 
500, P = 0.001; 200 vs. 600, P < 0.0001; 200 vs. 800, P = 0.001; 1000 vs. 400, P < 0.0001; 
1000 vs. 500, P < 0.0001; 1000 vs. 600, P < 0.0001; 1000 vs. 800, P < 0.0001). The SBRs 
of the 400, 500, 600, and 800 µM concentration groups were not significantly different, 
although a trend was found favoring the 600 µM concentration group (500 vs. 600, P 
= 0.06). The decline of the SBR in the 1000 µM concentration group was caused by 
decreased NIR fluorescence signal of the SLN (800 vs. 1000, P = 0.001), which suggests 
that quenching of ICG indeed occurred in the SLN.
dISCuSSIoN
Near-infrared (NIR) fluorescent light in the wavelength range of 700 to 900 nm is 
invisible to the human eye. It is also capable of penetrating millimeters into living 
tissue and is not obscured by autofluorescence. For these reasons, NIR fluorescent 
light is ideal for image-guided surgery. Indeed, several NIR fluorescence surgical 
imaging systems are already FDA-approved or are in the process of obtaining approval 
(reviewed in 17). The Mini-FLARE™ camera system used in this study is capable of 
displaying NIR fluorescence signal in relation to the surgical anatomy and illuminates 
the surgical field with white light. This enabled the surgeon to perform surgery under 
direct image guidance.
NIR fluorescence optical imaging using Mini-FLARE™ offers the advantages of 
real-time, continuous, high-resolution, and high sensitivity detection of SLNs, without 
the need for ionizing radiation. Because NIR light is invisible, there is no staining of 
the surgical field as with blue dyes, and the class of chemicals in which ICG belongs 
has a remarkable safety record in humans. ICG:HSA adds approximately $150 to the 
cost of a case, but if future studies show that the blue dye and/or Tc-99m sulfur colloid 
can be eliminated when using NIR fluorescence, a much larger savings will offset this 
cost. And, the surgeon can perform the injection procedure only minutes before SLN 
identification and resection. Although a technologist was used in this first-in-human 
study, Mini-FLARE™ is equipped with hand-free operation and there is virtually no 
learning curve because unlike other SLN techniques, the lymphatic tracer can be 
visualized in real-time throughout the procedure.
 An important objective of the study was to optimize NIR fluorescent contrast 
agent dose for breast cancer SLN mapping. The only clinically available NIR fluorescent 
lymphatic tracer, albeit approved for other indications, is ICG.7, 11, 13, 18, 19 We have 
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previously proposed simple mixing of ICG and HSA (ICG:HSA) prior to injection14, 15 
because ICG is a small molecule and like blue dyes can pass through SLNs, and exhibit 
a relatively low quantum yield in aqueous environments.15 Indeed, the product insert 
for ICG notes that it rapidly binds albumin when injected intravenously, so pre-mixing 
merely improves kinetics. Importantly, though, pre-mixing increases quantum yield 
table 2. Patient and Tumor Characteristics
Characteristic N %
Age (Median, Range) 59.5 (33-81)
Menopausal State
- Premenopausal 5 21
- Postmenopausal 19 79
Body Mass Index (Median, Range) 25 (18-38)
Skin Type
- II 4 17
- III 20 83
Previous Breast Surgery a 3 13
Multifocality 4 17
Tumor Side
- Left 14 58
- Right 10 42
Tumor Localization
- Central 5 21
- Lower Inner 1 4
- Lower Outer 1 4
- Upper Inner 6 25
- Upper Outer 11 46
Type of Operation
- Ablation 9 38
- Wide Local Excision 15 63
Pathological Tumor Size (Median, Range) 15 (3-35)
Histological Type
- Infiltrating Ductal Adenocarcinoma 18 75
- Infiltrating Lobular Adenocarcinoma 2 8
- Ductal Carcinoma In Situ 4 17
Histological Grade
- I 3 13
- II 13 54
- III 8 33
Receptor Status b
- ER+ HER2- 16 67
- ER+ HER2+ 3 13
- ER- HER2- 1 4
- Missing c 4 17
a Previous breast surgery: silicone breast implantation, breast reduction and re-excision. 
b HER2 status was determined using the chromogenic in situ hybridization (CISH) kit of Zymed 
(Invitrogen, Carlsbad, CA) 
c Not applicable in four patients with ductal carcinoma in situ. 
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Figure 2. Optimization of ICG:HSA Dose as a Function of the Complex Tradeoff Between Fluorescence 
Quenching at the Injection Site and Dilution of Fluorophore in Lymphatic Channels: a. Pre-clinical studies in 
Yorkshire pigs. Subcutaneous injection sites (left; white arrows) showing quenching and resected SLNs (right) 
showing NIR fluorophore dilution for increasing concentrations of ICG:HSA. For each are displayed color video 
(left columns) and 800 nm NIR fluorescence (right columns) images obtained using 760 nm excitation light at 
7.7 mW/cm2. All camera exposure times were 45 msec. Data are representative of n = 3 pigs. b. Optimization of 
ICG:HSA dose for breast cancer SLN mapping: Signal-to-background ratio (mean ± S.D) of the SLNs (ordinate) 
as a function of injected dose of ICG:HSA (abscissa) in women undergoing SLN mapping for breast cancer. 
Statistical comparisons are as follows: 200 µM vs. 400 µM, P = 0.001; 200 µM vs. 500 µM, P = 0.001; 200 µM vs. 
600 µM, P < 0.0001; 200 µM vs. 800 µM, P = 0.001; 1000 µM vs. 400 µM, P < 0.0001; 1000 µM vs. 500 µM, P < 
0.0001; 1000 µM vs. 600 µM, P < 0.0001; 1000 µM vs. 800 µM, P < 0.0001). The SBRs of the 400, 500, 600 and 
800 µM concentration groups were not significantly different, although a trend was found favoring the 600 µM 
concentration group (500 vs. 600, P = 0.06).
A
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(i.e., brightness) 3-fold and also results in a final hydrodynamic diameter (≈ 7 nm) that 
is better retained in the SLN.15 
NIR fluorescent signal in the SLN is a complex function of the concentration 
of the injected NIR lymphatic tracer, the distance between the injection site and the 
SLN, the volume of ultra-filtrate within the lymphatic channels encountered by the 
NIR fluorophore, and retention of the NIR fluorophore by the SLN. Of these, only 
the injection concentration can be controlled. Our study suggested that an optimal 
ICG:HSA concentration is in the range 400 μM and 800 μM. In the 1000 μM 
concentration group, the fluorescence intensity of the SLN and the SBR decreased 
rapidly, most likely due to quenching. Furthermore, since lymphatic vessels could 
be visualized percutaneously and directly after incision, particularly in the optimal 
dose range groups, a more efficient identification of SLNs was facilitated. This is of 
particular benefit for lymph nodes located deeper in the axilla, which exceed the 1-2 
cm depth limit of the technology. These nodes could often be located by following the 
NIR fluorescent signal of the afferent lymphatic tract.
The accuracy of SLN identification using ICG fluorescence was similar to 
that using conventional radioisotope scanning, as both techniques identified all 
Figure 3. Real-Time NIR Fluorescence Imaging during Sentinel Lymph Node Mapping in Women with Breast 
Cancer: Shown are typical in vivo (top row) and ex vivo (bottom row; post-resection) results from a subject 
injected with 500 µM ICG:HSA. White arrow identifies the SLN. NIR fluorescence (left) and pseudo-colored 
(lime green) merge with the color video image (right). Exposure times were 50 msec for in vivo images and 30 
msec for ex vivo images. 760 nm excitation fluence rate was ≈ 7.7 mW/cm2 for all images. Scale bars indicate 
1 cm.
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SLNs and no additional fluorescent lymph nodes were identified. However, blue dye 
identification was not successful in 5 of 35 (14%) SLNs. These results suggest that 
patent blue staining can be replaced by NIR fluorescence using ICG:HSA. Replacing 
patent blue has the additional advantage of absent tattooing of the breast and visual 
alteration of the surgical field. Moreover, the intrinsic dark color of patent blue dye 
can obscure the fluorescence intensity of any fluorescent lymphatic tracer. Indeed, in 
vitro tests using a fixed ICG:HSA concentration showed that addition of patent blue 
dye decreased NIR fluorescence of ICG:HSA (data not shown). An as yet unanswered 
question is whether radioisotope scanning can be omitted from the SLN procedure. A 
larger trial to address whether NIR fluorescence imaging alone can replace blue dyes 
and/or radiocolloids is ongoing. 
table 3. SLN Identification Results
Characteristic N %
Injection Site Patent Blue and ICG:HSA
- Periareolar 20 83
- Peritumoral 4 17
SLN Detection
- Number of SLNs Identified 35
- Average Number of SLNs Identified (range) 1.45 (1-3)
Method of Detection
- Radioactive  35 100
- Blue 30 86
- Near-Infrared Fluorescence 35 100
Average Time between Injection of ICG:HSA and Skin Incision (S.D.) 16 minutes ± 3
Average Time between Skin Incision and SLN Resection (S.D.) 17 minutes ± 5
Histology
- Negative 26 74
- Isolated Tumor Cells 3 9
- Micrometastases 0 0
- Macrometastases 6 17
Axillary Treatment
- None 16 67
- Axillary Lymph Node Dissection 5 21
- Axillary Radiotherapy 3 13
Complications
- No 21 87
- Yes 3 a 13
Abbreviations: ICG:HSA = indocyanine green adsorbed to human serum albumin, SLN = 
sentinel lymph node, S.D. = standard deviation 
a Two patients experienced postoperative wound infection requiring treatment with antibiotics 
and one patient underwent surgical re-exploration because of an expanding hematoma following 
axillary lymph node dissection.  
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In summary, this study demonstrated feasibility and accuracy of NIR 
fluorescence imaging using ICG:HSA and the Mini-FLARE™ imaging system for SLN 
mapping in breast cancer patients. The optimal dose of injected ICG:HSA lies between 
400 µM and 800 µM and can be chosen based on local preparation preferences. For 
example, in the United States, a dose of 500 µM is most convenient since it requires 
minimal manipulation of albumin volumes.
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abStraCt
Near-infrared (NIR) fluorescence imaging has the potential to improve sentinel lymph 
node (SLN) mapping in breast cancer. Indocyanine green (ICG) is currently the only 
clinically available fluorophore that can be used for SLN mapping. Preclinically, 
ICG adsorbed to human serum albumin (ICG:HSA) improves its performance as a 
lymphatic tracer in some anatomical sites. The benefit of ICG:HSA for SLN mapping 
of breast cancer has not yet been assessed in a clinical trial. We performed a double-
blind, randomized study to determine if ICG:HSA has advantages over ICG alone. 
The primary endpoint was the fluorescence brightness, defined as the signal-to-
background ratio (SBR), of identified SLNs. Clinical trial subjects were 18 consecutive 
breast cancer patients scheduled to undergo SLN biopsy. All patients received 
standard of care using 99mTechnetium-nanocolloid and patent blue. Patients were 
randomly assigned to receive 1.6 mL of 500 µM ICG:HSA or ICG that was injected 
periareolarly directly after patent blue. The Mini-Fluorescence-Assisted Resection and 
Exploration (Mini-FLARE) imaging system was used for NIR fluorescence detection 
and quantitation. SLN mapping was successful in all patients. Patient, tumor and 
treatment characteristics were equally distributed over the treatment groups. No 
significant difference was found in SBR between the ICG:HSA group and the ICG 
alone group (8.4 vs. 11.3, respectively, P = 0.18). In both groups, the average number 
of detected SLNs was 1.4 ± 0.5 SLNs per patient (P = 0.74). This study shows that there 
is no direct benefit of premixing ICG with HSA prior to injection for SLN mapping 
in breast cancer patients, thereby reducing the cost and complexity of the procedure. 
With these optimized parameters that eliminate the necessity of HSA, larger trials can 
now be performed to determine patient benefit.
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INtroduCtIoN
Sentinel lymph node (SLN) mapping is currently regarded as standard of care in staging 
of the axilla in breast cancer patients with clinically negative axillary lymph nodes.1 In 
general, a combination of radioactive colloid and blue dye is used for SLN mapping. 
Using this combination, identification rates of 95% to 97% are achieved.2-5 The use of 
only one of these two detection methods results in significantly lower identification 
rates.2-5 Both detection methods possess certain disadvantages. Radioactive colloids 
require involvement of a nuclear medicine physician, can be difficult to localize with a 
handheld gamma probe, and the time-window for SLN identification is limited due to 
the short half-life (6 hours) of 99mTechnetium. Blue dyes cannot be seen through skin 
and fatty tissue, and permit only limited visualization of afferent lymphatic vessels and 
the SLN. 
Optical imaging using the near-infrared (NIR) fluorescence lymphatic tracer 
indocyanine green (ICG) enables real-time transcutaneous and intraoperative 
visualization of lymphatic channels and SLNs.6-13 Therefore, NIR fluorescence imaging 
could provide an alternative for, or an addition to, conventional techniques used for 
SLN mapping. Recently, our group has demonstrated that NIR fluorescence performed 
equally well as the combination of radioactive colloid and blue dye in SLN mapping of 
breast cancer patients.14 
ICG is currently the only clinically available NIR lymphatic tracer. However, 
due to its relatively low fluorescence brightness and its small hydrodynamic diameter, 
which permits flow through the SLN to higher tier nodes, it is not an optimal lymphatic 
tracer. Preclinical work has demonstrated that adsorption of ICG to human serum 
albumin (HSA, complex is ICG:HSA), by simply mixing it, increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection 
and better retention in the SLN in certain anatomical sites, such as the intestine.15 
Another parameter that must be considered when using ICG or ICG:HSA is the effect 
of fluorescence quenching, which results in a decrease in fluorescence intensity as the 
concentration of ICG (or ICG:HSA) is increased above 50 μM. The use of 50 μM ICG 
for SLN imaging, however, is suboptimal, because ICG will be diluted once taken up by 
the lymphatic system. To assess the magnitude of this in vivo dilution effect, our group 
has conducted a dose-finding study to demonstrate that the optimal concentration of 
ICG:HSA for NIR-based SLN mapping in breast cancer patients lies between 400 µM 
and 800 µM.14 
A theoretical disadvantage of the use of ICG alone is poor retention of the 
lymphatic tracer in the SLN, which as a consequence results in fluorescent staining 
of higher tier nodes and background staining of the axilla. Although not compared 
directly, studies using ICG alone reported a higher average number of identified SLNs 
(range = 1.8-5.4; aggregate average = 3.4),6-10 than with the use of ICG:HSA (aggregate: 
1.5).11, 14 However, comparison of these data is difficult because the concentration of 
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ICG used was significantly higher (typically 6.4 mM) than in the trials using ICG:HSA 
(10 µM to 1000 µM). 
Although we have obtained good results with the use of ICG:HSA for SLN 
mapping in breast cancer patients, the use of albumin adds cost and complexity to 
the procedure. Moreover, the use of human blood products, such as HSA, poses 
regulatory hurdles in certain countries, such as the United States. Therefore, the use 
of ICG alone would be favorable. After intravenous administration, ICG binds rapidly 
and completely to plasma proteins.16 Lymph fluid has a similar protein constitution 
as serum, albeit in a lower concentration (20.6 g/L for lymph fluid versus 73.7 g/L for 
plasma).17 After intradermal or subcutaneous injection, ICG could theoretically bind 
to these proteins, eliminating the need for premixing ICG and HSA. We therefore 
hypothesized that ICG alone could render the same fluorescence intensity in SLNs as 
ICG:HSA, and tested this hypothesis in a double-blind randomized trial.
MaterIaLS aNd MetHodS
Preparation of Indocyanine Green adsorbed to Human Serum albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 
mM) stock solution. To obtain a 500 µM dilution, 7.8 mL of the 3.2 mM ICG solution 
was diluted in 50 cc vial of sterile water for injection or 50 cc vial of Cealb (20% human 
serum albumin, Sanquin, Amsterdam, The Netherlands) for the preparation of ICG 
alone or ICG:HSA, respectively. Prior to the addition of ICG, 7.8 mL was drawn from 
the 50 cc vials. In a previous study, we determined that the optimal dose of ICG:HSA 
lies between 400 µM and 800 µM.14 A dose of 500 µM was chosen because it requires 
minimal manipulation of ICG and albumin volumes. 
Intraoperative Near-Infrared Imaging System (Mini-FLare)
SLN mapping was performed using the Mini-Fluorescence-Assisted Resection 
and Exploration (Mini-FLARE) image-guided surgery system as in Chapter 6. 
Briefly, the system consists of two wavelength isolated light sources: a “white” light 
source, generating 26,600 lx of 400-650 nm light, and a “near-infrared” light source, 
generating 7.7 mW/cm2 of 760 nm light. Color video and NIR fluorescence images are 
simultaneously acquired and displayed in real-time using custom optics and software 
that separate the color video and NIR fluorescence images. A pseudo-colored (lime 
green) merged image of the color video and NIR fluorescence images is also displayed. 
The imaging head is attached to a flexible gooseneck arm, which permits positioning 
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of the imaging head at extreme angles virtually anywhere over the surgical field. For 
intraoperative use, the imaging head and imaging system pole stand are wrapped in a 
sterile shield and drape (Medical Technique Inc., Tucson, USA).
Clinical trial
The double-blind, randomized, single-institution, non-inferiority trial comparing 
ICG:HSA with ICG alone was approved by the Medical Ethics Committee of the 
Leiden University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. All patients planning to undergo a 
sentinel lymph node procedure whether for invasive breast cancer or for high-risk 
carcinoma in situ were eligible for participation in the study. Patients had clinically 
negative axillary nodes as assessed by palpation and ultrasonography. Exclusion 
criteria were pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine 
green.
All patients gave informed consent and were anonymized. Patients were 
randomized by the Department of Clinical Pharmacy. Treatment allocation was 
performed by block randomization. Patients received the standard-of-care sentinel 
lymph node procedure. For our institution, this implies one periareolar injection of 
approximately 100 MBq 99mTechnetium-nanocolloid (mean ± S.D. = 96.6 ± 14.7 MBq, 
no difference between treatment groups [P = 0.47]) the day before surgery. Before 
the start of the operation, one mL of patent blue V was injected. Directly after patent 
blue injection, the surgeon injected a total of 1.6 mL of 500 µM ICG:HSA or ICG 
alone. Both dyes were injected intradermally and periareolarly at four sites. Gentle 
pumping pressure was applied to the injection site for 1 min. After surgical scrub and 
sterile covering of the operation field, NIR fluorescence imaging was performed with 
the imaging head of the Mini-FLARE at approximately 30 cm distance to the surgical 
field. Camera exposure times were between 5 to 200 msec. A SLN exhibiting a signal-
to-background ratio (SBR) ≥ 1.1 in situ was considered positive by NIR fluorescence. 
Both the surgeon and the Mini-FLARE operator, who was responsible for analyzing 
the data, were blinded to the treatment allocation.
Routine histopathological frozen analysis of SLNs was performed during 
surgery. SLNs were fixed in formalin and embedded in paraffin for routine hematoxylin 
and eosin staining and immunohistopathological staining for AE1/AE3 at three levels, 
with an interval of 150 to 250 µm, according to the Dutch guidelines for SLN analysis. 
Patients underwent an axillary lymph node dissection if the SLN was found to contain 
metastases. If isolated tumor cells were found (< 0.2 mm), no axillary lymph node 
dissection was performed.
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Power Calculation and Statistical analysis
A power calculation based on data from our previous study14 revealed that 18 patients 
are needed to achieve 91% power to detect non-inferiority using a one-sided, two-
sample t-test (α = 0.025) with a margin of equivalence of 5.0 while assuming no 
difference between the SBRs of ICG:HSA and ICG alone. For statistical analysis, SPSS 
statistical software package (Version 16.0, Chicago, USA) was used. Graphs were 
generated using GraphPad Prism Software (Version 5.01, La Jolla, USA). To compare 
the SBR and the number of SLNs identified between ICG:HSA and ICG alone, a one-
sided, two-sample t-test was performed. P < 0.05 was considered significant.
reSuLtS
Eighteen consecutive breast cancer patients undergoing standard-of-care SLN mapping 
were randomized to ICG:HSA or ICG alone for the NIR-based SLN imaging. Patient, 
tumor, and treatment characteristics were equally distributed over the treatment 
groups (Table 1). Use of the Mini-FLARE during surgery did not interfere with the 
standard of care. Average time between lymphatic tracer injection and skin incision 
was 15.6 ± 2.2 minutes (Table 2). In all patients (N = 18), NIR fluorescence imaging 
enabled visualization of one or more SLNs (Figure 1). In the ICG:HSA group (N = 8 
subjects), a total of 11 SLNs were identified (average per patient = 1.4 ± 0.5); 9 (82%) 
were radioactive, 8 (73%) were blue and 11 (100%) were NIR fluorescent. In the ICG 
alone group (N = 10 subjects), a total of 14 SLNs were identified (average per patient 
= 1.4 ± 0.5); 14 (100%) were radioactive, 10 (71%) were blue and 14 (100%) were 
NIR fluorescent. The average number of SLNs identified was not significantly different 
between both groups (P = 0.74). 
The primary endpoint of this study was the average brightness of the SLN in 
both groups, expressed in signal-to-background ratio (SBR). The results are presented 
in Table 2. The average SBR of ICG:HSA (8.4 ± 3.6) and ICG alone (11.3 ± 4.8) was 
not significantly different (P = 0.18). However, in the ICG alone group, the afferent 
lymphatics were significantly better visualized percutaneously compared to the 
ICG:HSA group (P = 0.004; Table 2 and Figure 1).
In all patients, the NIR fluorescence signal in the SLN was detected earlier in 
the procedure before patent blue was visualized. Average time between skin incision 
and resection of the first SLN was 11.0 ± 4.1 minutes and was not different between 
both groups (t-test, P = 0.74). No adverse reactions associated with the use of ICG, 
ICG:HSA, or Mini-FLARE occurred.
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dISCuSSIoN
The use of NIR fluorescence for SLN mapping has several advantages over conventional 
methods, such as better tissue penetration when compared to blue dyes, and lack of 
ionizing radiation and real-time visualization when compared to radiotracers. A 
number of clinical studies have been published on the use of NIR fluorescence in the 
SLN procedure in breast cancer, all of which use ICG, which is currently clinically 
available.6, 9, 11, 12, 14 Preclinical studies indicated that adsorption of ICG to human serum 
albumin (HSA, complex is ICG:HSA), by simply mixing it, increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection and 
better retention in the SLN.15 Our group has subsequently conducted a dose-finding 
Figure 1. NIr fluorescence imaging during sentinel lymph node mapping in breast cancer patients: a. 
ICG:HSA. In the upper panel, the periareolar injection site (arrow) is shown, but percutaneously, no lymphatic 
channel can be visualized. In the lower panel, identification of the SLN (arrow) and an afferent lymphatic channel 
(open arrowhead) with NIR fluorescence imaging is demonstrated 27 min after injection of 1.6 mL of 500 µM 
ICG:HSA. Camera exposure times were 60 msec (top row) and 150 msec (bottom row). Scale bars represent 1 cm. 
b. ICG alone. In the upper panel, the periareolar injection site (arrow) and a lymphatic channel (arrowhead) are 
clearly visualized. In the lower panel, identification of the SLN (arrow) and an afferent lymphatic channel (open 
arrowhead) with NIR fluorescence imaging is demonstrated 28 min after injection of 1.6 mL of 500 µM ICG. 




table 1. Patient and Tumor Characteristics
ICG:HSA (N = 8) ICG alone (N = 10)
Characteristic N % N % P
Age (Median, Range) 59.5 (38-72) 57.5 (40-73) 0.99
Menopausal State 0.74
- Premenopausal 3 37.5 3 30
- Postmenopausal 5 62.5 7 70
Body Mass Index (median, range) 26 (20-41) 23.5 (21-30) 0.26
Skin Type 0.40
- II 2 25 1 10
- III 6 75 9 90
Previous Procedure of Breast 0.12
- Breast Implants 1 0
- Breast Reduction 0 1
- Lumpectomy 2 0
- Radiotherapy 0 1
- Neoadjuvant Chemotherapy 1 0
Multifocality 0 0 1.00
Tumor side 0.81
- Left 2 25 3 30
- Right 6 75 7 70
Tumor localization 0.23
- Upper Outer 6 75 4 40
- Lower Outer 0 0 1 10
- Lower Medial 1 12.5 2 20
- Upper Medial 0 0 3 30
- Central 1 12.5 0 0
Type of Operation 0.15
- Mastectomy 3 37.5 1 10
- Wide Local Excision 4 50 9 90
- SNB Only 1 12.5 0 0
Pathological Tumor Size (Median, Range) 7 (5-11) 12 (8-15) 0.13
Histological Type 0.62
- Infiltrating Ductal Adenocarcinoma 7 87.5 7 70
- Infiltrating Lobular Adenocarcinoma 0 0 1 10
- Ductal Carcinoma In Situ 1 12.5 1 10
- Other 0 0 1 10
Histological Grade 0.15
- I 1 16.7 3 33.3
- II 2 33.3 5 55.6
- III 3 50 1 11.1
Abbreviations: ICG:HSA = indocyanine green adsorbed to human serum albumin Skin type = American 
Academy of Dermatology Skin Types I-VI: 
I. Pale, white skin: always burns easily; never tans (Celtic, Scandinavian, and infants)  
II. White: usually burns easily; tans minimally (Northern European)  
III. White (average): sometimes burns; tans gradually to light brown (Central European)  
IV. Beige or lightly tanned: burns minimally; always tans to moderately brown (Mediterranean, Asian)  
V. Moderate brown or tanned: rarely burns; tans well (South American, Indian, Native American)  
VI. Dark brown or black: never burns; deeply pigmented (African, African-American, Aborigine)
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study and demonstrated that the optimal concentration of ICG:HSA for NIR-based SLN 
mapping in breast cancer patients lies between 400 µM and 800 µM.14 Indeed, above 
800 µM ICG:HSA, the fluorescent intensity dropped due to quenching. Based on these 
results a concentration of 500 µM ICG:HSA, which requires minimal manipulation 
of albumin volumes and uses only one vial of ICG, was chosen for further studies to 
identify whether premixing with albumin indeed increases the fluorescent intensity of 
the node in a clinical setting. In the current study, SLN mapping after ICG or ICG:HSA 
injection was successful in all patients. ICG showed a comparable or even slightly 
increased (though not significantly) brightness than ICG:HSA while identifying 
an equal average number of SLNs. Although no macrometastases in the SLNs were 






N % N % N %
Number of SLNs Identified 25 11 14
Number of SLNs Identified per Patient 0.91
- One SLN 11 61 5 63 6 60
- Two SLNs 7 39 3 37 4 40
Average Number of SLNs Identified ± S.D. 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 0.92
Method of Detection
- Radioactive  23 92 9 82 14 100 0.18
- Blue 18 72 8 73 10 71 1.00
- NIR Fluorescent 25 100 11 100 14 100 1.00
Signal-to-Background Ratio 10.0 ± 4.4 8.4 ± 3.6 11.3 ± 4.8 0.18
Percutaneous NIR Fluorescent Lymph 
Drainage Visualization 0.004
- Yes 10 56 1 13 9 90
- Partiallya 3 17 3 38 0 0
- No 5 28 4 50 1 10
Average Time between Injection and Skin 
Incision ± S.D. (minutes) 15.6 ± 2.2 15.3 ± 1.7 15.9 ± 2.6 0.55
Average Time between Skin Incision and 
SLN Resection ± S.D. (minutes) 11.0 ± 4.1 10.6 ± 5.1 11.3 ± 3.3 0.74
Histology 0.44
- Negative 24 96 10 91 14 100
- Isolated Tumor Cells 1 4 1 9 0 0
- Macrometastases 0 0 0 0 0 0
Axillary Lymph Node Dissection 1.00
- No 18 100 8 100 10 100
- Yes 0 0 0 0 0 0
Abbreviations: ICG:HSA = indocyanine green adsorbed to human serum albumin; S.D. = standard deviation; 
SLN = sentinel lymph node.  
a Partial percutaneous visualization was noted when lymphatic channels could be visualized percutaneously 
from the injection site, but did not reach the axilla.
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observed in the current study, our previous study showed that tumor-positive SLNs 
were also detected by NIR fluorescence, signifying ICG uptake.14 However, lymph node 
macrometastases continue to be a contraindication for SLN mapping and preoperative 
staging of the axilla remains pivotal to minimize false negatives.
The results of our study are discordant with preclinical work in intestine, which 
suggested an improvement in fluorescent brightness and retention in the SLN by 
premixing ICG with HSA.15 Although the current study was powered to determine 
non-inferiority in SBR of ICG alone when compared to ICG:HSA, it was not formally 
powered to assess the secondary endpoint, average number of SLNs identified. 
However, power analysis using data from our previous study14 demonstrated that a 
difference of at least one additional SLN identified per patient could be detected with 
90% power with the current sample size. The discrepancy between the current clinical 
results and these preclinical experiments could be caused by the increased distance 
that the injected dye has to travel, as the preclinical studies were performed in the 
bowel of healthy pigs.15 Lymph fluid contains a high concentration of albumin, among 
other proteins; therefore, a longer traveling distance could aid ICG in adsorbing to 
albumin or other proteins, as it would after intravenous injection,18 diminishing the 
need for premixing ICG with HSA. This observation implies that premixing might 
prove to be useful in other cancer types (such as colon cancer, for example), where ICG 
is less likely to completely adsorb to proteins before the SLN is reached. Therefore, the 
use of ICG:HSA or ICG alone should be tested for every anatomical site.
Although the fluorescent brightness did not differ significantly between both 
groups, ICG alone showed significantly improved percutaneous visibility of lymphatic 
channels when compared to ICG:HSA (Figure 1). It has been shown that in plasma, ICG 
preferably binds to α1-lipoprotein and γ-globulin, despite the higher concentration of 
albumin.19 Previous experiments have shown a higher increase in quantum yield when 
ICG is mixed with serum, in comparison to HSA.15 Therefore, the observed differences 
in visualization of lymphatics could likely be attributable to the protein constitution of 
lymph fluid. The high albumin content (20%) of ICG:HSA could also be a contributing 
factor, as the increased hydrodynamic diameter and higher viscosity could diminish 
ICG uptake in lymphatic channels. It should be noted that the anatomical variation 
(amount of tissue overlying the lymphatic channels) is also a major influencing factor 
and may be primarily responsible for the observed difference.
An optimal lymphatic tracer is non-toxic, has a high quantum yield (i.e., 
brightness), migrates quickly to the SLN, and does not migrate to higher tier nodes. 
If a tracer migrates to higher tier nodes, non-sentinel lymph nodes could incorrectly 
be identified as SLNs, causing more nodes than necessary to be resected. ICG is far 
from optimal; in aqueous solution the quantum yield is relatively low and due to its 
small hydrodynamic diameter, it can flow to higher tier nodes, as is the case with blue 
dyes. The synthesis and clinical introduction of an optimal probe will be the subject of 
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future studies and will greatly help to confirm the clinical benefit of NIR fluorescence 
imaging in the SLN procedure.15, 20 
In the current study, NIR fluorescence after ICG injection could consistently 
be visualized before the blue dye could be observed, which is consistent with earlier 
findings.14 Therefore, NIR fluorescence imaging has the potential to replace blue dyes 
in SLN mapping of breast cancer patients. Furthermore, as NIR fluorescence light 
penetrates relatively deep into tissue, it can potentially replace radiocolloids in SLN 
mapping in a selected group of patients, for example those with a low body mass index. 
A clinical trial on omitting blue dyes and using NIR fluorescence without the need for 
radiocolloids is currently ongoing (NTR2674).
In conclusion, this double-blind, randomized trial showed no advantage of 
ICG:HSA in comparison to ICG alone for the SLN procedure. To reduce the cost and 
complexity of the procedure, a dose of 500 µM ICG alone (1.6 ml) is recommended 
for NIR fluorescence SLN mapping in breast cancer patients. Therefore, this study has 
determined the optimal parameters that can be used to validate this technique in a 
larger series in order to investigate patient benefit.
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In early cervical cancer, a total pelvic lymphadenectomy is the standard of care even 
though most patients have negative nodes and thus undergo lymphadenectomy 
unnecessarily. Although the value of sentinel lymph node mapping in early stage 
cervical cancer has not yet been established, near-infrared (NIR) fluorescence imaging 
is a promising technique to perform this procedure. NIR fluorescence imaging is based 
on invisible NIR light and can provide high sensitivity, high-resolution, and real-time 
image-guidance during surgery.
Methods/materials
Clinical trial subjects were 9 consecutive cervical cancer patients undergoing total 
pelvic lymphadenectomy. Prior to surgery, 1.6 mL of indocyanine green adsorbed 
to human serum albumin (ICG:HSA) was injected transvaginally and submucosally 
in 4 quadrants around the tumor. Patients were allocated to 500, 750, or 1,000 µM 
ICG:HSA concentration groups. The Mini-FLARE™ imaging system was used for NIR 
fluorescence detection and quantitation.
results
Sentinel lymph nodes were identified in all 9 patients. An average of 3.4 ± 1.2 sentinel 
lymph nodes was identified per patient. No differences in signal to background of the 
sentinel lymph nodes between the 500, 750, and 1,000 µM dose groups were found 
(P = 0.73). In 2 patients, tumor-positive lymph nodes were found. In both patients, 
tumor-positive lymph nodes confirmed by pathology were also NIR fluorescent.
Conclusions
This study demonstrated preliminary feasibility to successfully detect sentinel lymph 
nodes in cervical cancer patients using ICG:HSA and the Mini-FLARE™ imaging 
system. When considering safety, cost-effectiveness, and pharmacy preferences, an 
ICG:HSA concentration of 500 µM was optimal for sentinel lymph node mapping in 
cervical cancer patients. 
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INtroduCtIoN
Approximately 11,000 women are diagnosed with cervical cancer annually in the 
United States, resulting in over 4,000 deaths per year.1 Cervical cancer is also the 
most common cause of cancer-related death in women in developing countries.2 
The prognosis of cervical cancer patients depends on tumor stage and tumor size, 
but nodal status remains the single most important prognostic factor.  The surgical 
treatment of invasive cervical cancer depends upon the FIGO stage of the patient at 
time of diagnosis.3 In early stage cervical cancer, a radical hysterectomy is performed 
in combination with a bilateral pelvic lymphadenectomy to detect lymphatic spread. 
Nodal tumor involvement occurs in up to 27% of early stage cervical cancer patients4 
and in these patients, radiotherapy or chemoradiation is the primary treatment of 
choice.5 Therefore, a total lymphadenectomy is performed unnecessarily in a substantial 
fraction of patients, exposing them to the risk of lymphedema and surgical injuries. 
SLN mapping and biopsy is an accepted procedure for vulvar cancer, cutaneous 
melanomas, and breast cancer; however, its reliability for clinical use in the treatment 
of early stage cervical cancer has not yet been established.6, 7 Research on the use of the 
SLN procedure in early stage cervical cancer patients has been extensively described 
using a blue dye, a radiocolloid such as 99mTechnetium (99mTc), or a combination of 
both with various results.8, 9 Van de Lande et al. published a literature review involving 
over 800 patients with cervical cancer in which they described detection rates of 
84%, 88%, and 97% when using blue dye alone, 99mTc alone, or a combination of 
both, respectively.10 Regarding the sensitivity to detect the SLNs, 99mTc, alone or in 
combination with blue dye, yielded the highest pooled sensitivity (92%, range 79%-
98%); however, this was not significantly higher than the pooled sensitivity of blue dye 
alone (82%, range 67%-92%). 
Due to the midline position of the cervix, it often has a bilateral multifarious 
drainage pattern, which makes the SLN procedure in cervical cancer patients more 
challenging than in breast cancer patients, for example. The main lymphatic drainage 
patterns have been described previously,11 and several studies have shown that 
satisfactory SLN detection in cervical cancer is established when SLNs are detected 
on both sides of the pelvis. Of note, status of a SLN on one side of the pelvis does not 
predict the nodal status of the other side.12 
NIR fluorescence imaging is a technique that can be used in real time during 
surgery. This technique uses invisible near-infrared light that can be visualized using 
specialized camera systems.13 NIR fluorescence imaging has several advantages, such as 
relatively high tissue penetration (up to 5 millimeters without special techniques), low 
autofluorescence, and the lack of ionizing radiation.14 Recent preclinical and clinical 
studies have demonstrated that near-infrared (NIR) fluorescence imaging using the 
NIR fluorescence agent indocyanine green (ICG) enables real-time intraoperative 
visualization of lymphatic channels and detection of the SLNs in various forms of 
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cancer without the need for radioactivity.15 Furthermore, previous preclinical work 
has demonstrated that adsorption of ICG to human serum albumin (HSA, complex 
is ICG:HSA) increases the fluorescence intensity and the hydrodynamic diameter, 
thereby providing improved detection and better retention in the SLN.16
Crane et al. recently described that the use of NIR fluorescence imaging in 
cervical cancer patients is technically feasible.17 ICG was injected after laparotomy. 
In this pilot study, a detection rate of 60% was reached, bilateral SLNs were detected 
in 30% of patients and 1 of 2 patients who had nodal involvement was false-negative. 
The aim of the current study was to assess the intraoperative use of NIR 
fluorescence imaging using ICG:HSA and the Mini-FLARE™ imaging system in SLN 
biopsy in cervical cancer patients. A secondary goal was to optimize the dose of the 
ICG:HSA NIR fluorescent lymphatic tracer.
MaterIaLS aNd MetHodS
Preparation of Indocyanine Green adsorbed to Human Serum albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2 
mM) stock solution for the 500-µM concentration group. Of this solution, 7.8 cc was 
transferred to a 50- cc vial of Cealb (20% human serum albumin (HSA) solution; 
Sanquin, Amsterdam, The Netherlands) to yield ICG in HSA (ICG:HSA) at a final 
concentration of 500 µM. ICG (25 mg vials) was resuspended in 5 cc of sterile water for 
injection to yield a 5.0 mg/ml (6.4 mM) for the 750-µM and 1,000-µM concentration 
groups. Of this solution, 5.8 cc or 7.8 cc was transferred to a 50-cc vial of Cealb (20% 
human serum albumin (HSA) solution to yield ICG in HSA (ICG:HSA) at a final 
concentration of 750 µM or 1,000 µM, respectively.
Intraoperative NIr Imaging System (Mini-FLare™)
SLN mapping was performed using the Mini-FLARE™ image-guided surgery system 
as described in Chapter 6. Briefly, the system consists of 2 wavelength-isolated light 
sources: a “white” light source, generating 26,600 lx of 400-650 nm light and a “near-
infrared” light source, generating 7.7 mW/cm2 of 760 nm light. Color video and NIR 
fluorescence images are simultaneously acquired and displayed in real time using 
custom optics and software that separate the color video and NIR fluorescence images. 
A pseudo-colored (lime green) merged image of the color video and NIR fluorescence 
images is also displayed. The imaging head is attached to a flexible gooseneck arm, 
which permits positioning of the imaging head virtually anywhere over the surgical 
field, and at extreme angles. For intraoperative use, the imaging head and imaging 
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system pole stand are wrapped in a sterile shield and drape (Medical Technique Inc., 
Tucson, USA).
Clinical trial
The single-institution clinical trial was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and was performed in accordance with the 
ethical standards of the Helsinki Declaration of 1975. A total of 9 consecutive patients 
with cervical cancer that planned to undergo a radical abdominal trachelectomy or a 
radical hysterectomy and a total pelvic lymphadenectomy were included. All patients 
provided informed consent and were anonymized. Exclusion criteria were pregnancy, 
lactation or an allergy to iodine, shellfish, or indocyanine green. All procedures were 
performed by 2 gynecologists who were assisted by experienced researchers.  Before 
the start of surgery, 1.6 mL ICG:HSA (concentration: 500, 750 or 1,000 µM) was 
transvaginally injected submucosally in 4 quadrants around the cervical tumor using 
a 21G, 1½ inch needle. Directly after the ICG:HSA injection, surgical scrub and sterile 
covering of the operation field commenced, and a laparotomy was performed. Before 
the systematic pelvic lymphadenectomy was performed, all standard locations (along 
the external iliac vessels and the hypogastric artery, along the common iliac artery, 
the obturator fossa and the lateral parametrium) were examined for NIR fluorescence 
using the Mini-FLARE™ imaging system. Fluorescent hotspots exhibiting a signal-to-
background ratio (SBR) ≥ 1.1 in vivo were considered positive by NIR fluorescence. 
All fluorescent hotspots were denominated as SLNs and were subsequently resected 
and measured for fluorescence ex vivo. Then, the systemic pelvic lymphadenectomy 
was performed and all resected LNs were also measured for fluorescence ex vivo. 
Lymphadenectomy consisted of removal of all lymph node-bearing fatty tissue along 
the external iliac vessels, the common iliac artery, the hypogastric artery, and from the 
obturator fossa.18 Also, the area lateral to and underneath the superior vesical arteries 
(lateral parametrium) was cleared from the lymphatic tissue. The radical hysterectomy 
and abdominal trachelectomy were performed according to the standard procedure. 
In case of a radical trachelectomy, histopathological frozen analysis was performed 
and when nodes were found to contain metastases, a hysterectomy was performed 
in addition. Afterwards, all resected lymph nodes were examined by routine 
histopathological analysis, and lymph nodes were fixed in formalin and embedded 
in paraffin for routine hematoxylin and eosin staining. SLNs and non-SLNs were 
examined separately. 
Statistical analysis
For statistical analysis and to generate graphs, GraphPad Prism Software (Version 5.01, 
La Jolla, USA) was used. Differences in SBR between concentration groups were tested 
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with a one-way analysis of variance (ANOVA) with subsequent pairwise comparisons 
corrected according to the Bonferroni correction. Assumption of equal variances was 
confirmed using Levene’s test. All statistical tests were two-tailed and P < 0.05 was 
considered significant. 
reSuLtS
Patient and tumor Characteristics
Patient and tumor characteristics are described in Table 1. Nine patients with stage 
Ib cervical cancer undergoing primary surgery were included in the study. Of these 
patients, median BMI was 21 (range 18-35), median age was 40 years (range 29-77 
years), and median tumor size was 3.05 cm (range 0.7-11 cm). One patient presented 
with an exophytic cervical tumor measuring 11 cm in length and 4 cm in width 
protruding into the vagina. Five patients underwent a radical hysterectomy and 3 
patients underwent a radical trachelectomy. In one patient, extensive endometriosis 
precluded radical hysterectomy. In this patient, the uterus was left in situ, but a pelvic 
lymphadenectomy was performed.
Intraoperative NIr Fluorescence Imaging
In all patients (N = 9), NIR fluorescence imaging enabled identification of 1 or more 
fluorescent hotspots. An example of the NIR fluorescence images of the procedure 
in cervical cancer is shown in Figure 1. Average time between injection of ICG:HSA 
and NIR fluorescence imaging was 51 ± 18 min. A total of 31 fluorescent hotspots 
were detected. On average, 3.4 ± 1.2 (range 1-5) fluorescent hotspots per patient were 
identified by NIR fluorescence (Table 2). Within these hotspots, a total of 41 lymph 
nodes were found after histopathological examination, yielding an average of 4.6 ± 
2.1 true lymph nodes per patient . In 3 fluorescent hotspots, adipose tissue only, with 









Type of Surgery Tumor Type Tumor 
Size (cm)
1 500 35 35 IB1 Trachelectomy Adenosquamous 2.5
2 500 43 26 IB2 Hysterectomy Squamous 4.5
3 500 77 21 IB2 Hysterectomy Squamous 11.0
4 750 46 30 IB1 No resection Squamous n/a
5 750 59 21 IB1 Hysterectomy Squamous 4.2
6 750 29 22 IB1 Trachelectomy Squamous 2.5
7 1000 30 18 IB1 Trachelectomy Squamous 1.0
8 1000 40 20 IB1 Hysterectomy Squamous 0.7
9 1000 34 21 IB1 Hysterectomy Squamous 3.6
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no lymph tissue present, was found after histopathological examination. An average 
of 25.1 lymph nodes (range 10-39) per patient were harvested. Histological analysis 
showed that 2 of 9 patients had metastases in a total of 3 SLNs. No other lymph node 
metastases were observed. 
Localization of Sentinel Lymph Nodes
A total of 31 fluorescent hotspots were confirmed to be SLNs. All SLNs were pelvic 
nodes and were identified along the left (n = 8) and right (n = 6) external iliac vessels, 
the right common iliac vessels (n = 4), the left (n = 5) and right (n = 4) obturator 
fossa, and the left (n = 2) and right (n = 2) lateral parametrium. Table 2 provides exact 
locations for all SLNs. In 8 of 9 patients, bilateral SLNs were found. After histological 
confirmation, 3 positive SLNs were found in 2 patients. In the first patient, the positive 
SLNs were located in the left lateral parametrium and along the right external iliac 
vessels. In the second patient, the positive SLN was located along the left external iliac 
vessels. 
Ex vivo imaging of lymph nodes
All lymph nodes were examined for fluorescence ex vivo using the Mini-FLARE™ 
imaging system. In 4 of 9 patients additional fluorescent hotspots (N=10) were 
identified, which were not identified during in vivo NIR fluorescence imaging 
(Table 2). Within 8 of these 10 hotspots, a total of 10 lymph nodes were found after 
histopathological examination and within 2 of 10 these hotspots, adipose tissue only, 
with no lymph node tissue present, was found after histopathological examination. 
The hotspots that contained lymph nodes were harvested along the left (n = 1) and the 
right (n = 1) external iliac vessels, and the left (n = 1) and the right (n = 5) obturator 
fossa. The hotspots that contained only adipose tissue were harvested along the left (n 
Figure 1. NIr Fluorescence-based SLN mapping using ICG:HSa and Mini-FLare™: Identification of two 
SLNs (arrows), located along the left iliac vessels, with NIR fluorescence imaging is demonstrated in a cervical 
cancer patient, 45 min after administration of 750 µM ICG:HSA. Camera exposure time was 100 msec. Scale bar 
represents 1 cm.
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= 1) and the right (n = 1) external iliac vessels. No additional metastases were found 
during ex vivo analysis. 
optimization of ICG:HSa dose
In all dose groups (500, 750, and 1,000 µM), fluorescence intensity of the SLN was 
significantly higher than the fluorescence intensity of surrounding tissue (P<0.001). 
Mean SBRs of the SLNs were 10.1 ± 1.2, 10.3 ± 1.2 and 12.0 ± 5.7 for the 500 µM, 
750 µM, and 1,000 µM dose groups, respectively (Figure 2). A one-way ANOVA test 
showed no significant differences in SBRs of SLNs between the different dose groups 
(P = 0.76). 
dISCuSSIoN
The current study showed the feasibility of the SLN procedure in early stage cervical 
cancer patients using ICG:HSA and the Mini-FLARE™ imaging system. The Mini-
FLARE™ imaging system that was used in the current study displays NIR fluorescence 
signal, color signal, and a merge of both and illuminates the surgical field with white 
light. This enabled the gynecologist to perform the SLN detection and resection under 
direct image guidance. The imaging head of the Mini-FLARE™ system is attached to 
a flexible gooseneck arm, which permitted flexible positioning of the imaging head 
at extreme angles over the surgical field. This is of particular importance in large 
abdominal surgery. During all procedures, intraoperative imaging using this imaging 
system was successful and uneventful.
No differences in SBR of the SLNs between the 500, 750, and 1,000 µM dose 
groups were found. The location of the NIR fluorescent SLNs was in concordance with 
formerly published drainage patterns.11 Furthermore, bilateral SLNs were found in 8 
of 9 patients. The 3 tumor-positive SLNs (in 2 patients) were located along the left 
external iliac vessels (n = 1), the right external iliac vessels (n = 1), and in the left lateral 
Figure 2. brightness of SLNs as a Function of ICG:HSa dose: Signal-to-background ratio (mean ± S.D) of the 
SLNs (ordinate) as a function of injected dose of ICG:HSA (abscissa). Statistical comparisons are as follows: The 
SBRs of the 500, 750, and 1,000 µM concentration groups were not significantly different. 




















































































































































































































































































































































































































































































































































parametrium (n = 1). Identification of a parametrial SLN is rather remarkable because 
there is presently no consensus on removal of parametrial lymph nodes during total 
pelvic lymphadenectomy.19-22 Although larger clinical trials will be required to answer 
this question, from this study we can at least conclude that parametrial lymph nodes 
are identifiable using ICG:HSA and Mini-FLARE™. 
The detection rate of SLNs in our pilot-study was 100% and this detection rate 
is in concordance with a prospective, multicenter cohort study of 590 patients that 
examined SLN mapping in cervical cancer patients and observed a detection rate of 
93.5% when a combination of patent blue and radiocolloids was used.23 In the current 
study, on average, a total of 3.4 SLNs were identified per patient intraoperatively, which 
is also consistent with previously published data.8, 9 In the recently published study 
by Crane et al.17 on NIR fluorescence SLN mapping in cervical cancer patients, ICG 
was injected after laparotomy and NIR fluorescence measurements were made directly 
after injection. Furthermore, ICG was diluted in patent blue prior to injection. These 
differences in study design along with the use of a different imaging system hinder a 
direct comparison of the results.
The optimal time interval between injection of ICG:HSA and NIR fluorescence 
imaging is still unknown.  Nevertheless, timing of imaging could be of great importance 
in terms of detection rate, sensitivity, and SBRs of SLNs. The mean interval between 
administration of ICG:HSA and NIR fluorescence measurements in the current study 
was 51 min. This time interval was relatively long because the ICG:HSA injection was 
performed prior to surgery, followed by surgical scrub and operation time to expose 
the iliac vessels. During surgery, no more than several minutes were needed for SLN 
detection and resection.
Ex vivo NIR fluorescence imaging of total lymphadenectomy specimens 
detected 10 additional fluorescent hotspots in 4 of 9 patients. Detection of these 
additional fluorescent hotspots during ex vivo imaging could possibly be explained by 
the relatively long time interval between ICG:HSA administration and performance 
of the total lymphadenectomy. Although ICG:HSA has an improved hydrodynamic 
diameter compared to ICG alone, passage through the SLN to second tier nodes can 
still possibly occur if the time interval is long enough. An alternative explanation for 
the additional ex vivo detected fluorescent hotspots is that these hotspots were missed 
in vivo due to technical limitations, as for example, the limited penetration depth 
(millimeters) for NIR fluorescent light. Future larger studies are needed to optimize 
timing and to evaluate the importance of additional fluorescent hotspots that are 
missed in vivo and are detected in the resection specimen. Nevertheless, to bypass this 
pitfall, the development of new lymphatic tracers that are retained in the SLN without 
flowing through to higher tier nodes is imperative to optimize NIR fluorescence SLN 
mapping in cervical cancer.
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In the current study, fluorescent hotspots were found in vivo (n = 3) and ex vivo 
(n = 2) that did not contain lymphatic tissue but consisted of adipose tissue, which 
is not an uncommon observation in the SLN procedure. A plausible explanation 
for these fluorescent hotspots is that fluorescent lymph fluid can exit the lymphatic 
channel, due to extensive manipulation during surgery or anatomical aberrations, for 
example. If detection of a relatively small number of these hotspots does not obfuscate 
the identification of the true SLNs, this phenomenon does not negatively influence the 
SLN procedure.
In a recently published dose-finding clinical study performed by our group using 
NIR fluorescence SLN mapping in breast cancer patients, an optimal ICG:HSA dose 
range between 400 and 800 µM was found.15 In the 1,000 µM ICG:HSA dose group, 
the fluorescent intensity and the SBR of the SLNs decreased, most probably caused by 
an effect known as fluorescence quenching.24 In the current study, no differences were 
found in SBRs between the 500, 750, and 1,000 µM dose groups. This lack of difference 
combined with pharmacy preferences, safety, previous results, and costs make a dose 
of 500 µM most convenient to perform the SLN procedure in cervical cancer patients.
As in other areas of surgery, the use of laparoscopy is expanding in cancer 
surgery. Lymphadenectomies are being performed laparoscopically as standard of care 
in several centers. NIR fluorescence may also be of great value in laparoscopic surgery 
because palpation is not possible and the surgeon can only rely on visual inspection 
and preoperative imaging. To implement NIR fluorescence in laparoscopic surgery, 
laparoscopic NIR fluorescence camera systems are currently being developed and 
tested.25
In conclusion, we assessed the potential value of NIR fluorescence imaging in 
SLN mapping in early stage cervical cancer patients. Although sample size was small, 
this study showed a high SLN detection rate (100%) and no false-negative lymph 
nodes. However, to prove actual patient benefit and to assess sensitivity more precisely, 
larger clinical trials will be necessary.
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Near-infrared (NIR) fluorescence imaging has the potential to improve sentinel 
lymph node (SLN) mapping in vulvar cancer, which was assessed in the current study. 
Furthermore, dose optimization of indocyanine green adsorbed to human serum 
albumin (ICG:HSA) was performed. 
Methods
Nine vulvar cancer patients underwent the standard SLN procedure using 
99mtechnetium-nancolloid and patent blue. In addition, intraoperative imaging was 
performed after peritumoral injection of 1.6 mL of 500, 750 or 1000 μM of ICG:HSA.
results
NIR fluorescence SLN mapping was successful in all patients. A total of 14 SLNs 
(average 1.6, range 1-4) were detected: 14 radioactive (100%), 11 blue (79%), and 14 
NIR fluorescent (100%). 
Conclusions
This study demonstrates feasibility and accuracy of SLN mapping using ICG:HSA. 
Considering safety, cost, and pharmacy preferences, an ICG:HSA concentration of 500 
M appears optimal for SLN mapping in vulvar cancer.
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INtroduCtIoN
Vulvar cancer is a relatively rare disease with an annual incidence of approximately 
4000 cases in the United States, resulting in 900 deaths per year.1 Tumor size and 
invasion into adjacent tissues are important factors for staging vulvar cancers, but 
nodal status remains the single most important prognosticator.2 Radical vulvectomy 
with en bloc inguinofemoral lymphadenectomy has been replaced in the surgical 
treatment of vulvar cancer by radical wide local excision or radical vulvectomy 
with inguinofemoral lymphadenectomy using separate groin incisions.3 The latter 
modification has significantly decreased surgery-related morbidity.3 However, 30% 
to 70% of patients treated with full inguinofemoral lymphadenectomy still suffer 
from lymphedema.4-6 Only 27% of patients with clinically stage I or II vulvar cancer 
have tumor positive lymph nodes; therefore, approximately 70% of patients undergo 
unnecessary lymphadenectomy.6
The sentinel lymph node (SLN) biopsy, as introduced in the management of 
cutaneous melanoma by Morton,7 was first described in vulvar cancer by Levenback in 
1994.8 The SLN procedure in vulvar cancer patients has been validated in multicenter 
trials and its introduction in regular clinical practice has marked a significant reduction 
in lymphedema, wound infection, and wound dehiscence.9, 10 Currently, the procedure 
usually involves a combination of a radioactive colloid and a blue dye. However, the 
use of radiotracers requires complex logistics including the involvement of a nuclear 
medicine physician and the transport of radioactivity, and is therefore not available 
in all clinics. Moreover, blue dyes cannot be visualized when the lymph nodes and 
lymphatic channels are covered by tissue, such as skin or fat.
The use of invisible near-infrared (NIR) light (700-900 nm) has several 
characteristics that can be advantageous in the SLN procedure, which include 
relatively high penetration into living tissue (millimeters to centimeters), when 
compared to blue dyes, and the lack of ionizing radiation.11 Indocyanine green (ICG) 
is one of only 2 clinically available NIR fluorescent agents and is currently the most 
optimal agent for SLN mapping.12 In several studies, intraoperative imaging systems 
in combination with ICG have been used for the SLN procedure for various types of 
cancer.13-18 The lymphatic channels and SLNs in vulvar cancer are often located in a 
relatively superficial location in the groin when compared to other tumors; therefore, 
NIR fluorescence imaging could be particularly useful for this indication. Indeed, 
Crane et al. reported the successful use of ICG alone at a concentration of 645 μM, in 
conjunction with an intraoperative imaging system for the SLN procedure in vulvar 
cancer.19 In that study involving 10 patients, 26 of 29 SLNs (90%) were detected in vivo 
by NIR fluorescence. Furthermore, lymphatic channels could be visualized in 5 of 16 
groins (31%) containing SLNs.
Preclinical evidence demonstrated that premixing of ICG with human serum 
albumin (HSA, complex is ICG:HSA) increases the fluorescence intensity and 
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hydrodynamic diameter of ICG, resulting in better retention in the SLN.20 The aims of 
the current study were to assess the use of NIR fluorescence imaging using ICG:HSA 
and the Mini-FLARE intraoperative imaging system for the SLN procedure in vulvar 
cancer and to optimize ICG:HSA dose.
MaterIaLS aNd MetHodS
Preparation of Indocyanine Green adsorbed to Human Serum albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 mL of sterile water for injection for the 500 µM group, or in 5 
mL of sterile water for injection for the 750 µM and 1000 µM groups, to yield stock 
solutions of 3.2 mM and 6.4 mM, respectively. Various amounts of this stock solution 
were transferred to a 50 cc vial of Cealb (20% human serum albumin [HSA] solution; 
Sanquin, Amsterdam, The Netherlands) to yield ICG in HSA (ICG:HSA) at a final 
concentration of 500 µM, 750 µM, or 1000 µM.
Intraoperative NIr Fluorescence Imaging
SLN mapping was performed using the Mini-FLARE image-guided surgery system as 
described in detail previously.14 Briefly, the system consists of 2 wavelength separated 
light sources: a “white” LED light source, generating 26,600 lx of 400 to 650 nm light 
to illuminate the surgical field and an NIR LED light source, generating 7.7 mW / cm2 
of fluorescence excitation light. White light and NIR fluorescence images are acquired 
simultaneously and displayed in real time, using custom designed optics and software. 
A pseudo-colored (lime green) image of NIR fluorescence superimposed over the 
white light image is also displayed, to provide the NIR fluorescence signal in proper 
anatomical context.
Clinical trial
The current dose escalation clinical trial was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and was performed in concordance with the 
ethical standards of the Helsinki Declaration of 1975. Nine consecutive patients that 
planned to undergo a SLN procedure for squamous cell vulvar carcinoma were included 
in this study between June 2010 and January 2011. All patients had clinically FIGO 
stage I vulvar cancer with a unifocal carcinoma measuring less than 4 cm in diameter, 
not encroaching the vagina, anus or urethra and with negative inguinofemoral nodes 
as determined by palpation and ultrasonography. Exclusion criteria were pregnancy, 
lactation or an allergy to iodine, shellfish, or indocyanine green.
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All patients gave informed consent and were anonymized. Patients received 
the standard-of-care SLN procedure.9 For our institution, this implies peritumoral 
injections of 60-100 MBq 99mtechnetium-nanocolloid on the afternoon of the day 
before, or the morning prior to surgery. Before the start of the operation, 1 mL total 
of patent blue V (Guerbet, France) was injected at 4 sites peritumorally. Immediately 
after injection of patent blue, 1.6 mL total of ICG:HSA was injected as 4 injections at 
the same location as the patent blue injections. After surgical scrub, the Mini-FLARE 
imaging head was positioned at approximately 30 cm above the surgical field. The 
NIR fluorescence signal was measured percutaneously, prior to skin incision, and 
continuously during the surgical procedure. Throughout the procedure, the surgeon 
was continuously provided with real-time NIR fluorescence image guidance. When the 
SLN could not be found easily by NIR fluorescence, the handheld gamma probe could 
be used for the localization of SLNs. Relative brightness of the SLNs was determined 
by measuring signal-to-background ratios (SBR), that is the NIR fluorescence signal 
of the SLN divided by a directly adjacent region. Excised sentinel lymph nodes were 
analyzed ex vivo for NIR fluorescence and radioactivity and were routinely analyzed by 
histopathological frozen section analysis. SLNs were fixed in formalin and embedded 
in paraffin for hematoxylin, eosin, and immunohistopathological staining for AE1/
AE3 at multiple levels, with an interval of 250 μm, according to the GROningen 
INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) study protocol.9 
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 17.0, Chicago, USA) 
was used. Graphs were generated using GraphPad Prism Software (Version 5.01, La 
Jolla, USA). To compare the SBR between concentration groups, a one-way analysis 
of variance (ANOVA) was performed with pairwise comparison with least square 
difference (LSD) adjustment for multiple comparisons. Assumption of homogeneity 
of variances was assessed using Levene’s test. All statistical tests were two-tailed and P 
< 0.05 was considered significant.
reSuLtS
Patient and tumor Characteristics
Nine consecutive patients with vulvar cancer undergoing SLN mapping were included 
in this study. Patients and tumor characteristics are described in Table 1. Median body 
mass index (BMI) was 27 (range 23-45), median age was 50 years (range 30-72 years), 
and median tumor size was 13 mm (range 4-22 mm). In 6 patients, the tumor was 
laterally located and in 3 patients the tumor was located on, or near, the midline.
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Intraoperative NIr Fluorescence Imaging
Average time between ICG:HSA injection and skin incision was 19 ± 4 minutes. In 
all patients (N = 9), NIR fluorescence imaging using the Mini-FLARE system enabled 
visualization of one or more SLNs (Figure 1). Average time between skin incision and 
resection of the first SLN was 13 ± 5 minutes. A total of 14 SLNs were detected, all of 
which were radioactive and fluorescent (Table 2). Four SLNs from 3 patients did not 
have blue staining from patent blue. After all NIR fluorescent nodes were resected, 
the surgical field was systematically inspected for remaining radioactivity or blue 
nodes. No additional nodes were found that were not detected by NIR fluorescence. 
No adverse reactions associated with the use of ICG:HSA or the Mini-FLARE imaging 
system were observed.







Tumor Type Tumor Size
(mm)
1 500 72 33 Right Squamous 22
2 500 30 22 Right Squamous 10
3 500 67 26 Left Squamous 10
4 750 37 29 Midline Squamous 17
5 750 42 45 Left Squamous 22
6 750 37 23 Right Squamous 20
7 1000 72 27 Midline Squamous 6
8 1000 50 26 Midline Squamous 4
9 1000 74 32 Left Squamous 13
Abbreviation: BMI = body mass index
Figure 1. Sentinel lymph node mapping using NIr fluorescence imaging in vulvar cancer: Peritumoral 
injection of 1.6 mL of 500 µM ICG:HSA (injection site covered by hand) identifies lymphatic channels, which 
converge in a SLN (arrow) that can be seen percutaneously (top row). Identification of the SLN (arrow) and two 
afferent lymphatic channels (arrowheads) is demonstrated using NIR fluorescence imaging 17 min after injection 
of ICG:HSA (bottom row). Camera exposure times were 100 msec (top row) and 45 msec (bottom row). Scale 
bars represent 1 cm.
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The effect of Lymphatic tracer dose on SLN brightness
The effect of injected lymphatic tracer dose on fluorescence brightness was determined 
by comparing SBRs between concentration groups. Mean SBRs of the SLNs were 
12.3 ± 2.9, 16.6 ± 4.3, and 9.5 ± 4.3 for the 500, 750 and 1000 µM concentration 
groups, respectively (Figure 2). A one-way ANOVA showed no significant effect of 
concentration on SBR (P = 0.16), and pairwise comparison with LSD adjustment for 
multiple comparison showed no difference between the individual concentration and 
SBR, although a trend was found for a decreased SBR of the 1000 µM group when 
compared to the 750 µM group (P = 0.07). However, due to the small sample size, the 
current pilot study may not have sufficient power to detect significant differences in 
dose groups.
Percutaneous visualization of Lymphatic Channels
The mean BMI of patients in which lymphatic channels were visualized percutaneously 
to all SLN containing groins (N = 5 patients) was 24.8 ± 2.2. In patients with bilateral 
SLNs in which percutaneous visualization was possible for the groin (N = 2 patients), 







1 2 (1 left, 1 right) 2 2 2 0 Unilateral
2 1 (right) 1 1 1 0 Yes
3 1 (left) 1 1 1 1 Yes
4 2 (1 right, 1 left) 2 1 2 0 Unilateral
5 1 (left) 1 1 1 0 No
6 1 (right) 1 1 1 0 Yes
7 1 (left) 1 0 1 0 Yes
8 4 (2 left, 2 right) 4 3 4 0 Yes
9 1 (left) 1 1 1 1 No
total 14 14 (100%) 11 (79%) 14 (100%) 2 8 of 12 groins
Abbreviation: SLN+ = number of SLNs containing tumor cells
Figure 2. optimization of ICG:HSa dose: Signal-to-background ratio (mean ± S.D.) of vulvar SLNs (ordinate) is 
plotted as a function of injected dose of ICG:HSA (abscissa). The SBRs of the 500, 750, and 100 µM concentration 
groups were not significantly different, although a trend was found favoring 750 µM over 1000 µM (P = 0.07).
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the mean BMI was 31.0 ± 2.8, and in patients where percutaneous visualization of 
lymphatic channels was not possible (N = 2 patients), the mean BMI was 38.5 ± 9.2. A 
one-way ANOVA showed a significant difference in the BMIs between these 3 groups 
(P = 0.024). A pairwise comparison with LSD adjustment for multiple comparison 
showed a significantly higher BMI for the group in which percutaneous visualization 
of lymphatic channels was not possible, when compared to the group in which 
percutaneous visualization of lymphatic channels was possible (P = 0.009).
dISCuSSIoN
The current study showed feasibility and accuracy of SLN mapping in vulvar cancer 
using ICG:HSA and the Mini-FLARE imaging system. In all 9 cases, the Mini-FLARE 
permitted the gynecologist to perform SLN mapping under direct image-guidance 
after skin incision. The flexible gooseneck of the Mini-FLARE could be used to 
position the system at any required location over the surgical field, which ensured no 
interference with the procedure. Indeed, no additional time was needed to complete 
the procedure, with an average time between skin incision and resection of the first 
SLN of 13 ± 5 minutes.
All radioactive SLNs could also be detected by NIR fluorescence. This higher 
detectability compared to the study by Crane et al. that utilized ICG alone19 may be 
due to improved brightness of ICG:HSA over ICG, better retention in the SLN, better 
imaging system performance, an optimized tradeoff between injection concentration 
and tracer dilution within lymphatic channels, or a combination thereof.14 In contrast, 
4 out of 14 SLNs could not be detected by patent blue, which is comparable to previous 
findings.10, 19, 21 Lymphatic channels could be visualized in the majority of patients 
prior to skin incision. This aided the gynecologist in determining the location of the 
incision and facilitated a more efficient identification of SLNs. In the patients where 
percutaneous visualization of lymphatic channels was not possible, a higher BMI 
was observed when compared to patients where the lymphatic channels could be 
visualized percutaneously. Crane et al. observed similar findings.19 Future studies will 
have to determine whether NIR fluorescence imaging can replace radiocolloids in the 
SLN procedure in vulvar cancer, which could potentially be feasible only in non-obese 
patients. This could be particularly beneficial in clinics where radiotracers are not 
available. Furthermore, as the patient population in Western societies tends to suffer 
from increasingly higher BMIs, the penetration depth has to be increased for NIR 
fluorescence imaging to be a generally usable imaging modality. To accomplish this, 
current research is focusing on improved fluorophores (some of which are currently 
in the process of clinical approval22) and  improved camera systems using optimized 
detection techniques to maximize the depth at which a fluorophore can be detected.23, 
24
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In the current study, no significant differences in NIR fluorescence signal were 
observed between the different concentrations that were administered. However, a 
trend was observed showing a decline of signal in the 1000 μM group, which is in 
line with previously reported results in breast cancer.14 A decrease of fluorescence 
signal with an increase in concentration can be explained by an effect in fluorescence 
quenching.12 Fluorescence quenching occurs when the concentration of a fluorophore 
is too high, causing molecules to absorb the emitted light of other nearby molecules, 
thereby effectively attenuating the fluorescence signal. In the current study, ICG was 
adsorbed to HSA prior to injection. Preclinical work has shown premixing to increase 
the fluorescence brightness of ICG and improve retention in the SLN.20 Flow to higher 
tier nodes seemed to have been avoided, as no additional NIR fluorescent nodes were 
identified that were not radioactive.  An ongoing study is investigating whether the 
albumin is actually needed for optimal SLN mapping in vulvar cancer. When the 
optimal imaging parameters have been determined, larger trials can be performed to 
assess patient benefit.
In conclusion, the current study demonstrates the feasibility of SLN mapping 
in vulvar cancer patients using ICG:HSA and the Mini-FLARE image-guided surgery 
system. The preferred dose can be determined by local preparation preferences 
because no differences between tested doses were observed. In general, a dose of 500 
μM seemed to be optimal, as it requires minimal manipulation of ICG and albumin 
volumes.
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Chapter 10 
The FLare™ intraoperative near-infrared 
fluorescence imaging system: a first-in-
human clinical trial in perforator flap 
breast reconstruction
Lee BT, Hutteman M, Gioux S, Stockdale A, Lin SJ, Ngo LH, Frangioni JV




The ability to determine flap perfusion in reconstructive surgery is still primarily based 
on clinical examination. In this study, we demonstrate the use of an intraoperative, 
near infrared (NIR) fluorescence imaging system for evaluation of perforator location 
and flap perfusion.
Methods
Indocyanine green (ICG) was injected intravenously in six breast cancer patients 
undergoing a deep inferior epigastric perforator (DIEP) flap breast reconstruction after 
mastectomy. Three dose levels of ICG were assessed using the Fluorescence-Assisted 
Resection and Exploration (FLARE™) imaging system. This system uses light emitting 
diodes (LED) for fluorescence excitation; different from current commercially available 
systems. In this pilot study, the operating surgeons were blinded to the imaging results.
results
Use of the FLARE™ system was successful in all six study subjects with no complications 
or sequelae. Among the three dose levels, 4-mg per injection resulted in the highest 
observed contrast-to-background ratio (CBR), signal-to-background ratio, and 
signal-to-noise ratio. However, due to small sample size, we did not have sufficient 
power to detect statistical significance for these pairwise comparisons at the multiple-
comparison adjusted type-I error of 0.017. Six mg per injection provided a similar 
CBR, but also a higher residual background signal.
Conclusions
Based on this pilot study, we conclude that NIR assessment of perforator flap breast 
reconstruction is feasible with an LED based system, and that a dose of 4 mg of ICG per 
injection yields the best observed CBR compared to a dose of 2 or 6 mg for assessment 
of flap perfusion.
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INtroduCtIoN
The use of imaging as an adjunct is becoming increasingly popular in perforator flap 
reconstruction. As perforating vessels demonstrate a high degree of variability in size 
and location, identification of target vessels can decrease operative time and increase 
reliability. The currently used techniques for imaging include duplex ultrasound, CT, 
and MRI.1-8 With improvements in technology and resolution, reconstructive surgeons 
are able to visualize small perforating vessels.
The current imaging modalities, however, rely on a static preoperative assessment. 
Ideally, the use of an intraoperative imaging adjunct would be most beneficial in order 
to provide a dynamic assessment. Changes in flap physiology and microsurgical flap 
transfer could be assessed more accurately if imaging was performed during surgery.
Our laboratory has previously described the use of a real time, near-infrared 
(NIR) Fluorescence-Assisted Resection and Exploration (FLARE™) imaging system in 
large animal surgery.9-11 This system uses light-emitting diodes (LEDs) for fluorescence 
excitation and requires an intravenous injection of indocyanine green (ICG), an FDA-
approved fluorophore. Because NIR light is invisible, the surgical field is unaltered. 
Our current system simultaneously displays real-time color video, up to two NIR 
fluorescence images, and merged images of all. Rapid recall of images is also available 
as needed.
We have described previously the ability of NIR imaging to identify suitable 
perforators during large animal surgery.12 In addition, we validated the number of 
perforators identified with conventional x-ray angiography.13 The identification of 
perforators can be performed reliably at multiple anatomic sites, including abdominal 
and submental flaps.14 Finally, we were able to describe quantitative metrics to assess 
arterial and venous compromise.15
During an extensive pre-clinical laboratory experience with NIR fluorescence 
angiography using the FLARE™ imaging system, we have demonstrated safety in use 
in over 200 rodent and 100 large animal surgeries. This study describes the successful 
clinical translation of this technology for use in a six-subject pilot trial in patients 
undergoing microsurgical perforator flap breast reconstruction with a deep inferior 
epigastric perforator (DIEP) flap. In addition, determination of ideal ICG dosage was 
performed based on a quantitative assessment.
MaterIaLS aNd MetHodS
Preparation of NIr Fluorophore
Indocyanine green (ICG) USP (25-mg vials) was purchased from Akorn (Decatur, 
USA) and resuspended in 10 mL of supplied diluent to yield a 2.5 mg/mL (3.2 mM) 
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stock solution. For each participant, four syringes were loaded with either 0.8 mL, 
1.6 mL, or 2.4 mL of the ICG stock solution, equivalent to 2 mg, 4 mg, or 6 mg per 
injection.
FLare™ Intraoperative Imaging System
The FLARE™ imaging system and its use in a clinical setting have been described 
previously for sentinel lymph node resection.9 Briefly, the imaging system consists 
of an imaging head mounted on an articulated arm and a cart containing control 
equipment, computer, and monitors (Figure 1). The imaging head has a 43” to 70” 
reach relative to the floor and a 50.7” reach from the cart, and can be positioned 
anywhere in 3-D space with six degrees of freedom. The system is engineered to 
meet all relevant subsections of the Association for the Advancement of Medical 
Instrumentation (AAMI)/International Electrotechnical Commission (IEC) standard 
#60601. A customized software system enables the real-time display of color video 
and two NIR fluorescence channels at up to 15 frames-per-sec. The software is capable 
of displaying the NIR fluorescence signal as a pseudo-colored overlay on the color 
video, thereby providing anatomical guidance to the surgeon. For intraoperative use, 
the entire system is wrapped in a sterile shield and drape (Medical Technique Inc., 
Tucson, USA). Additional details can be found in 10 and at www.frangionilab.org.
Clinical trial during breast reconstruction Surgery
The clinical trial was approved by the Institutional Review Board (IRB) of the Beth 
Israel Deaconess Medical Center and performed in concordance with the ethical 
standards of the Helsinki Declaration of 1975. The IRB deemed the FLARE™ imaging 
system a “non-significant risk” device. All subjects gave written informed consent 
Figure 1. The FLaretM Imaging System: The cart-based imaging system is shown with major parts identified. A 
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and identifying information was anonymized. Clinical trial participants were women 
undergoing unilateral mastectomy and reconstruction with a microsurgical deep 
inferior epigastric perforator (DIEP) flap. Subjects received four injections of either 
2 mg, 4 mg, or 6 mg ICG each. Two patients received each dose level. Before flap 
elevation, the camera was positioned 18” over one side of the abdomen and NIR 
imaging was performed using the FLARE™ system after an intravenous injection of 
ICG. Imaging system settings included 14 mW/cm2 of 760-nm NIR fluorescence 
excitation light and a 67-msec camera exposure time. After ICG was cleared from 
the body and fluorescence levels restored to pre-injection levels, the contralateral 
side of the abdomen was imaged in an identical fashion. In this feasibility and dose-
finding study, the operating surgeons were blinded to the FLARE™ images, thereby not 
changing the standard-of-care that patients were receiving during surgery.
After dissection of the vessels through the intramuscular course and isolation of 
the selected perforator vessels and vascular pedicle, the flap was imaged at the abdomen 
with a third ICG injection prior to transfer. The flap was then transferred to the chest 
and a microsurgical anastomosis was performed of the deep inferior epigastric artery 
and vein to the internal mammary vessels. A final assessment was performed with a 
fourth ICG injection. Subjects were evaluated for complications at one week and six 
weeks after surgery as part of regular postoperative follow-up.
analysis of Near-Infrared Fluorescence data
After each injection, NIR fluorescence data were acquired using the FLARE™ system 
continuously preceding the vascular signal; acquisition continued until two minutes 
after onset of vascular fill. Contrast-to-background ratio (CBR) was defined as the mean 
fluorescence intensity of the region of interest (ROI) minus the mean fluorescence 
intensity of a background ROI on the flap, divided by the mean camera noise. Signal-
to-background ratio (SBR) was defined as the mean fluorescence intensity of the ROI, 
divided by the mean fluorescent intensity of a background ROI on the flap. Signal-to-
noise ratio (SNR) was defined as the mean fluorescence signal of the ROI divided by 
the mean camera noise.
CBR, SBR, and SNR were calculated and recorded for each injection and 
compared among the three dose groups. Since this is a repeated-measures analysis 
with each subject receiving multiple injections, we used a modeling method to account 
for within-subject measurements correlation. We first examined the distribution of 
CBR, SBR, and SNR via the use of the Shapiro-Wilks test to check for normality of 
each variable. The assumption of normality was satisfied for CBR, and SNR, but not 
for SBR. The variability was also heterogeneous with the standard deviation for dose 
4 mg and 6 mg higher than that of dose 2 mg. Thus the modeling would also need to 
take into account the difference in dose-specific variability of these three variables. 
For CBR and SNR, with the normality assumption satisfied, we made use of the linear 
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mixed-effects model,16, 17 which allows the modeling of the variance-covariance matrix 
of the within-subject measurements. We used the compound symmetry structure to 
model the within- and between-subject variance components, which was assumed to 
be heterogeneous among the three different dose levels (the variances for dose 4 mg 
and 6 mg were estimated higher than that of the dose 2 mg, and these variances were 
used in the linear mixed-effects model). For SBR, due to the non-normality of the 
distribution, we used a generalized estimating equation (GEE),18 which could model 
the within-subject correlation via the exchangeable working correlation structure. 
We used linear contrasts to obtain the pairwise comparisons among the three dose 
levels. We set the adjusted level of significance (type-I error) to 0.017 (0.05 divided 
by 3 comparisons) when we made inference on the pairwise comparisons. We used 
the SAS/STAT (SAS/STAT Software, Version 8, SAS Institute, Cary, USA) procedure 
MIXED and GENMOD for our statistical modeling.
reSuLtS
deployment of the FLare™ System in the operating room
The preparation and ergonomics of the FLARE™ system in the operating room are 
similar to our previous description.9 The system was draped in a sterile fashion using a 
shield/drape combination that could be applied by a single person (scrub nurse). After 
draping, the imaging head enters the sterile field and is positioned at a fixed distance 
and position before each injection. Including positioning of the system, each injection 
and subsequent FLARE™ measurement required less than three minutes, thereby not 
significantly affecting the normal operative course. 
The FLARE™ system is housed in a portable cart for easy transfer into the 
operating room. The cart houses two monitors for the technologist operating the system; 
one monitor displays the control software while the other displays a duplicate of the 
surgeon’s monitor. The surgeon’s monitor is on a satellite pole that can be positioned 
up to 16 feet away from the cart. The articulating head is specifically designed with six 
degree-of-freedom movements. Depression of a brake release button on the handle 
permits smooth and precise positioning over the field. Release of the button engages 
the brakes, thereby fixing the head in three-dimensional space. The maximum reach 
of the articulating head is 50.7 inches from the cart.
Intraoperative NIr Imaging of Perforator vessels during reconstructive Surgery
After IRB approval, six subjects participated in a first-in-human clinical trial using 
the FLARE™ system in reconstructive breast surgery after mastectomy. Precautions 
were taken to maintain the standard-of-care by blinding the surgeons to the results 
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of NIR imaging. Subjects were assigned to three dose groups (n = 2 subjects per dose 
group) of 2 mg, 4 mg, or 6 mg per injection. Clinical study subject characteristics are 
displayed in Table 1. 
Subjects received an intravenous bolus injection of ICG that was administered 
by the anesthesiologist at four separate, fixed moments during surgery, as described 
above. Representative FLARE™ images of each dose group are shown in Figure 2. 
CBR, SBR, and SNR were quantified using the ROI as displayed in Figure 1 and are 
summarized in Table 2 and Figure 3. Observed mean and median values of all three 
variables were higher in the 4-mg group when compared to the 2-mg and 6-mg group. 
The variability of all three variables was also higher in the 4-mg and 6-mg dose. For 
CBR, the only comparison statistically significant at the multiple-comparison adjusted 
type-I error of 0.017 was between 2-mg and 6-mg (p-value: 0.0007) (see footnote Table 
2). No statistically significant differences at the level of 0.017 were found for SBR and 
SNR among the 3 dose levels.
The average time intervals between injections 1 and 2, 2 and 3, and 3 and 4 
were 19 min/36 sec, 3 h/16 min/41 sec, and 2 h/12 min/42 sec, respectively. The effect 
of dose on mean background fluorescence intensity between injections 1 and 2 was 
significant (ANOVA, F (2, 20) = 5.761, p = .011). Notably, the background fluorescence 
intensity was higher in the 6-mg group, when compared to both the 2-mg (p = .009) 
and 4-mg groups (p = .008), indicating residual ICG fluorescence.
In two cases, the surgeon selected and dissected perforator vessels that, by NIR 
imaging, were not the dominant vessels (example in Figure 3). CBR was measured 
for the NIR-dominant perforator vessel and the selected perforator vessel (Figure 4A) 
after all injections. As is displayed, the CBR of the previously NIR-dominant perforator 
vessel decreases after ligation and the CBR of the selected perforator vessel increases. 
These findings are consistent with the visual display seen during NIR imaging (Figure 
4B).
Postoperative Complications
None of the subjects developed any adverse reactions to the injected ICG. Minor 
complications were reported in three cases: a small area of fat necrosis, a breast seroma, 
and a small area of mastectomy skin loss. All complications were within normal range 
and resolved uneventfully. No partial or total flap loss occurred.
dISCuSSIoN
This study demonstrates the successful translation of NIR angiography with the 
FLARE™ imaging system for use in microsurgical perforator-flap breast reconstruction. 
The design of our optical imaging system incorporated the ergonomic needs for 
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Figure 2. NIr Fluorescence Imaging after ICG Injection: a. Identification of perforating vessel (dashed circle) 
after injection of 2 mg (top), 4 mg (middle), or 6 mg (bottom) ICG on transferred skin flaps. Contrast was 
quantified using fluorescence intensity of the perforating vessel and background (solid circle). b. Typical CBR 




Figure 3. Near-infrared fluorescence contrast per dose of indocyanine green (ICG): a. Contrast-to-
background ratio (CBR), signal-to-background ratio (SBR), and signal-to-noise ratio (SNR) in each dose group. 
Contrast-to-background ratio was defined as (Iperforator – Ibackground)/Inoise, where I is fluorescence intensity. Observed 
mean and median values of all three variables were higher in the 4-mg group compared with those in the 2-mg 
and 6-mg groups, though the only statistically significant difference was contrast-to-background ratio of the 2-mg 
group compared to the 6-mg group. The p values for 2 mg versus 4 mg were as follows: contrast-to-background 
ratio, p = 0.053; signal-to-background ratio, p = 0.084; and signal-to-noise ratio, p = 0.028. The p values for 2 mg 
versus 6 mg were as follows: contrast-to-background ratio, p = 0.0007; signal-to- background ratio, p = 0.068; 
and signal-to-noise ratio, p = 0.024. b. Effect of indocyanine green dose on contrast after repeated injections. C. 
Effect of indocyanine green dose on background intensity after injection 2. After repeated injection of 6 mg of 
indocyanine green, the background intensity remains increased in comparison with the 2-mg (p = 0.009) and 
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Figure 4 – Selected perforator is not the NIr fluorescence dominant perforator: a. Quantification of the 
signal confirms the increase in fluorescence intensity of the selected perforator and decrease in intensity of the 
perforator that was not chosen. b. Left and right sides of the abdomen are assessed before perforator dissection 
(two top rows) and the right side is chosen. Since the surgeon was blinded, NIR fluorescence information was 
not available for perforator selection. The perforator with the highest intensity (small arrow) was not selected in 
favor of a less fluorescent perforator (large arrow). After perforator dissection (third row) and subsequent transfer 




completely self-contained; it can easily be transferred into the operating room and 
deployed rapidly. The ability to visualize the operative field simultaneously with NIR 
fluorescence is particularly advantageous. As the reconstructive surgeon is able to 
recall stored video and images, the findings can be correlated with surgical findings 
without any distortion.
NIR fluorescence imaging has the potential to find widespread use in plastic 
and reconstructive surgery, as well as general and oncologic surgery. It provides real-
time guidance for tumor resection,19, rapid identification of sentinel lymph nodes,9 
real-time avoidance of critical structures, such as nerves and blood vessels,20 and 
quantitation of tissue metrics.15 
By altering the intravenous dose of the fluorophore ICG we determined that 4 
mg of ICG per injection had the highest observed CBR for clinical NIR angiography, 
although a larger study with more statistical power will be needed to better define 
the optimal dose. In addition, at a time interval of ≈ 20 min between injections, 4 mg 
resulted in significantly less residual background fluorescence intensity compared to 6 
mg. Use of a higher dose would require a longer time interval, i.e., a longer clearance 
period, between doses to avoid dose stacking. It should be noted that even with repeat 
dosing at 6 mg, the total dose (24 mg) was below the standard package size (25 mg).
The use of a real-time, intraoperative imaging system is particularly 
advantageous in microsurgical perforator flap reconstruction in order to provide a 
dynamic assessment of flap perfusion. In this study, we performed four assessments: 
both sides of the abdominal flap prior to elevation, the selected abdominal flap after 
isolation on the perforators prior to transfer, and the same flap after microsurgery. This 
permitted a comparison of perforator vessel selection and identification, analysis of flap 
perfusion after isolation on the perforating vessels, and differences after flap harvest 
and microsurgical transfer. Flap physiology changes with vessel isolation, harvest, 
and transfer, so that obtaining real-time NIR imaging at multiple points becomes a 
dynamic process. This is in contrast to preoperative imaging modalities such as duplex 
ultrasound, CT, or MRI, where identification of the dominant perforator is a static one-
time assessment. In the future, we plan to use NIR imaging to assist directly in vessel 
selection and isolation, as well as to apply quantitative metrics previously validated in 
large animal model systems,15 to determine arterial or venous insufficiency. 
In two cases, the dominant perforator identified by NIR imaging was not the 
perforator selected by the operating surgeon. This occurred as the surgeon was blinded 
to the results of the FLARE™ system. Of note, the CBR at the dominant perforator 
decreased after ligation, and the CBR at the selected perforator increased to the 
previous level of the dominant perforator (Figure 3A). This further demonstrates 
that flap physiology is often altered during surgery and the results will differ from 
preoperative imaging. The changes in flap physiology from perforator vessel isolation 
can only be seen with a real-time, intraoperative system. 
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The early clinical use of NIR imaging has been described previously.21-29 The 
imaging systems used in these studies were limited to a handheld camcorder device. 
These systems provide subjective, qualitative results with low resolution. In addition, 
the outputs from previous generation devices were single grayscale images. As these 
systems used laser-induced fluorescence, the ICG dose was also higher at 0.5 mg/kg,29 
so that an average 70-kg patient would require a 35-mg dose. 
Newer commercially available NIR imaging systems, such as the SPY 
system (Novadaq Technologies Inc., Toronto, Canada), have been used recently in 
reconstructive surgery.30, 31 These early clinical experiences mirror the results seen in 
our study. There are major differences between the two imaging systems, however. 
The SPY system is laser-based while the FLARE™ system is LED-based; this may 
pose differences in eye safety in the operating room. More importantly, the FLARE™ 
imaging system acquires color video and NIR fluorescence images simultaneously 
and is capable of real-time overlay of the invisible NIR light images onto the color 
video images. This provides the surgeon with unambiguous surgical landmarks for 
image-guided surgery. The FLARE™ system also has the ability to quantify perforator 
perfusion metrics, as previously shown by our laboratory.14, 15, 32 The cost of parts in 
quantity 1 for the FLARE™ imaging system is ≈ $120,000 USD. A miniaturized version 
of FLARE™, termed Mini-FLARE™, costs ≈ $40,000 USD (Chapter 6). 
Although this is the first successful clinical pilot study with the FLARE™ system in 
reconstructive surgery, there are many areas that will need to be evaluated. Larger-
scale studies need to be performed to assess clinical benefits. Each NIR angiography 
evaluation takes only two minutes, and a more effective decision-making process for 
perforator selection could potentially decrease overall operative times. Other benefits 
include the potential ability to prevent complications associated with poor perfusion. 
The costs associated with the additional use of this type of technology also need to 
be assessed. One limitation of the FLARE™ system is its 15-cm field of view:  it is 
possible that flaps larger than this size would not be completely captured. For example, 
imaging was performed on each side of the abdomen, as the entire abdominal flap 
could not be captured with one scan. Finally, the surgeons in this study were blinded 
to the results of NIR imaging; in future studies we plan to have the surgeons directly 
apply the imaging results in perforator choice and flap design. 
CoNCLuSIoN 
This is the first-in-human study demonstrating use of the FLARE™ system for NIR 
angiography in microsurgical perforator-flap breast reconstruction. It represents 
the successful translation of the technology from pre-clinical to clinical use. In this 
pilot study, an ICG dose of 4 mg per injection resulted in the highest observed CBR, 
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SBR, and SNR relative to 2-mg and 6-mg dose; however, a larger study with sufficient 
statistical power is needed to confirm this result.
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Intraoperative visualization of pancreatic tumors has the potential to improve radical 
resection rates. Intraoperative visualization of the common bile duct and bile duct 
anastomoses could be of added value. In this study, we explored the use of indocyanine 
green (ICG) for these applications, and attempted to optimize injection timing and 
dose.
Methods
Eight patients undergoing a pancreaticoduodenectomy were injected intravenously 
with 5 or 10 mg ICG. During and after injection, the pancreas, tumor, common bile 
duct, and surrounding organs were imaged in real-time using the Mini-FLARE™ near-
infrared (NIR) imaging system.
results
No clear tumor-to-pancreas contrast was observed, except for incidental contrast in 
one patient. The common bile duct was clearly visualized using NIR fluorescence, 
within 10 minutes after injection, with a maximal contrast between 30 to 90 min after 
injection. Patency of biliary anastomoses could be visualized due to biliary excretion 
of ICG. 
Conclusion 
No useful tumor demarcation could be visualized in pancreatic cancer patients after 
intravenous injection of ICG. However, the common bile duct and biliary anastomoses 
were clearly visualized during the observation period. Therefore, these imaging 
strategies could be beneficial during biliary surgery in cases where the surgical anatomy 
is aberrant or difficult to identify.
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INtroduCtIoN
Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United 
States, with an incidence of approximately 38,000 cases and an estimated 34,000 
deaths. The overall 5-year survival rate is very low (< 5%).1 Approximately 10% to 15% 
of patients are eligible for surgical resection, which is presently the only potentially 
curative treatment option. Even after curative resection, the reported 5-year survival 
rates are disappointing and vary from 10% to 17 %.2-5 Several factors, such as tumor 
size, lymph node status, tumor grade, and blood vessel invasion are correlated with 
prognosis. Involvement of tumor margins is an important prognostic factor, as reported 
survival for R0 (radical) resections (20.3 months) is twice that of R1 resections (10.3 
months).6 For preoperative staging and determination of resectability, the imaging 
procedure of choice is a multiphase, multidetector helical computed tomography (CT) 
with intravenous administration of a contrast agent combined with an endoscopic 
ultrasonography.7 
During pancreatic surgery, assessment of the extent of the pancreatic tumor 
is made based on visual inspection and palpation, sometimes in conjunction with 
intraoperative ultrasonography.8, 9 Intraoperative tumor identification remains 
challenging, partly because the surrounding pancreatic tissue is frequently inflamed. 
Local recurrence rates of 72% to 86% are reported,10-12 which in part could be caused by 
inadequate intraoperative evaluation of the location and extent of the tumor.   
Near-infrared (NIR) fluorescence imaging is a promising technique to 
facilitate intraoperative, real-time, visual information.13-15 In order to detect tumors 
using NIR fluorescence, contrast agents that target tumor-specific characteristics can 
be used to selectively label tumor cells.16-19 Novel NIR fluorescent agents have been 
developed that target tumor-specific cell surface markers,16, 20 enzymatic activity,17, 19, 
21 or increased glucose metabolism.22 However, these tumor-specific agents are not yet 
available for clinical use. The only NIR fluorescent contrast agents currently available, 
methylene blue and indocyanine green (ICG), are not tumor-specific. However, the 
enhanced permeability and retention (EPR) effect can potentially be used to obtain 
accumulation of non-targeted contrast agents in tumors.23, 24 Due to newly formed, 
more porous blood vessels, molecules can passively accumulate into the surrounding 
tissue. Furthermore, poorly developed lymphatics in the tumor result in an increased 
retention. Previous studies showed breast carcinomas and liver tumors could be 
identified noninvasively with NIR fluorescence using ICG based on the EPR effect.25-28 
The aim of our study was to assess the applicability of NIR fluorescence imaging using 
ICG to provide a clear tumor-to-background contrast in oncologic pancreatic surgery. 
Because ICG is almost exclusively excreted into the bile, it can also be used for
intraoperative NIR fluorescence exploration of the biliary anatomy.29-31 This can be 
useful in patients with a difficult laparoscopic cholecystectomy, due to an aberrant 
biliary anatomy or an acute cholecystitis, for example. Furthermore, ICG can potentially 
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be used to assess anastomosis patency in patients undergoing bile duct reconstruction. 
This is a well-suited setting to study both biliary anatomy and anastomosis patency 
intraoperatively, as the common bile duct can be visualized for a long time during 
pancreaticoduodenectomy.
MaterIaLS aNd MetHodS
Intraoperative Near-Infrared Imaging System (Mini-FLare™)
Intraoperative imaging was performed using the hand-held Fluorescence-Assisted 
Resection and Exploration (Mini-FLARE™) image-guided surgery system as described 
in Chapter 6.32 This system consists of two wavelength isolated light sources: a 
“white” light source, generating 26,600 lx of 400-650 nm light and a NIR light source, 
generating 7.7 mW/cm2 of 760 nm light. Color video and NIR fluorescence images are 
simultaneously acquired and displayed in real-time using custom optics and software 
that separate the color video and NIR fluorescence images. A pseudo-colored (lime 
green) merged image of the color video and NIR fluorescence images is also displayed. 
The imaging head is attached to a flexible gooseneck arm, which permits positioning 
of the imaging head virtually anywhere over the surgical field, even at extreme angles. 
For intraoperative use, the imaging head and imaging system pole stand are wrapped 
in a sterile shield and drape (Medical Technique Inc., Tucson, USA).
Preparation and administration of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 mM) 
stock solution. Of this stock solution 2 or 4 mL, corresponding with doses of 5 or 10 
mg, was administered. 
Clinical trial
The study was approved by the Local Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975. A total of 8 consecutive patients with suspected 
ampullary or pancreatic head carcinoma planned to undergo curative resection 
were included. All patients provided informed consent. Exclusion criteria included 
pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine green. The 
surgical technique used in our center implies a standard pancreaticoduodenectomy 
with resection of peripancreatic tissues and lymph nodes. Following resection, 
reconstruction is performed with pancreaticojejunostomy, choledochojejunostomy, 
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and pylorojejunostomy for pylorus preserving pancreaticoduodenectomy or a 
gastrojejunostomy as part of Whipple’s procedure. After opening the omental bursa, 
performing the Kocher maneuver, and exploration of the hepatoduodenal ligament, 
the pancreatic tumor was fully exposed. The Mini-FLARE imaging system was 
positioned 30 centimeters above the surgical field. Next, 4 patients were intravenously 
administrated 5 mg ICG diluted in 2 mL sterile water as a bolus and 4 patients were 
intravenously administrated 10 mg ICG diluted in 4 mL sterile water as a bolus. All 
operating room lights, with the exception of the white light and NIR light of the Mini-
FLARE imaging system, were dimmed. The NIR fluorescence measurements of the 
pancreatic tumor, pancreas, duodenum, stomach, liver, gall bladder, and common bile 
duct were recorded at the time of injection (T=0), 45 seconds and 3-, 10-, 30-, 60-, 90-, 
120-, 180- min post-injection. At each measurement, camera exposure times were set 
appropriately to prevent the NIR fluorescence signal from reaching saturation. Bile duct 
imaging ended at 90 min because the bile duct was resected at this time as part of the 
pancreaticoduodenectomy. Furthermore, imaging of the choledochojejunostomy was 
performed to assess leakage and patency. Fluorescent intensity of these structures was 
quantified using the custom Mini-FLARE software. To calculate tumor-to-pancreas 
ratios, tumor and healthy pancreas regions of interest were manually drawn, guided by 
palpation. Signal-to-background ratios (SBR) for the common bile duct were manually 
drawn, and a background region of interest was drawn on direct surrounding tissue.  
Statistical analysis
For statistical analysis and graph design, GraphPad Prism Software (Version 5.01, La 
Jolla, USA) and SPSS (Version 17.0, Chicago, USA) were used. All data were reported as 
mean ± standard deviation or median and range. To compare the signal-to-background 
ratios between the two concentration groups, T-tests were used. Repeated-measures 
ANOVAs were used to test differences between time points. All statistical tests were 
two-tailed and P < 0.05 was considered significant.
reSuLtS
Patient and tumor characteristics are listed in Table 1. Eight patients undergoing 
surgery for a suspected ampullary or pancreatic head carcinoma were included in 
the study. In one patient, the common bile duct was cut several minutes after ICG 
administration and therefore measurements beyond 3 min were excluded from the 
analysis. Four patients underwent a complete Whipple procedure, three patients 
underwent a pylorus preserving pancreaticoduodenectomy, and one patient had an 
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tumor Imaging
Directly after injection, superficial arterial flow of ICG was identified by NIR 
fluorescence on the surface of the pancreas followed by venous drainage. In the 5- mg 
patient group (N = 4), a mean tumor-to-pancreas ratio of 0.89 ± 0.25 was observed. In 
the 10-mg patient group (N = 4), a mean tumor-to-pancreas ratio of 1.22 ± 0.39 was 
observed (Figure 1a). Time had no significant effect on tumor-to-pancreas ratio (P = 
0.899). Tumor-to-pancreas ratios were significantly higher in the 10-mg group, when 
compared to 5-mg group (P = 0.002). In one patient (patient 5, 10-mg dose group), a 
clear NIR fluorescent hotspot was observed on the pancreas (Figure 1b). Histological 
analyses confirmed that the signal corresponded to tumor tissue surrounding the 
pancreatic duct. Other than this incidental finding, no contrast was observed.
Imaging of the Common bile duct using NIr Fluorescence
Within 10 min after administration of ICG, the common bile duct, cystic duct, and 
common hepatic duct could clearly be identified by NIR fluorescence (Figure 2a 
and b) in all patients. The NIR fluorescence signal of the liver outshined the left and 
Figure 1. tumor-to-Pancreas Contrast using NIr Fluorescence and ICG: a. Tumor-to-pancreas ratios (mean 
± SD) of the pancreatic tumors over time, per dose group. b. Color video (left panel), NIR fluorescence (middle 
panel) and a color-NIR overlay (right panel) of intraoperative imaging of the pancreas. In this example, clear 
contrast (arrow) is shown between pancreatic tumor and normal pancreatic tissue (P), 20 min after administration 





right hepatic ducts and therefore prevented a clear visualization. The fluorescent 
signal of the bile ducts lasted until 90 min postinjection, at which point the bile duct 
was resected, along with the head of the pancreas and the duodenum, as part of the 
pancreaticoduodenectomy. No difference was observed between the 5-mg and 10-
mg groups (P = 0.849). Time significantly influenced signal-to-background ratio 
(P = 0.002). An optimum was found between 30 and 90 min postinjection, with a 
maximum mean signal-to-background ratio of 6.24 ± 1.32 at 60 min postinjection. 
After completion of the choledochojejunostomy, anastomotic patency could be 
confirmed by visualizing the NIR fluorescence signal passing the anastomosis into the 
jejunum (Figure 2c). 
Figure 2. Intraoperative Imaging of the Common bile duct using NIr Fluorescence and ICG: a. Signal-
to-background ratios (mean ± SD) of the common bile duct over time, per dose group. Signal-to-background 
ratios (SBR) for the common bile duct were calculated. A background region-of-interest was drawn on direct 
surrounding tissue. b. Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right 
panel) of intraoperative imaging of the common bile duct in a patient who underwent a cholecystectomy during 
previous surgery, 30 min after administration of 5 mg ICG. A clear contrast is shown between common bile 
duct (arrow) and surrounding tissue. C. Color video (left panel), NIR fluorescence (middle panel) and a color-
NIR overlay (right panel) of a choledochojejunostomy (arrow), 30 min after completion of the anastomosis. NIR 
fluorescence signal of excreted ICG is visualized intraluminally in the jejunum, indicating anastomotic patency 
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biodistribution of ICG
The NIR fluorescence signal of the pancreas, stomach, liver, duodenum and common 
bile duct was measured at fixed time intervals (Figure 3). As reported in preclinical 
studies 30, within the first 2 min vascular signal (an arterial phase followed by a venous 
phase) could be visualized. The pancreas, stomach and duodenum showed comparable 
washout patterns. As ICG is cleared by the liver, the liver and common bile duct 
exhibited high levels of NIR fluorescence, indicating hepatic uptake and clearance in 
bile.
dISCuSSIoN
The first objective of this study was to exploit the EPR effect23, 24 to induce retention 
of the non-targeted probe ICG in pancreatic tumors. However, in all but one patient, 
no useful intraoperative tumor-to-pancreas ratios in pancreatic cancer patients were 
observed using NIR fluorescence and ICG. In one patient, a clear hotspot was observed 
on the pancreas, which corresponded with the resected adenocarcinoma. No specific 
pathological characteristics were observed that could account for this phenomenon. 
Several factors might explain the observed lack of contrast in all other patients. 
Healthy pancreas tissue showed a relatively high uptake of ICG, whereas tumor tissue 
showed similar uptake. As washout of NIR fluorescence signal was comparable in both 
healthy pancreas tissue and tumor tissue, no EPR effect could be visualized. This is 
possibly the result of different tumor biology of pancreatic cancer when compared to 
breast cancer, in which the EPR effect has been observed in previous studies. Several 
earlier studies reported a lower perfusion of tumor tissue in comparison with healthy 
pancreas tissue,33, 34 which might decrease availability of ICG for a potential EPR effect 
of the tumor. Furthermore, previous studies that reported an EPR effect of ICG in 
breast tumors used detection methods (laser scanning or optical tomography), that 
Figure 3. biodistribution of ICG in organs exposed during Pancreaticoduodenectomy: Shown are NIR 
fluorescence intensities of organs exposed during pancreaticoduodenectomy. Measurements of the duodenum 
were taken over an area not containing bile. Intensities are shown over time for both 5 mg (left panel) and 10 mg 
(right panel) groups. 
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may detect lower concentrations of ICG but require post-processing, and are therefore 
not applicable for real-time intraoperative imaging.26, 27
Novel NIR fluorescent probes are being developed to increase signal 
penetration depth and decrease background uptake. For multiple applications within 
cancer surgery, it is imperative to design improved tumor targeting probes. Tumor 
targeting can be accomplished by conjugating a fluorophore to a targeting ligand such 
as antibodies or peptides, for example.16, 19, 21, 22 It is expected that several of those tumor 
targeted probes will be available for first-in-human trials within the coming years.
The second objective of this study was to evaluate the biodistribution of ICG and 
its clearance by the liver into the bile. Patients undergoing a pancreaticoduodenectomy 
are well suited for this study, as the bile ducts and abdominal organs can be studied 
for a relatively long time. As stated before, iatrogenic common bile duct injury occurs 
in patients undergoing cholecystectomy. A non-invasive imaging modality that can 
visualize the common bile duct intraoperatively could potentially reduce the incidence 
of common bile duct injury in these patients. For example, this technique can help 
the surgeon identify vital structures during difficult laparoscopic cholecystectomies 
in patients with acute cholecystitis or aberrant biliary anatomy. This technique could 
potentially prevent the need to convert to an open procedure. 
In this study, the common bile duct was identified using NIR fluorescence 
imaging after ICG administration in all patients. This is in concordance with 
preclinical data, described by Matsui et al.30 and in clinical studies of patients 
undergoing cholecystectomy.29, 31 A useful contrast between the common bile duct 
and surrounding tissue was observed starting at 10 min postinjection. The optimal 
timing of ICG administration prior to imaging lies between 30 and 90 min. In this 
interval, mean SBRs of 5 to 6 were observed. Ideally, background fluorescence levels 
of all surrounding organs should be minimal. In this study, the liver signal remained 
high throughout the imaging interval. Although this did not prevent a contrast being 
observed between common bile duct and surrounding tissues, future studies should 
focus on optimal timing to minimize background fluorescence, especially when 
studying the liver. Indeed, in a separate study, in which patients with colorectal liver 
metastases were injected intravenously with 10 mg ICG at 24 hours prior to liver 
surgery, liver fluorescence decreased to background levels, while bile duct imaging 
was still possible. However, compared to the fluorescent intensity observed in the 
present study, the bile duct signal was significantly decreased by 88 % (van der Vorst 
et al., manuscript in preparation). Therefore, novel NIR fluorescent agents should be 
developed that are excreted into bile, with minimal liver uptake, thereby reducing 
background fluorescence and increasing the ability to visualize bile ducts. In contrast 
to most other imaging systems, the Mini-FLARE imaging system used in this study 
can display the NIR fluorescence signal in relation to the surgical anatomy, by 
simultaneously displaying color video and NIR fluorescence. This feature is of added 
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benefit in performing true image-guided surgery. The Mini-FLARE can only be used 
during open surgery. However, most cholecystectomies are performed by laparoscopy. 
In order to enable intraoperative NIR fluorescence imaging during laparoscopic 
surgery, laparoscopic camera systems are currently being developed and tested.30, 31, 35 
Furthermore, as with all novel techniques, large clinical studies are necessary to prove 
the added value of NIR fluorescence imaging in patients undergoing a cholecystectomy. 
These trials can use the data presented in this study to select the optimal time of 
imaging after ICG administration.
This study showed that no useful tumor demarcation could be visualized in 
pancreatic cancer patients using intraoperative NIR fluorescence imaging after ICG 
administration. Furthermore, our study showed the ability to visualize the common 
bile duct after ICG administration and demonstrated the influence of time on signal-
to-background ratio. Moreover, patency of the jejunal-biliary anastomosis could be 
visualized. For a translation to clinical practice, larger trials should be executed.  This 
is dependent on broad availability of commercial intraoperative NIR fluorescence 
imaging systems. When these imaging systems become available for use in the clinic 
in the coming years, the true value of this technique can be assessed.
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Chapter 12 
Identification and image-guided resection 
of occult superficial liver metastases using 
indocyanine green and near-infrared 
fluorescence imaging
van der Vorst JR1, Hutteman M1, Schaafsma BE, Mieog JSD, Verbeek FPR, Liefers 
GJ, Hartgrink HH, Löwik CWGM, Kuppen PJK, Smit VTHBM, Frangioni JV, van de 
Velde CJH, Vahrmeijer AL





Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) is a 
promising technique for identifying and resecting colorectal liver metastases, however, 
optimal dosage and timing is not known. The current study was performed to assess 
feasibility of NIR fluorescence in liver surgery and to assess the optimal dose of ICG 
and timing of ICG administration.
Methods
The Mini-FLARE™ imaging system was used for real-time identification of colorectal 
liver metastases in 22 patients undergoing liver resection. NIR fluorescence imaging 
was performed 24 or 48 h after systemic administration of 10 or 20 mg ICG. Resected 
specimens were prepared for ex vivo macroscopic and microscopic evaluation of 
fluorescent patterns.
results
A total of 40 superficially located colorectal liver metastases were identified and 
resected using NIR fluorescence imaging and ICG. In all patients, ICG fluorescence 
was seen as a rim around the tumor, located microscopically in the transition zone 
between tumor and normal liver tissue. Median tumor-to-liver ratio (TLR) was 
7.4 (range 1.9 – 18.7) and no significant differences between time-points or doses 
were found. Four metastases detected using NIR fluorescence were occult and not 
visible using preoperative CT, palpation, or intraoperative ultrasound (IOUS). NIR 
fluorescence also distinguished benign liver lesions from metastases. Preoperative CT, 
IOUS, and/or palpation, however, found seven lesions, all deeper than 8 mm, which 
were not seen using NIR fluorescence.
Conclusions
This study suggests that NIR fluorescence imaging is complementary to conventional 
imaging for liver metastasectomies, and has the potential to improve surgical care.
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INtroduCtIoN
Prognosis and survival of colorectal cancer patients depends primarily on the 
occurrence of distance metastases, which occur most frequently in the liver.1 A 
resection with curative intent can offer patients with colorectal liver metastases a 
5-year survival rate of 36% to 60%.2-5 Despite improvements in preoperative imaging 
modalities, surgical techniques, and chemotherapy regimens, intrahepatic recurrence 
rates vary from 11% to 37.5%, and 65% to 85% of these recurrences appear within 2 
years after resection.2, 6-9 A possible explanation for this high intrahepatic recurrence 
rate is that some hepatic metastases are already present at time of liver resection, 
but were undetected by preoperative imaging, intraoperative ultrasound (IOUS), 
and inspection by the surgeon. It is known that small and superficially located liver 
metastases are difficult to identify using conventional imaging modalities such as 
preoperative computed tomography (CT) and IOUS.10-12
Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) is a 
promising technique to intraoperatively visualize the contrast between liver metastases 
and normal liver tissue in real time.13, 14 ICG is excreted exclusively into the bile 
after intravenous injection. It has been hypothesized that colorectal liver metastases 
can be visualized due to passive accumulation of ICG caused by hampered biliary 
excretion, which results in a fluorescent rim around the metastasis. Recently, Ishizawa 
et al.13 described the intraoperative detection of colorectal liver metastasis using NIR 
fluorescence imaging after intravenous ICG injection 1 to 14 days prior to surgery. 
The interval between ICG injection and surgery is one of the key determinants of 
the remaining background fluorescence signal of the liver and the fluorescent rim 
surrounding the tumor. In a preclinical study in rats, performed by our group, the 
influence of injection time prior to surgery and dose of ICG on the contrast between 
the fluorescent rim around the hepatic metastases and normal liver tissue (tumor-to-
liver ratio) was examined.15 In this preclinical study, the highest tumor-to-liver ratio 
was reached when ICG was injected 72 hours prior to surgery. Furthermore, this study 
demonstrated that even small liver metastases (1 mm) could be identified using NIR 
fluorescence. In the current study, these preclinical results were translated to a clinical 
trial in colorectal cancer liver metastases patients in order to optimize intraoperative 
identification of liver metastases using ICG. 
MaterIaLS aNd MetHodS
Intraoperative Near-Infrared Imaging System
Intraoperative NIR fluorescence imaging of the liver was performed using the Mini-
FLARE™ image-guided surgery system as described in Chapter 6.16 Briefly, the system 
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consists of 2 wavelength isolated light sources: a “white” light source, generating 
26,600 lx of 400 to 650 nm light and a “near-infrared” light source, generating 7.7 mW/
cm2 of 760 nm light. Color video and NIR fluorescence images are simultaneously 
acquired and displayed in real-time using custom optics and software that separate 
the color video and 800 nm NIR fluorescence images. A pseudo-colored (lime green) 
merged image of the color video and NIR fluorescence images is also displayed. The 
imaging head is attached to a flexible gooseneck arm, which permits positioning of 
the imaging head virtually anywhere over the surgical field, and at extreme angles. For 
intraoperative use, the imaging head and imaging system pole stand are wrapped in a 
sterile shield and drape (Medical Technique Inc., Tucson, USA).
Preparation and administration of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2 mM) 
stock solution. Of this stock solution 4 or 8 mL, corresponding to doses of 10 or 20 mg, 
was administered intravenously. 
Clinical trial
The study was approved by the Local Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical standards 
of the Helsinki Declaration of 1975. A total of 22 consecutive patients with suspected 
colorectal liver metastases who were planning to undergo curative intended liver 
resection were included. All patients provided informed consent. Exclusion criteria 
were pregnancy, lactation or an allergy to iodine, shellfish or indocyanine green. 
Patients received 10 mg or 20 mg of ICG diluted in a total volume of 4 mL and 
8 mL, respectively, as an intravenous bolus at 24 or 48 hours prior to surgery on an 
inpatient base. This resulted in 4 groups of 4 patients per group (N = 16 patients). 
Subsequently, six patients were included at the optimal combination of ICG dose and 
injection time. During surgery and after mobilization of the liver, NIR fluorescence 
signal of metastases and normal liver were measured using the Mini-FLARE™ imaging 
system. Directly following liver resection, liver resection specimens were immediately 
delivered to the Department of Pathology, where the specimens were sliced into 5 to 7 
mm thick slices and examined for NIR fluorescence using the Mini-FLARE™ imaging 
system.
Fluorescence Microscopy
Based on macroscopic evaluation and ex vivo fluorescence imaging, the transition area 
between tumor and normal liver tissue was identified whereupon these areas were 
snap-frozen on dry ice. Frozen tissue sections of 20 μm were measured for fluorescence 
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using the Nuance multispectral imager (CRi, Woburn, USA) mounted on a Leica DM 
IRE2 inverted microscope (Leica, Wetzlar, Germany) and subsequently stained with 
hematoxylin and eosin. White light images where created using the same microscope 
and subsequently merged with fluorescence images.
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 17.0, Chicago, 
USA) was used. Graphs were generated using GraphPad Prism Software (Version 
5.01, La Jolla, USA). Tumor-to-liver (TLR) signal, rim fluorescence, and background 
fluorescence were reported as median and range. Tumor size was reported as mean 
and standard deviation. To test differences between groups, the Kruskal-Wallis one-
way analysis of variance test and the Dunn’s Multiple Comparison Test were used to 
test for differences between time and dose groups. Statistical tests were two-tailed and 
P < 0.05 was considered significant.
reSuLtS
Study Subjects
Patient and tumor characteristics of the 22 patients included are listed in Table 1. In 
five patients, no liver resection was performed due to invasion of tumor into the portal 
vein (N = 3), the presence of additional irresectable liver metastases (N = 1), or the 
appearance of lymph node metastases (N = 1). These patients were included for TLR, 
rim fluorescence and background fluorescence analysis. 
Intraoperative detection of colorectal liver metastases
Results of liver metastases detection are summarized in Table 1. Using a combination 
of preoperative CT scanning, IOUS, visual inspection, and/or palpation, a total of 49 
lesions were identified as suspected colorectal liver metastases. After resection, six of 
these lesions were histologically proven to be benign, for a net detection of 43 metastatic 
lesions by conventional imaging. NIR fluorescence imaging (Fig. 1) detected a total of 
40 lesions proven histologically to be metastases (Table 1), all of which were ≤ 6.2 mm 
from the surface of the liver capsule. 
However, only 36 of the 40 lesions identified using NIR fluorescence 
overlapped with conventional imaging. In four patients, superficially located, occult 
liver metastases were detected using NIR fluorescence but not by conventional 
imaging (Fig 2). After resection, these lesions were found to be 2, 4, 6, and 9 mm in 
diameter. Histopathological examination confirmed these lesions to be colorectal liver 
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metastases. One of these 4 occult lesions was labeled as a complicated cyst based on 
IOUS and CT, whereas the clear NIR fluorescent ring around the lesion suggested that 
it was a liver metastasis. Seven liver metastases identified by conventional imaging 
could not be identified using NIR fluorescence and were located 8, 13, 13, 16, 24, 30, 
and 32 mm beneath the liver surface. 
In addition to liver metastases, a total of four hemangiomas and four cysts 
were identified in four patients. These hemangiomas and cysts did not show a NIR 
fluorescent signal or rim (Fig. 2). Thus, NIR fluorescence imaging appeared to 
differentiate benign from malignant lesions. 
optimization of ICG dose and injection timing
To determine the effect of ICG dosage and post-injection imaging time, patients were 
allocated to two dose groups and imaged at two time-points after ICG administration, 
resulting in four groups containing four patients per group. Subsequently six more 
patients were included at the most favorable combination of ICG dose and time of 
table 1. Patient Characteristics
Characteristic Median (range) /
N (%)
Age 63 (49 - 77)
BMI 25 (19 - 38)
Sex (M / F) 10 (45%) / 12 (55%)
Primary tumor location
  - Colon 11 (50)
  - Sigmoid 5 (22.7)
  - Rectum 5 (22.7)
  - Anus 1 (4.5)
Primary Tumor type
  - Adenocarcinoma 14 (63.6)
  - No vital tumor cells 2 (9.1)
  - No resection 6 (27.3)
Primary Tumor size (mm) 20 (1.7 - 70)
Type of resection
  - Right hemihepatectomy 1 (4.5)
  - Left hemihepatectomy 1 (4.5)
  - Left lateral hepatic resection + metastasectomy 3 (13.6)
  - Metastasectomy 9 (40.9)
  - Metastasectomy + Radiofrequency ablation 1 (4.5)
  - Radiofrequency ablation 1 (4.5)
  - No resection 6 (27.3)
Number of liver metastases identified A 
  - Preoperative CT scan, IOUS, and/or palpation 43 B
  - Intraoperative (NIR fluorescence) 40 C
A  Liver metastases were confirmed by histology or in the case of non-resected lesions 
by clinical appearance, IOUS, and CT. 
B  7 of these lesions were not seen by NIR fluorescence imaging. 
C  4 of these lesions were not seen by preoperative CT scan, IOUS, and/or palpation.
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injection. Fluorescence intensity of the rim around the liver metastases was significantly 
higher than the fluorescent signal in the liver (P < 0.001). Median tumor-to-liver ratio 
(TLR) in all patients was 7.4 (range: 1.9 – 18.7). Median TLRs were 6.4 (range: 2.2 – 
15.4), 6.7 (range: 2.7 – 9.2), 10.5 (range: 1.9 – 18.7), 8.0 (range: 7.0 – 9.3) for the 10 mg 
at 24 hr, 20 mg at 24 hr, 10 mg at 48 hr and 20 mg at 48 hr patient group, respectively 
(Fig. 4). Median rim fluorescence (normalized pixel value) was 700.1 (range: 220.7 – 
1144.5), 938.4 (range: 902.3 – 1239.1), 648.6 (range: 137.1 – 1929.36), 608.5 (range: 
507.6 – 688.1) for the 10 mg at 24 hr, 20 mg at 24 hr, 10 mg at 48 hr and 20 mg at 48 
hr patient group, respectively (Fig. 4). Median background fluorescence (normalized 
pixel value) was 97.9 (range: 53.6 – 165.9), 209.1 (range: 96.1 – 356.5), 64.6 (range: 53.4 
Figure 1 – NIr fluorescence imaging of colorectal liver metastases: A colorectal liver metastasis (arrow) is 
clearly identified by a rim around the tumor in vivo (top row), 24 h after injection of 10 mg ICG. Normal liver 
tissue (arrowhead) shows minimal background uptake of ICG. After resection and slicing of the specimen, the 
rim around the tumor can be visualized ex vivo (bottom row). 
Figure 2 – Identification of occult metastases and differentiation from benign lesions: In 4 patients, small 
superficial metastases (top row, arrow) were identified by NIR fluorescence imaging that were otherwise occult. 
Benign lesions (bottom row, arrow) could be differentiated from malignant lesions by a lack of a fluorescent rim 
around the lesion.
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– 112.4), and 77.4 (range: 67.5 – 96.2) for the 10 mg at 24 hr, 20 mg at 24 hr, 10 mg at 
48 hr, and 20 mg at 48 hr patient group, respectively (Fig. 4). Using the independent 
samples Kruskal-Wallis Test no significant differences in signal-to-background ratios 
(P = 0.72) and rim fluorescence (P = 0.38) were observed. Using the independent 
samples Kruskal-Wallis Test, a significant difference in background fluorescence was 
observed (P = 0.038). Post tests using Dunn’s Multiple Comparison Test showed a 
significant difference between the 20 mg at 24 hr and the 10 mg at 48 hr groups. No 
differences were observed between other separate groups. Because no differences in 
TLRs were observed between the various groups, the optimal dose was determined by 
clinical and logistical preferences (the minimal dose of 10 mg of ICG administered 24 
h prior to surgery).
ex vivo detection of colorectal liver metastases and fluorescence microscopy
Liver resection specimens were sliced in 5-7 mm slices and subsequently the slices 
were imaged with the Mini-FLARE imaging system. In all patients for whom a liver 
resection was performed (N = 17), ex vivo NIR fluorescence imaging was performed. 
All known metastases were identified ex vivo by a clear fluorescent ring around the 
lesion. A tissue section containing both tumor tissue and normal liver tissue was then 
snap frozen and sectioned at 20 μm for fluorescence microscopy. After fluorescence 
microscopy, tissue sections were stained with hematoxylin and eosin and overlay 
images of NIR fluorescence were created (Fig. 3). Fluorescence signal was located in 
liver transition tissue surrounding the tumor and appeared to be located in the vicinity 
of blood vessels.
dISCuSSIoN
The current study investigated the use of intraoperative NIR fluorescence imaging in 
patients undergoing liver surgery for colorectal cancer liver metastases. The aim of 
this study was to assess the effect of timing of ICG administration and dose of ICG. 
Furthermore, ex vivo imaging of the liver resection specimen was performed. All 
superficially located (< 6.2 mm beneath the liver surface) metastases were identified 
using NIR fluorescence. Additionally, in four patients occult metastases were detected 
using NIR fluorescence, which were missed by conventional detection methods.
A major problem with NIR fluorescence imaging, though, is the limited 
penetration depth of ≈ 6 - 8 mm. Indeed, in the current study, seven metastases that 
were located 8 mm or more beneath the liver capsule could not be identified using NIR 
fluorescence. Preoperative CT scanning and IOUS are more appropriate for deeper 
located lesions and did successfully identify these seven lesions. However, superficially 
located, small occult metastases are known to be difficult to detect using IOUS, 
inspection and palpation. Indeed, in the current study, four superficially located, 
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malignant lesions were detected by NIR fluorescence that were otherwise missed and 
would not have been resected. Although IOUS is still required to identify deep (≥ 
6 mm) metastases in the liver, our results suggest that NIR fluorescence imaging is 
complementary and helps find small, superficially located liver metastases. However, 
to prove clinical outcome and patient benefit, larger clinical trials must be performed.
The use of NIR fluorescence imaging to detect liver metastases is dependent on 
the clearance of ICG by the liver. To optimize the use of this technique, it is necessary to 
examine the influence of ICG dose and timing of ICG administration prior to surgery. 
In the current study, differences in dose and timing did not significantly influence the 
TLR. A previously performed study in rats by our group showed an optimal TLR in the 
group where ICG was administered at 72 hours prior to surgery.15 In the current clinical 
study, liver signal was comparable to pre-injection baseline level (data from Hutteman 
and van der Vorst et al, manuscript submitted) at 24 to 48 hours post-injection of 10 
mg ICG, eliminating the need to test other time-points. Therefore, NIR fluorescence 
imaging at 72 hours after ICG administration was not performed. Other clinical work 
performed by Ishizawa et al. suggested an interval between administration of ICG and 
liver surgery of at least 2 days to lower background fluorescence and to obtain adequate 
TLRs.13 However, in that study a substantially higher dose of ICG (0.5 mg/kg; ≈ 35 mg 
per subject) was administered. In the current study, a relatively low dose of ICG (0.13 
– 0.26 mg/kg) was used and it was therefore possible to reach acceptable TLRs and 
sufficiently low background liver fluorescence at 24 hours after administration of 10 
mg ICG, which is safe and desirable from a logistical point of view. 
The liver can be a challenging organ for optical imaging, as liver tissue has 
a relatively high light absorptivity and scatter, and many fluorescent probes show 
hepatic accumulation.17, 18 In a previously reported preclinical study by our group, 
using a tumor-targeted NIR fluorescent probe in a rat model of colorectal liver 
metastases, TLRs of approximately 2 were observed.19 Preclinical work using ICG for 
NIR fluorescence imaging in the same tumor model showed TLRs of approximately 
4,15 whereas in the current clinical study, a median TLR of 7.4 was observed.  These 
results demonstrate excellent performance of  ICG as a non-targeted NIR fluorescent 
probe for intraoperative imaging of colorectal metastases. The development of novel, 
tumor-targeted probes with minimal background uptake is, however, essential to be 
able to detect other tumor types or extrahepatic colorectal tumors.20
Liver function, and in particular liver clearance capacity, affects the clearance 
rate of ICG and its biliary secretion and thereby retention of ICG fluorescence in the 
liver. However, the liver has a large reserve capacity, as has been shown in patients 
with cirrhosis and patients undergoing hepatic resection, potentially enabling the use 
of NIR fluorescence imaging after ICG administration even in patients with reduced 
liver function.21 In these patients, however, the optimal time interval between ICG 
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administration and imaging could differ from patients with a normal liver function. 
Future clinical studies must clarify this issue. 
In addition to tumor detection, NIR fluorescence imaging appears capable of 
differentiating between benign and malignant tumors. In three patients, additional 
benign liver lesions were intraoperatively identified. These lesions could be clearly 
differentiated from malignant lesions due to the lack of fluorescent signal in the lesion 
and the lack of a fluorescent rim around them. Using fluorescence microscopy, we 
observed accumulation ICG in the transition area between tumor and normal liver 
tissue, in the vicinity of blood vessels. This phenomenon of rim enhancement is 
observed in arterial phase CT-scans of patients with liver metastases.22 This peripheral 
enhancement seen in metastases may be caused by disrupted vasculature surrounding 
the tumor tissue, causing delayed drainage of ICG from the tumor surroundings.
Figure 3 – Microscopic analysis of the tumor border: Shown are hematoxylin and eosin staining (left), NIR 
fluorescence images (middle), and a pseudo-colored green merge of the two (right) of a 20 μm frozen tissue 
section of a colorectal liver metastasis using a 2.5 X objective (top row) and 10 X objective (bottom row). The 
fluorescent rim in stromal tissue appears in the border between tumor (T) and normal liver tissue (L).
Figure 4 – Influence of ICG dose and injection time on NIr fluorescence signal: Fluorescence intensity of the 
rim around the tumor (left panel), normal liver (middle panel), and the ratio between the two (right panel) is 
plotted for the various dose and time groups as indicated. No differences were observed between the groups. Liver 
signal approaches baseline fluorescence of the liver (middle panel, dotted line) in all groups except 20 mg, 24 h. 
All ratios observed were above the clinically relevant ratio of 2 (right panel, dotted line).
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As in other areas of surgery, the use of laparoscopy is expanding to liver surgery. 
Minor liver resections such as the left lateral hepatic resections are being performed 
laparoscopically as standard-of-care in several centers.23 NIR fluorescence may 
also be of great value in laparoscopic surgery because palpation of the liver is not 
possible and the surgeon can only rely on visual inspection, IOUS, and preoperative 
imaging. To implement NIR fluorescence in laparoscopic liver surgery, laparoscopic 
NIR fluorescence camera systems are currently being developed and tested.24, 25 
In conclusion, this study suggests that NIR fluorescence imaging is complementary 
to conventional imaging for liver metastasectomies, and has the potential to improve 
surgical care.
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SuMMary
Intraoperative imaging using NIR fluorescence has the potential to be of major 
impact on surgical practice, and cancer surgery in particular.1 The ability to visualize 
tumors and lymph nodes that need to be resected, simultaneously with nerves, 
bile ducts and other structures that need to be spared, can improve outcomes and 
reduce complications in a wide variety of surgical procedures (chapter 1). Since NIR 
fluorescence imaging involves no ionizing radiation, requires only relatively low-
cost camera systems and can be used for real-time visualization during surgery, the 
technique can be disseminated all around the world, potentially also to areas were less 
healthcare budget is available.
Multiple NIR fluorescence imaging systems have recently become available,2 two 
NIR fluorescent probes are already clinically available (indocyanine green, ICG, and 
methylene blue, MB) and many novel probes are being developed. This thesis focuses 
on preclinical validation of this technique for intraoperative tumor identification and 
image-guided resection (Part I), and a clinical translation of this technique using 
clinically available probes (Part II).
Part I, chapter 2 describes the use of an integrin αvβ3-targeted NIR fluorescent probe 
for the intraoperative detection of colorectal liver metastases in a syngeneic rat tumor 
model. In this study, all of the induced colorectal liver metastases could be identified 
intraoperatively using a NIR fluorescent imaging system. Furthermore, several intra-
abdominal metastases, were detected by NIR fluorescence. The study shows proof-of-
principle of the application of novel tumor-targeted probes and NIR fluorescence for 
intraoperative tumor detection.
Positive resection margins are a major problem in the treatment of breast 
cancer, with reported rates of up to 40 percent. The possibility of visualizing breast 
tumors during surgery could reduce the number of irradical resections and therefore 
be of great impact on patient care. In chapter 3, a protease-activatable NIR fluorescent 
probe was used to intraoperatively detect breast tumors in a syngeneic rat model of 
breast cancer. Subsequently, tumors were resected under direct image-guidance, with 
minimal excision of healthy tissue. NIR fluorescent image-guidance allowed for radical 
resection of all tumors, with minimal margins of healthy tissue (mean minimum and a 
mean maximum tumor-free margin of 0.2 ± 0.2 mm and 1.3 ± 0.6 mm, respectively). 
When these tumor specific probes become clinically available, patient benefit and the 
effect on the number of radical resections can be assessed.
The clinically available probe ICG is cleared by the liver and has been shown 
to passively accumulate around colorectal liver metastases. Chapter 4 focuses on 
preclinical optimization of the use of indocyanine green for intraoperative detection 
of colorectal liver metastases, in a syngeneic rat model. All liver metastases could be 
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identified intraoperatively after ICG injection. The optimal interval between ICG 
injection and intraoperative imaging was 72 h.
In part II, focus lies on clinical translation of intraoperative NIR fluorescence imaging. 
Analysis of the sentinel lymph node (SLN), the first node that drains from a tumor, 
is an important procedure in the staging and treatment of breast cancer, cutaneous 
melanoma and vulvar cancer. This procedure has been studied extensively in colorectal 
cancer patients, but it has yet to show clear patient benefit. This could be caused by a 
suboptimal technical procedure for SLN mapping in colorectal cancer. As an oncologic 
resection involves the en bloc resection of regional lymph nodes, ex vivo tracer injection 
and SLN mapping are possible. In chapter 5, the use of NIR fluorescence imaging for 
ex vivo SLN mapping in combination with an experimental, more optimized probe are 
studied in colorectal cancer patients. This technique was optimized in a swine model 
and subsequently tested in a pilot series of colorectal cancer patients. NIR fluorescence 
imaging enabled the detection of SLNs in all cases. In one case, a mesenteric metastasis 
was encountered that was not NIR fluorescent, however, this was a tumor mass without 
any remaining lymph node tissue, preventing lymphatic flow.
SLN mapping in breast cancer typically involves the use of a radiotracer and 
a blue dye. NIR fluorescence imaging has the potential to improve SLN mapping in 
breast cancer, by possibly replacing one of the current modalities, or even both, or 
functioning as an adjunct. In chapter 6, optimization of imaging system and injected 
ICG dose are performed. In this study, ICG is premixed with human serum albumin 
(HSA), to increase the retention in the SLN and increase fluorescence brightness of 
ICG. SLN mapping using NIR fluorescence was uneventful in all patients and allowed 
the detection of on average 1.45 SLNs. Optimal ICG:HSA dose was between 400 and 
800 µM.
In previous preclinical studies, premixing of ICG with HSA showed clear 
advantages: it improved the retention of the dye in the SLN and increased the 
fluorescence brightness.3 Chapter 7 aims to test this advantage in a clinical, randomized 
setting, as injection into a human breast might induce coupling with the physiologically 
available albumin and eliminate the need of premixing. Patient groups injected with 
or without premixed ICG showed no difference in fluorescence contrast (P = 0.18), or 
in number of identified nodes (P = 0.74), indicating that premixing of ICG with HSA 
can be omitted in case of breast cancer. This simplifies the clinical procedure and can 
facilitate the introduction of this technique in clinical practice. 
Chapter 8 describes the use of NIR fluorescence for the intraoperative 
detection of SLNs in cervical cancer patients. Shortly prior to surgical scrub, patients 
received peritumoral injections of ICG:HSA. After exposure of lymph node basins, 
NIR fluorescence imaging enabled successful detection of SLNs in all patients. No 
false negatives were observed. In chapter 9, the use of NIR fluorescence imaging was 
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described in SLN mapping in vulvar cancer patients, who also received standard-
of-care injections of radiotracer and patent blue dye. In all patients, SLNs (N = 11) 
could be detected by NIR fluorescence and radiotracer, 3 nodes, however, were not 
blue. These pilot studies show the successful use of NIR fluorescence imaging in the 
detection of SLNs in gynecologic malignancies.
Nowadays, the majority of breast cancer resections are breast-conserving 
surgeries, where only the tumor itself and a safety margin around it are resected. 
When a mastectomy is performed, several reconstructive techniques are available. 
The use of free skin flaps is associated with good cosmetic results and high patient 
satisfaction. The surgical procedure, however, can be challenging and creation of skin 
flaps for autotransplantation requires careful planning to select the right blood vessels 
for optimal flap perfusion. In chapter 10, the use of NIR fluorescence imaging for 
visualizing flap vascularization is assessed in a clinical trial of breast cancer patients 
undergoing deep inferior epigastric perforator flap reconstructive surgery after 
mastectomy. ICG was injected at 3 dose levels and NIR fluorescent angiography was 
performed at fixed moments during surgery. NIR fluorescence permitted visualization 
of flap vascularization in all patients and a dose of 4 mg ICG was found to be optimal.
Intraoperative visualization of pancreatic tumors could help reduce the number 
of irradical resections. As no tumor specific probes are clinically available, in the 
study described in chapter 11, ICG was injected in order to test if tumors could be 
identified by passive accumulation (the enhanced permeability and retention effect). 
Furthermore, as ICG is excreted into bile, it was evaluated if bile ducts could be visualized 
intraoperatively. Unfortunately, no useful tumor contrast could be observed in all but 
one patient. NIR fluorescence did, however, enable the identification of extrahepatic 
bile ducts during surgery. Chapter 12 then describes a study in which patients 
suffering from colorectal liver metastases were injected intravenously with ICG, prior 
to surgery. During surgery, superficially located metastases could clearly be identified 
by a fluorescent rim around the tumor. This could be caused by hampered excretion 
of ICG into bile, by compression of liver tissue by the expanding tumor. Importantly, 
other than tumors identified preoperatively by CT or MRI, and intraoperatively by 
visual inspection and palpation, NIR fluorescence enabled the detection of 4 hotspots 
that were not found by other modalities. These were histologically confirmed to be 
metastases. Tumor-to-liver ratios of 7.4 (range 1.9 – 18.7) were observed, which is 
higher than any of the preclinically tested tumor-targeted probes.
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Future PerSPeCtIveS
Future perspectives
The availability of already clinically approved NIR fluorescent probes has been 
essential for the first clinical trials. However, these probes, indocyanine green and 
methylene blue were not designed as contrast agents for image-guided surgery and 
are not optimal, but can be used off-label for imaging applications. When the first 
intraoperative imaging systems became available in the course of the last decade, 
research groups all around the world have used these probes for many applications.4-9 
For NIR fluorescence imaging to perform up to its full potential and have a significant 
impact on patient care, several new developments are necessary.
Probe development
The ability to selectively visualize tumor cells and nerves can be a game changer in 
cancer surgery, and can potentially result in higher radical resection rates and lower 
complication rates. However, for this to be a reality, tumor and nerve specific probes 
need to be approved for clinical application.10, 11 In general, these targeted probes consist 
of a fluorophore and a targeting ligand. Currently clinically available fluorophores have 
suboptimal properties and cannot be conjugated to targeting ligands, necessitating the 
development of novel fluorophores. These fluorophores should be non-toxic, highly 
fluorescent (high quantum yield) and have the possibility of conjugation to a targeting 
ligand. IRDye 800CW (LI-COR Biosciences, United States) is a fluorophore that 
matches these requirements and has recently completed its toxicity tests in rodents.12 
Choi et al. have shown that quantum dots can be cleared rapidly from the body, if the 
hydrodynamic diameter is smaller than 5.5 nm and the surface charge is balanced of the 
molecule.13 Following these observations, the Frangioni Lab (Harvard Medical School, 
United States) has developed a novel organic fluorophore that is zwitterionic (ZW800-
1).14 Both IRDye 800CW and ZW800-1 are currently manufactured following cGMP 
guidelines and it is expected that the first clinical studies can start within the next 
months to years. Future research should be focused on maximizing the fluorescent 
properties of probes, optimizing rapid excretion and further reduction background 
uptake.15
To selectively label tumor cells, various distinguishing hallmarks of cancer, 
as described by Hanahan and Weinberg, can be used as targets.16 An optimal target 
is exclusively and abundantly expressed by tumor cells and can be targeted without 
causing toxicity. Novel NIR fluorescent probes have been developed that target growth 
factor receptors,17-20 glucose metabolism,21 angiogenesis,22-24 and enzymatic activity,25, 
26 and these probes have been studied in preclinical tumor models. First-in-human 
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results of intraoperative fluorescence imaging in debulking surgery for metastatic 
ovarian cancer have been reported with a folate-receptor targeted probe (van Dam 
et al., manuscript accepted for publication). Although the probe used in these studies 
was based on fluorescein, which fluoresces in the non-optimal visible light spectrum, 
these results are highly promising for clinical application of targeted NIR fluorescent 
probes in image-guided surgery.
Iatrogenic nerve damage is a major complication in oncologic surgery, 
which could potentially be avoided by NIR fluorescence imaging. Small molecule, 
nerve specific agents BMB and its derivative GE3082 pass the blood-nerve-barrier 
and selectively target nerves (although background uptake in adipose tissue is also 
observed).10 These probes, however, do not fluoresce in the NIR spectrum and have 
therefore limited tissue penetration. Furthermore, these probes show in vivo toxicity. 
Further research is currently focused on reducing toxicity and shifting the fluorescence 
excitation and emission wavelengths to the NIR window. Whitney et al. developed a 
nerve-specific probe by using phage display to select a peptide specific for peripheral 
nerves and conjugating to a NIR fluorophore.11 Although the chemical properties of 
this probe prevent it from penetrating the blood-nerve-barrier, nerve staining was 
observed in vivo. Future research will have to show what strategy is most optimal to 
selectively target nerves.
Intraoperative imaging systems
Currently available imaging systems all have their drawbacks, some only show NIR 
fluorescence signal without displaying anatomical context, others are relatively large 
and most are not yet unobtrusive and sufficiently user friendly to be used outside of a 
research setting.5, 7, 9, 27 Furthermore, laparoscopic systems are not widely available, and 
currently available systems do not provide anatomical context.6 Depth penetration of 
NIR light is limited and novel camera system designs are focused on increasing the 
depth at which a fluorophore can be detected. Various strategies can be followed to 
achieve higher detection depth. Detection of tissue autofluorescence will minimize 
background noise and increase the maximal depth at which a fluorophore can be 
detected. For this purpose, fluorescence lifetime imaging (FLIM, which measures the 
decay of fluorescence intensity of a fluorophore) can be utilized.28 Temporal and spatial 
frequency domain modulation of the light source can be used to determine depth 
information of the fluorescent signal (as reviewed by Gioux et al.2). Optimized camera 
systems are being developed by various groups and companies and research is focused 
on improving performance, and improving the ease of use in the operating room. 
When these optimized imaging systems become available, NIR fluorescence imaging 
has a chance to leap from the research setting into general clinical practice.
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Conclusions
Intraoperative imaging using NIR fluorescence is a highly promising imaging modality 
that has the potential to revolutionize cancer surgery. The studies described in this 
thesis show proof of principle that it is possible to use NIR fluorescence imaging in 
surgical practice. When targeted contrast agents and optimized camera systems 
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Ondanks vele verbeteringen bij niet-chirurgische behandelvormen van kanker 
(bijvoorbeeld chemotherapie, immunotherapie, bestraling), blijft chirurgische 
verwijdering van een gezwel in bijna alle vormen van kanker de belangrijkste 
curatieve behandeloptie. Voor een curatieve verwijdering van een gezwel is het van 
groot belang dat alle tumorcellen verwijderd worden, om het ontstaan van een recidief 
te voorkomen. Het is evenzeer van groot belang om vitale structuren (zenuwen, 
urinewegen, galwegen) te sparen. Preoperatieve beeldvorming zoals CT, PET, SPECT 
en MRI maken het mogelijk om voorafgaand aan de operatie inzicht te krijgen in de 
tumorgrootte, locatie en positie ten opzichte van vitale structuren. Tijdens de operatie 
is de chirurg echter voornamelijk aangewezen op zicht en gevoel om te bepalen welk 
weefsel verwijderd en welk weefsel gespaard moet worden. Helaas is het onderscheid 
tussen tumorweefsel en gezond weefsel vaak lastig te maken op zicht en gevoel, 
waardoor onvolledige (irradicale) resecties regelmatig voorkomen. Daardoor bestaat 
de behoefte aan een beeldvormende modaliteit, die de chirurg tijdens de operatie helpt 
te beslissen welk weefsel verwijderd dient te worden en welk niet. 
Het onderzoek beschreven in dit proefschrift betreft een dergelijke beeldvormende 
modaliteit, ‘nabij-infrarode fluorescentie imaging’, die de potentie heeft deze structuren 
in real-time, tijdens de operatie zichtbaar te maken (hoofdstuk 1). Nabij-infrarood 
(NIR) licht heeft een golflengte tussen de 700 en 900 nm en is voor het menselijk oog 
niet zichtbaar. Dit licht heeft als voordeel dat het minder door weefsel geabsorbeerd 
wordt, waardoor het dieper door weefsel penetreert in vergelijking met zichtbaar 
licht. Doordat het niet zichtbaar is voor het menselijk oog, heeft het gebruik van 
deze techniek daarnaast als voordeel dat het operatieveld niet wordt verkleurd. Om 
tijdens de operatie tumoren zichtbaar te maken zijn tumorspecifieke, NIR fluorescente 
contrastmiddelen (probes) nodig en gespecialiseerde camerasystemen om deze stoffen 
zichtbaar te maken.
Dit proefschrift is verdeeld in 2 delen: in deel I wordt het gebruik van nabij-infrarode 
fluorescentie imaging gevalideerd in preklinische tumormodellen. In deel II worden 
klinische trials beschreven met deze techniek, gebruikmakend van contrastmiddelen 
die reeds klinisch beschikbaar zijn.
deel I, hoofdstuk 2 beschrijft het gebruik van een tumorspecifieke NIR fluorescente 
probe, gericht op het integrine αvβ3 eiwit, voor de detectie van uitzaaiingen van 
dikkedarmkanker in een syngeen ratmodel. In deze studie konden alle geïnduceerde 
leveruitzaaiingen intraoperatief worden geïdentificeerd door middel van NIR 
fluorescentie. Daarnaast konden ook enkele intra-abdominale metastasen worden 
gedetecteerd door middel van NIR fluorescentie. Hiermee toonde deze studie “proof of 
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principle” voor het gebruik van nieuwe, tumorspecifieke stoffen en NIR fluorescentie 
voor de intraoperatieve detectie van tumoren.
Tumorpositieve snijvlakken vormen een groot probleem bij de behandeling 
van borstkanker. Percentages oplopend tot 40% aan irradicale operaties worden 
gerapporteerd. De mogelijkheid om borsttumoren tijdens de operatie te visualiseren 
zou het aantal irradicale resecties kunnen verlagen en daardoor een grote impact 
hebben op de uitkomst voor patiënten. In hoofdstuk 3 werd een protease-geactiveerde 
NIR fluorescente stof gebruikt om borsttumoren intraoperatief te detecteren in een 
syngeen ratmodel voor borstkanker. Vervolgens werden deze tumoren op geleide 
van het NIR fluorescentiebeeld gereseceerd, met verwijdering van een minimale 
hoeveelheid gezond weefsel. NIR fluorescentie maakte het mogelijk alle tumoren 
geheel te verwijderen, met een minimale marge van gezond weefsel (gemiddelde 
minimale en maximale tumorvrije marge van respectievelijk 0.2 ± 0.2 mm en 1.3 ± 
0.6 mm). Zodra deze tumorspecifieke stoffen beschikbaar komen voor toepassing bij 
patiënten kan het effect op het aantal volledige tumorresecties en bijkomend voordeel 
voor de patiënt worden onderzocht.
De al klinisch beschikbare fluorescente stof indocyanine groen (ICG) wordt 
na intraveneuze injectie geklaard door de lever en kan daardoor passief ophopen 
rondom colorectale levermetastasen. In hoofdstuk 4 wordt het gebruik van ICG voor 
de intraoperatieve detectie van colorectale levermetastasen geoptimaliseerd in een 
syngeen ratmodel. Alle levermetastasen konden intraoperatief worden geïdentificeerd 
na injectie van ICG. Het optimale interval tussen ICG injectie en intraoperatieve 
tumorbeeldvorming was 72 uur.
In deel II wordt het gebruik van intraoperatieve NIR fluorescentie imaging 
beschreven in een klinische setting. Analyse van de schildwachtklier, de lymfklier 
die direct draineert van een tumor en dus de grootste kans heeft om tumorcellen te 
bevatten in het geval van uitzaaiing naar lymfklieren, is een belangrijke procedure 
bij de behandeling van borstkanker, melanomen en vulvakanker. Hierbij worden een 
kleurstof en/of een radioactieve tracer geïnjecteerd rondom de tumor, waarna de 
lymfklieren, die verkleuren of radioactief worden, verwijderd worden en onderzocht 
op aanwezigheid van tumorcellen. De procedure is ook uitgebreid bestudeerd bij 
dikkedarmkanker, maar heeft daar nog geen duidelijke meerwaarde laten zien. De 
oorzaak hiervan zou kunnen zijn dat de huidige technieken minder geschikt zijn voor 
de schildwachtklierprocedure bij dikkedarmkanker. Doordat bij een oncologische 
resectie van dikkedarmkanker de regionale lymfklieren en bloc worden verwijderd 
met de primaire tumor, is het mogelijk om ex vivo de tracer te injecteren voor de 
schildwachtklierprocedure. In hoofdstuk 5 werd het gebruik van NIR fluorescentie 
imaging voor de ex vivo schildwachtklierprocedure met een experimentele, 
geoptimaliseerde probe bestudeerd bij dikkedarmkankerpatiënten. De techniek werd 
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eerst geoptimaliseerd in een varkenmodel en vervolgens getest in een pilotstudie bij 
dikkedarmkankerpatiënten. Het was in alle gevallen mogelijk met behulp van NIR 
fluorescentie imaging de schildwachtklier te identificeren. In één geval werd een 
uitzaaiing gevonden in het mestenterium, die niet fluorescent was. Er was hier echter 
sprake van een tumormassa zonder residu van lymfklierweefsel, waardoor er geen 
lymfdrainage meer was.
De schildwachtklierprocedure bij borstkankerpatiënten omvat normaliter 
een injectie van een radioactieve tracer en een blauwe kleurstof. NIR fluorescentie 
imaging heeft de potentie om de schildwachtklierprocedure bij borstkankerpatiënten 
te verbeteren, mogelijk door het vervangen van een van de huidige modaliteiten, 
of als aanvulling. In hoofdstuk 6 werden een intraoperatief camerasysteem en de 
geïnjecteerde dosis ICG geoptimaliseerd bij borstkankerpatiënten. In deze studie werd 
ICG gekoppeld aan humaan serum albumine (HSA), om hierdoor de eigenschappen 
als lymftracer te verbeteren. Er ontstonden bij patiënten geen complicaties en in alle 
gevallen werd de schildwachtklier succesvol geïdentificeerd (gemiddeld 1,45 klieren 
per patiënt). De optimale dosis ICG:HSA lag tussen 400 en 800 μM.
In eerder beschreven preklinische studies liet het koppelen van ICG aan HSA 
duidelijke voordelen zien: de retentie in de schildwachtklier werd verbeterd en er was 
sprake van een verhoogde fluorescente helderheid. In hoofdstuk 7 werd dit voordeel 
in een gerandomiseerde klinische studie bestudeerd, daar injectie in borstweefsel zou 
kunnen betekenen dat ICG zich bindt aan daar aanwezige eiwitten, waardoor vooraf 
koppelen overbodig kan zijn. Er werd geen verschil gevonden tussen patiënten waarbij 
ICG wel of niet gekoppeld werd met HSA: niet in fluorescent contrast (P = 0.18), of het 
aantal klieren dat werd gevonden (P= 0.74). Hierdoor werd duidelijk dat koppelen met 
HSA niet nodig is, waardoor deze techniek gemakkelijker breed kan worden toegepast 
in een klinische setting.
Hoofdstuk 8 beschrijft het gebruik van NIR fluorescentie voor de 
intraoperatieve detectie van de schilwachtklier in baarmoederhalskankerpatiënten. 
Kort voor de operatie werd bij deze patiënten ICG:HSA rondom de tumor geïnjecteerd. 
Na vrij leggen van de lymfklierstations kon door middel van NIR fluorescentie 
imaging de schildwachtklier gevonden worden in alle patiënten, waarbij geen fout-
negatieven werden gevonden (een fout-negatief ontstaat als de geïdentificeerde 
schildwachtklieren tumornegatief zijn, terwijl andere klieren tumorcellen bevatten). 
In hoofdstuk 9 wordt het gebruik van NIR fluorescentie imaging beschreven bij de 
schildwachtklierprocedure bij vulvakankerpatiënten, die daarnaast ook de standaard 
schildwachtklierprocedure met blauw en een radioactieve  tracer ondergingen. Bij 
alle 9 patiënten werden lymfklieren gevonden (in totaal 11 klieren) met zowel NIR 
fluorescentie als de radioactieve tracer; 3 klieren waren echter niet blauw. In deze 
pilotstudies werd met succes het gebruik van NIR fluorescentie imaging voor de 
detectie van schildwachtklieren bij gynaecologische tumoren getoond.
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De meerderheid van de operaties bij borstkanker kan borstsparend worden 
uitgevoerd, waarbij alleen de tumor zelf en een veiligheidsmarge hier omheen 
worden verwijderd. Wanneer toch de gehele borst moet worden verwijderd, zijn 
diverse reconstructieve operaties mogelijk. Het gebruik van vrije huidflappen van 
het eigen lichaam wordt geassocieerd met een goede cosmetische uitkomst en hoge 
patiënttevredenheid. De chirurgische procedure kan echter lastig zijn en voor het 
creëren van een vrije flap voor autotransplantatie moet met nauwkeurigheid bepaald 
worden welke bloedvaten gebruikt gaan worden. Hoofdstuk 10 beschrijft het gebruik 
van NIR fluorescentie imaging voor het visualiseren van flapvascularisatie in een 
pilot trial bij borstkankerpatiënten, waarbij een “deep inferior epigastric perforator 
flapreconstructie” wordt uitgevoerd na een borstamputatie. ICG werd geïnjecteerd op 
3 dosisniveaus en de doorbloeding werd geanalyseerd door NIR fluorescentie imaging 
op vaste momenten. NIR fluorescentie imaging toonde de flapvascularisatie in alle 
patiënten, waarbij een dosis van 4 mg ICG optimaal was.
Intraoperatieve visualisatie van alvleeskliertumoren zou kunnen helpen het 
aantal irradicale resecties te verkleinen. Daar nog geen tumorspecifieke stoffen klinisch 
toegepast kunnen worden, werd in de studie, beschreven in hoofdstuk 11, ICG 
geïnjecteerd, om een contrast te verkrijgen door passieve accumulatie (het “enhanced 
permeability and retention” effect). Voorts werd bekeken of door uitscheiding in 
de gal, de galwegen intraoperatief zichtbaar konden worden gemaakt. Helaas werd 
geen bruikbaar tumorcontrast gezien, bij alle behalve 1 patiënt. De extrahepatische 
galwegen werden echter bij alle patiënten geïdentificeerd door NIR fluorescentie.
Hoofdstuk 12 beschrijft een studie, waarbij bij patiënten met een uitzaaiing 
in de lever van dikkedarmkanker, ICG werd geïnjecteerd voorafgaand aan de 
operatie. Tijdens de operatie konden de oppervlakkige uitzaaiingen duidelijk worden 
geïdentificeerd door een fluorescente rand rondom de tumor. Dit wordt mogelijk 
veroorzaakt door verstoorde galuitscheiding, door compressie van gezond leverweefsel 
door de tumor. Daarnaast werden behalve de reeds bekende uitzaaiingen, extra laesies 
gevonden, die niet vooraf op CT of MRI en intraoperatief door inspectie en palpatie 
waren geïdentificeerd. Deze extra laesies waren histologisch bewezen uitzaaiingen. 
Deze studie toonde tumor-tot-lever fluorescentieratio’s van gemiddeld 7.4 (bereik 1.9 
– 18.7), wat beduidend hoger is dan alle preklinisch geteste tumorspecifieke probes.
CoNCLuSIe
Intraoperatieve imaging met gebruik van NIR fluorescentie is een veelbelovende 
beeldvormende modaliteit, die de potentie heeft oncologische chirurgie te verbeteren. 
De studies beschreven in dit proefschrift tonen ‘proof of principle’, niet alleen 
preklinisch, in diermodellen, maar ook klinisch bij diverse typen tumoren. Zowel 
specifieke contrastmiddelen als camerasystemen kunnen nog verder verbeterd 
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worden. Zodra deze beschikbaar komen, heeft de techniek de kans zijn meerwaarde 
voor patiënten te laten zien.
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